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ABSTRACT 
Alzheimer’s Disease and other dementias are one of the most challenging 
illnesses confronting countries with ageing populations. Treatment options 
for dementia are limited, and the costs are significant. There is a growing 
need to develop new treatments for dementia, especially for the elderly. 
There is also growing evidence that centrally acting angiotensin converting 
enzyme (ACE) inhibitors, which cross the blood-brain barrier, are associated 
with a reduced rate of cognitive and functional decline in dementia, 
especially in Alzheimer’s disease (AD).  
 
The aim of this research is to investigate the effects of centrally acting ACE 
inhibitors (CACE-Is) on the rate of cognitive and functional decline in 
dementia, using a three phased KDD process. KDD, as a scientific way to 
process and analysis clinical data, is used to find useful insights from a 
variety of clinical databases. The data used are from three clinic databases: 
Geriatric Assessment Tool (GAT), the Doxycycline and Rifampin for 
Alzheimer’s Disease (DARAD), and the Qmci validation databases, which 
were derived from several different geriatric clinics in Canada. 
 
This research involves patients diagnosed with AD, vascular or mixed 
dementia only. Patients were included if baseline and end-point (at least six 
months apart) Standardised Mini-Mental State Examination (SMMSE), 
Quick Mild Cognitive Impairment (Qmci) or Activities Daily Living (ADL) 
scores were available. Basically, the rates of change are compared between 
patients taking CACE-Is, and those not currently treated with CACE-Is. 
 
The results suggest that there is a statistically significant difference in the 
rate of decline in cognitive and functional scores between CACE-I and 
NoCACE-I patients. This research also validates that the Qmci, a new short 
assessment test, has potential to replace the current popular screening tests 
for cognition in the clinic and clinical trials. 
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CHAPTER 1 INTRODUCTION 
“A lion doesn't concern himself with the opinion of a sheep.” 
               
1.1 Introduction 
This chapter provides an overview of the PhD research1. It introduces the 
global realities of cognitive impairment, and the need to develop new 
treatments for CI (cognitive impairment), especially for the elderly. This 
chapter also presents a description of the objectives for this research. In 
order to better locate the objectives, three research questions are raised. 
Finally, this chapter concludes with a presentation of the publications based 
on this research, and introduces the subsequent chapters. 
 
1.2 Global Realities of Cognitive Impairment 
Cognitive impairment (CI), also called cognitive deficit, is an inclusive term 
to describe when a person has trouble learning, concentrating, remembering, 
or making decisions, that impact their daily life (Coren, 2003). It ranges 
from mild to severe. Mild cognitive impairment (MCI) is a clinical state of 
cognitive functioning, between age associated memory impairment and 
dementia (Chertkow, 2002).  Petersen and colleagues (Petersen et al., 1999) 
characterised MCI as a certain degree memory impairment type, referred to 
as amnestic MCI in subsequent years. Most MCI patients progress to 
dementia, eventually. The symptoms of cognitive impairment include 
memory loss, frequently asking the same question or repeating the same 
story over and over, not recognising familiar people and places, changes in 
mood or behaviour, vision problems, trouble exercising judgment, difficulty 
planning and carrying out tasks (Petersen et al., 2001). 
 
 
                                                        
1 This PhD study commenced in April 2011. The research is co-supervised through the 
Centre for Gerontology and Rehabilitation (CGR), within the School of Medicine, and 
Business information Systems, within the College of Business and Law in UCC. 
 2 
CI is a global problem. Take Alzheimer’s Disease (AD) as an example, the 
global prevalence of AD had raised to more than 35 million people in 2010, 
and was the seventh leading cause of death in the United States (Prince et al., 
2013). The prevalence varies among many different factors, including age, 
co-morbidities, genetics, and education level. The treatment of dementia is 
also very expensive, for example, the global annual cost of dementia was 
estimated at US$315 billion in 2009 (Dartigues, 2009). In recent decades, 
the focus has been on the fact that dementia can lead to unemployment and 
financial worries for families (Allen et al., 2009). There is no way to 
definitively diagnose AD without performing an autopsy.  
 
Dementia is defined as the significant loss of cognitive abilities severe 
enough to interfere with social functioning2. It can result from various 
diseases that cause damage to brain cells. There are many different types of 
dementia, each with its own cause and symptoms. AD is the most common 
form of dementia, caused by the build-up of beta amyloid plaques in the 
brain (Association, 2010). 
 
At present, it appears that none of the disease-modifying drugs in 
development prevent or cure Alzheimer’s (Mount and Downton, 2006). 
Donepezil, Galantamine, and Rivastigmine are cholinesterase inhibitors, and 
commonly used to treat dementia. They inhibit acetylcholinesterase, and 
increase the level of acetylcholine, which helps nerve cells communicate. 
These drugs may temporarily improve mental function in people with 
dementia, but do not slow the progression of dementia3. Another drug, 
Memantine, can be used with acetylcholinesterase inhibitors, although the 
research evidence is not convincing about the efficacy of this treatment, 
with some studies showing positive effects, while others contradict these 
findings (Reisberg et al., 2003). With this in mind, there will be a great need 
for a treatment of dementia in the coming years, to prevent or slow progress 
of dementia among the increasing number of dementia individuals. 
                                                        
2 http://www.medterms.com/script/main/art.asp?articlekey=2940 
3 
http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/delirium_and_dementi
a/dementia.html 
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Angiotensin Converting Enzyme Inhibitors, one of the first 
anti-hypertensives to be studied in dementia (Brunnström et al., 2009), may 
slow down the rate of decline in dementia (Sink et al., 2009). The goal in 
this research studies is to explore the effects of centrally acting ACE 
inhibitors (CACE-Is) on the rate of cognitive and functional decline in 
dementia patients using data analysis methods and techniques, to find a new 
approach to treat dementia. 
 
1.3 Research Objectives and Questions 
The impetus of this research was the growing evidence that centrally acting 
angiotensin-converting enzyme (ACE) inhibitors, which cross the 
blood-brain barrier, are associated with reduced rates of cognitive and 
functional decline in dementia, especially in Alzheimer’s disease (AD). The 
objective of this research is “to investigate the effects of centrally acting 
ACE inhibitors (CACE-Is) on the rate of cognitive and functional decline in 
dementia, using a three phased Knowledge Discovery in Databases (KDD) 
process”. This research also compares and validates the Quick Mild 
Cognitive Impairment (Qmci) test, a new and more efficient cognitive 
screening tool, as one of the key measures for cognition, with the other 
popular used screening tools, such as Standardised Mini-Mental State 
Examination (SMMSE) and Standardised Alzheimer’s Disease Assessment 
Scale-Cognitive Subscale (SADAS-cog). 
 
The findings of this research are based on the analysis of a variety of clinical 
databases from Canada. The data analysis is part of a three phased KDD 
process. Data are structured and warehoused in Oracle 11g. They are 
prepared by using Structured Query Language (SQL), and analysed using 
SPSS (Statistical Package for the Social Sciences) 18. The findings of this 
research not only focus on applying useful data analysis strategies and 
methods on geriatric clinical databases, but also have an even greater 
importance in obtaining interesting information to provide decision support 
to doctors and future academic research direction. This research raises the 
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following questions: 
RQ1: What are the key outcome instruments for measuring the rate of 
cognitive decline in dementia? 
RQ2: What are the effects of centrally acting ACE-Is on reducing the rate of 
cognitive decline in dementia? 
RQ3: What are the effects of centrally acting ACE-Is on reducing the rate of 
ADL (Activities of Daily Living) decline in dementia? 
 
The research questions that are central to achieving the research aim are 
identified and described in Table 1.1. 
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Table 1. 1 Research Questions Guiding this Study 
Research Objective 
To investigate the effects of centrally acting ACE inhibitors (CACE-Is) on the rate of cognitive and functional decline 
in dementia, using a three phased Knowledge Discovery in Databases (KDD) process. 
Research Questions RQ1 RQ2 RQ3 
Purpose (what?) 
To define the key outcome instruments for 
measuring the rate of cognitive decline in 
dementia. 
To prove that centrally acting 
ACE-Is may reduce the rate of 
cognitive decline in dementia. 
To prove that centrally acting ACE-Is 
may reduce the rate of functional 
decline in dementia. 
Motivation (why?) 
1. To distinguish the memory loss types. 
2. Reliable and more sensitive instruments 
are required. 
3. Short instruments are required. 
1. BP control is associated with 
rate of cognitive decline. 
2. There is little data on the 
effects of CACE-Is on the rate of 
cognitive decline in dementia. 
1. Hypertension may affect the risk of 
decline in ADL score in dementia. 
2. Few studies have investigated 
whether ACE-Is affect ADLs 
Results (How?) 
1. Develop a short and simple instrument. 
2. Enhance the properties of the test to 
differentiate NC from MCI. 
3. Prove that Qmci strongly correlates 
with SADAS-cog. 
4. Prove that Qmci has superior sensitivity 
and specificity for differentiating MCI 
from NC and dementia compared to the 
SMMSE, the ABCS 135, and MoCA. 
1. Prove that the use of CACE-Is 
is associated with a reduced rate 
of cognitive decline in dementia. 
2. Prove that cognitive scores 
may improve in the first six 
months after CACE-I treatment. 
1. Prove that CACE-Is are associated 
with a reduced rate of functional 
decline in dementia. 
2. Prove that CACE-Is may have more 
beneficial effects on instrumental 
ADLs. 
3. Prove that patients taking 
perindopril had a significant reduction 
in rate of functional decline. 
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These research questions are answered below in order to satisfy the research 
objectives: 
 
1.3.1 Research Question One 
What are the key outcome instruments for measuring the rate of 
cognitive decline in dementia? 
 
The purpose of this research question is to define the key outcome 
instruments for measuring the rate of cognitive decline in dementia. 
Screening instruments are required by clinicians to reliably diagnose 
MCI and differentiate between normal cognition, MCI, and dementia. 
Adults with memory loss present a challenge to clinicians, who must 
determine if the memory changes are part of normal aging, are 
consistent with mild cognitive impairment (MCI) or early dementia. 
MCI is characterised by a subjective decline in memory without a 
change in functional ability (Ivnik et al., 1992, Smith et al., 1996, Iqbal 
et al., 2003, Petersen, 2001). People with MCI typically complain of 
memory loss but have relatively normal general cognitive function. They 
maintain independence in instrumental activities of daily living (IADL) 
e.g. cooking, finances, driving and some can still function in their 
occupational activities. Since most patients with MCI go on to develop 
dementia (Morris et al., 2001), especially Alzheimer’s disease, when 
people present with memory loss, it is important to differentiate between 
age associated memory impairment, MCI and dementia, as treatment 
choices differ. Meanwhile, researchers and clinicians require short 
instruments that are reliable, valid, and responsive to change across a 
wide range of cognitive function. They need multiple standardised 
scoring formats that measure changes early (high ceiling) and in the later 
stages of dementia (low floor) (O'Caoimh et al., 2013b). 
    
The current instruments available to diagnose MCI, for example, the 
Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) 
(Rosen et al., 1984, Standish et al., 1996) and the Clinical Dementia 
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Rating (CDR) scale (Hughes et al., 1982), are not feasible for use by 
family doctors or other clinicians in the clinical setting because they take 
too long to administer. The Mini Mental State Examination (MMSE) 
(Folstein et al., 1975), a widely used screening test for cognitive 
impairment, is used primarily to screen patients with cognitive 
impairment to quantify cognitive deficits, identify dementia and follow 
cognitive progression over time. The Standardised Mini-Mental State 
Examination (SMMSE) (Molloy et al., 1991a, Molloy and Standish, 
1997b, Mitchell, 2009) has explicit guidelines for administration and 
scoring and improved inter-rater reliability compared to the traditional 
MMSE. Although it is sufficiently specific for dementia, the SMMSE is 
less sensitive in distinguishing between normal cognition, MCI and 
dementia.  
 
Under this situation, new instruments are required that have a higher 
ceiling and that are not as dependent on education. The AB Cognitive 
Screen 135 (ABCS 135) was developed to address this need (Molloy et 
al., 2005). The ABCS 135 is more sensitive in differentiating NC from 
dementia, and more importantly, MCI from dementia than the SMMSE. 
It is a short screening test, administered in 3–5 minutes. However, the 
subtests of orientation, registration and clock drawing in ABCS 135 did 
not enhance the discriminatory properties of the test in differentiating 
NC from MCI. For this reason, the Quick Mild Cognitive Impairment 
(Qmci) screen was developed to enhance the sensitivity of the ABCS 
135. 
 
The Quick Mild Cognitive Impairment screen (Qmci) is a new screening 
test for cognitive impairment (CI), that was developed as a rapid, valid 
and reliable tool (O'Caoimh et al., 2012a). It is scored out of 100 points 
and has a median administration time of four minutes (O'Caoimh et al., 
2013a). The Qmci was derived from the ABCS 135 (Molloy et al., 2005, 
Standish et al., 2007), by reweighting its subtests and adding LM 
(O'Caoimh et al., 2012a). It has superior sensitivity and specificity for 
differentiating MCI from normal cognition and dementia compared to 
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the SMMSE, the ABCS 135 (O'Caoimh et al., 2012a), and MoCA 
(Montreal Cognitive Assessment). It also correlates with the 
standardised Alzheimer`s Disease Assessment Scale-cognitive section 
(SADAS-cog), Clinical Dementia Rating (CDR) scale and the 
Lawton-Brody activities of daily living scale (O'Caoimh et al., 2013b). 
In this research, as the widely use of SMMSE, we used both SMMSE 
and Qmci, as the key outcome instruments to measure the rate of 
cognitive decline in dementia. 
 
1.3.2 Research Question Two 
What are the effects of centrally acting ACE-Is on reducing the rate of 
cognitive decline in dementia? 
 
The purpose of this question is to prove that centrally acting ACE-Is 
may reduce the rate of cognitive decline in dementia. ACE-Is were one 
of the first anti-hypertensives to be studied, particularly in AD, the most 
prevalent form of dementia (Brunnström et al., 2009). Blood pressure 
(BP) control is associated with both a reduced incidence of cognitive 
impairment (CI) and rate of cognitive decline (Whitmer et al., 2005). 
Independent of the BP lowering properties, ACE-Is affect the renin 
angiotensin system so they could reduce dementia risk (Kehoe and 
Passmore, 2012). Centrally acting ACE-Is (CACE-Is), a sub-group of 
ACE-Is, that cross the blood–brain barrier, may have a greater impact 
than those that do not. 
 
Outside of clinical trials, there is little data on the effects of CACE-Is on 
the rate of cognitive decline in patients with dementia. Given this, we 
compared rates of cognitive decline between those taking CACE-Is, to 
those not currently receiving (NoCACE-I) and to those newly started 
(first six months) on CACE treatment (NewCACE-I), in patients with 
dementia, from the GAT (Geriatric Assessment Tool) database. Data 
were collected in memory clinics in two university hospitals in Ontario, 
Canada. The GAT database contains over 8,000 individual assessments 
 9 
from 1,749 people, aged 41 to 104 years of age. Two cognitive screening 
tests, the Standardised Mini-Mental State Examination (SMMSE) and 
the Quick Mild Cognitive Impairment (Qmci) scores are used as the key 
cognitive measures for this research. Both tests were administered to 
patients by trained raters (clinic nurses), blind to the diagnosis, prior to 
each assessment to monitor progression. Only patients with AD, 
vascular or mixed dementias (Alzheimer’s-vascular) were included in 
this analysis. Of these, patients were included if baseline and end-point 
(at least six months apart) SMMSE or Qmci screen scores were available. 
Change between baseline and end-point (last visit) scores were 
standardised at six months to facilitate comparison between all groups. 
The change scores were calculated as the formula: Rate of decline = 
(Baseline score – End-point score)/Duration in months.  
 
The findings demonstrated that, there was a statistically significance 
difference, in the median, six-month, rate of decline in cognitive scores 
between CACE-I and NoCACE-I patients. There was a similar, 
non-significant change in SMMSE scores. For persons receiving 
NewCACE-Is, median SMMSE scores improved in the first six months 
of treatment compared to persons established on CACE-Is and NoCACE 
over the same period. These results suggest that cognitive scores may 
improve in the first six months of CACE-Is treatment and provide 
further evidence that use of CACE is associated with a reduction in the 
rate of deterioration in patients with dementia. 
 
1.3.3 Research Question Three 
What are the effects of centrally acting ACE-Is on reducing the rate of 
ADL (Activities of Daily Living) decline in dementia? 
 
The purpose of this question is to prove that centrally acting ACE-Is 
may reduce the rate of functional decline in dementia. There is growing 
evidence shows that, impaired activities of daily living (ADL) affect 
functional independence and patient quality of life (Liu et al., 1991). 
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Hypertension may increase the risk of decline in IADLs (Instrumental 
ADL score) (Caskie et al., 2010) in patients with dementia (Stuck et al., 
1999). Data from recent observational studies suggests that 
beta-blockers (Rosenberg et al., 2008a) may slow functional decline in 
patients with AD. However, few studies have investigated whether 
ACE-Is affect ADLs.  
 
ACE-Is may slow functional decline by improving endothelial function, 
increasing muscle blood flow and reducing inflammation and glucose 
delivery to cardiac and skeletal muscle (Onder et al., 2002). Available 
evidence suggests that ACE-Is are associated with lower falls risk 
(Sumukadas et al., 2007, Wong et al., 2013), increase muscle strength 
(Sumukadas et al., 2007) and improve exercise tolerance (Sumukadas et 
al., 2007), in older adults with normal cognition. However, other 
observational studies suggest that exposure to ACE-Is is associated with 
increased dependency in ADLs (Sink et al., 2009), and studies 
investigating ACE genotypes, some of which might mimic or have 
comparable biological ACE activity to ACE-Is, had conflicting results 
on functional decline in older adults, with both increased (Seripa et al., 
2011) and decreased disability (Kritchevsky et al., 2005) observed. 
Given this, we compared the rates of decline in patients with 
Alzheimer’s disease (AD) receiving CACE-Is to those not currently 
treated with CACE-Is (NoCACE-I), in patients with mild to moderate 
AD, from the DARAD database. There were 406 patients in total, with 
mild to moderate AD in the DARAD database. All patients were aged 50 
years or more. They were subdivided into a CACE-I group (patients 
currently prescribed centrally acting ACE-Is), and a NoCACE-I group 
not currently receiving CACE-Is, irrespective of BP readings, diagnosis 
of hypertension or receipt of other anti-hypertensives. The average 
12-month rate of change in outcomes, measured as the difference 
between baseline and 12-month scores, were compared between patients 
receiving CACE-Is and the NoCACE-I group. 
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While few research studies have investigated if CACE-Is differentially 
affect IADLs or BADLs. Another study was undertaken to compare the 
rates of IADLs and BADLs decline, in older adults with established 
dementia, taking CACE-Is (CACE-I) and perindopril in particular, to 
those not currently prescribed CACE-Is (NoCACE-I). The CACE-I 
group were divided into two sub-groups: Perindopril and an ‘other 
CACE-I’ groups. Data in this study were pooled from the GAT and 
DARAD databases. The outcome measures analysed in this study were 
the SMMSE, Qmci and a shortened version of the Lawton-Brody ADL 
scale. Similar to the previous study, only patients with AD, vascular or 
mixed AD-vascular dementia, aged 50 years or more, were included. We 
compared differences in the rate of change in Qmci, SMMSE and ADL 
scores, from baseline (the time point when cognitive scores were first 
available) to end-point (the time point when cognitive scores were last 
available), between CACE-I, perindopril, other CACE-I and NoCACE-I 
groups. 
 
The findings in these two studies showed that, there was a significant 
reduction in the rate of decline in total ADL scores in patients taking 
CACE-Is, compared to those who were not (NoCACE-I group). 
CACE-Is may have more beneficial effects on IADLs (Gao et al.). 
Patients taking perindopril had a significant reduction in their rate of 
decline in BADL scores compared to the NoCACE-I and other CACE-I 
groups. The results suggest that perindopril may be superior to other 
CACE-Is, with a relatively larger difference in median rates of 
functional decline over six months, compared to those not currently 
receiving CACE-Is.  
 
1.4 Legitimisation of the Research Work 
There were seven studies comprising this research study, five were 
published, and two were still in preparation. All of the studies were 
published in peer reviewed medical journals. Some of the studies, such as 
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“CACE study in GAT database”, were published in a journal, and were also 
presented at a conference. Table 1.2 lists the studies, including their 
publications, current status for each publication, and the chapters in this 
thesis where they feature.  
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Table 1. 2 Publications Associated with this Research Study 
Study names Publication Reference Status Publication 
Output 
Impact Factor 
(year) 
Thesis Sections 
(O'Caoimh et al., 2012a) published Age and Ageing 3.816 (2012) Chapter Four: Qmci Qmci vs SMMSE 
(O'Caoimh et al., 2012b) published Irish Journal of 
Medical Science 
0.506 (2012) Chapter Four: Qmci 
Qmci subtests (O'Caoimh et al., 2013a) published Age and Ageing 3.816 (2012) Chapter Four: Qmci 
Qmci vs SADAS (O'Caoimh et al., 2013b) published Journal of Clinical 
Epidemiology 
5.332 (2012) Chapter Four: Qmci 
(Gao et al., 2013a) published BMJ Open 1.583 (2013) Chapter Five: Drug analysis Study One: 
CACE study in GAT database 
(Gao et al., 2013b) published 
Irish Gerontological 
Society meeting 
2013 
N/A Chapter Five: Drug analysis 
Study Two: 
CACE study in DARAD database 
(O'Caoimh et al., 2014) published 
Journal of 
Alzheimer's 
Disease 
4.17 (2012) Chapter Five: Drug analysis 
Qmci cut offs (O'Caoimh et al.) In preparation JAMA 29.978 (2012) Chapter Four: Qmci 
Study Three: 
CACE study in GAT and DARAD 
databases combined 
(Gao et al.) In preparation   Chapter Five: Drug analysis 
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The Qmci vs SMMSE study compares the sensitivity and specificity of the 
Qmci with the Standardised Mini-Mental State Examination (SMMSE) and 
ABCS 135 (AB Cognitive screen 135), in their ability to differentiate NC, 
MCI and dementia. The objective was to prove that, the Qmci is more 
sensitive than the SMMSE in differentiating MCI and NC, making it a 
useful test, for MCI in clinical practice, especially for older adults. The 
Qmci subtests study compares the sensitivity and specificity of the subtests 
of the Qmci to determine which best discriminated between NC, MCI and 
dementia. The aim was to determine the contribution each subtest of the 
Qmci makes, to its sensitivity and specificity, in differentiating MCI from 
NC and dementia, to refine and shorten the instrument. The Qmci vs SADAS 
study compared the Qmci screening test with the SADAS-cog (Standardised 
Alzheimer’s Disease Assessment Scale-cognitive subscale) as outcome 
measures in clinical trials. The Qmci correlated strongly and significantly 
with the SADAS-cog. The results suggest that clinicians and investigators 
can substitute the shorter Qmci for the SADAS-cog. The Qmci cut offs study 
defined Qmci cut-off scores for patients with symptomatic memory loss, and 
determines the extent to which these require adjustment for age and 
education. 
 
The CACE study in GAT database study compared the rates of cognitive 
decline in clinic patients with dementia receiving CACE-Is (CACE-I) with 
those not currently treated with CACE-Is (NoCACE-I), and with those who 
started CACE-Is, during their first six months of treatment (NewCACE-I). 
Data was extracted from the GAT (Geriatric Assessment Tool) database. 
The results suggest cognitive scores may improve in the first six months 
after CACE-I treatment, and use of CACE-Is is associated with a reduced 
rate of cognitive decline in patients with dementia. 
 
The CACE study in DARAD database study compared rates of decline in 
patients with Alzheimer’s disease (AD) receiving CACE-Is to NoCACE-I 
patients. The data were from the DARAD (Doxycycline and Rifampicin for 
Alzheimer’s Disease) database. The findings found that CACE-Is, and 
perindopril in particular, are associated with a reduced rate of functional 
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decline in patients with AD, without associated changes in behaviour. The 
CACE study in GAT and DARAD databases combined study compared rates 
of cognitive and functional decline in patients with dementia receiving 
CACE-Is to NoCACE-I, using a combination of two research databases, 
namely the GAT and DARAD databases. This study found that CACE-Is are 
associated with a small but significant reduction in the rate of decline in 
ADLs, particularly instrumental ADLs, in dementia patients. 
 
1.5 Overview of the Chapters 
Chapter Two provides background by reviewing the prevalence and costs of 
dementia in geriatrics for treatment and health care. It introduces and 
defines dementia, specifically Alzheimer’s Disease (AD), Vascular, mixed 
dementia and MCI (Mild Cognitive Impairment). The chapter concludes 
with an illustration of the treatment for different types of dementia, 
including the symptomatic pharmacological and non-pharmacological 
treatments.  
 
Chapter Three conveys a better understanding of the research methodology 
for this research. It introduces Knowledge Discovery in Databases (KDD), 
statistics and data mining with regard to the associated technologies and 
relevant processes. This chapter illustrates the position of data analysis 
within the KDD process, and includes the innovation of knowledge 
discovery, KDD definition and process, and KDD application areas. 
Statistics and data mining technologies, which are the core step of the KDD 
process (data analysis), are introduced in this chapter. Three databases were 
used in this research: GAT, DARAD and Qmci validation databases. The 
key instruments in these databases are introduced as outcome measures. The 
last part of the chapter presents a comprehensive overview of the analytical 
methods, including how to conduct medical research which requires the use 
of data analysis (e.g. statistics) throughout the research process, and 
introduces the statistical methods used in this research across the various 
studies. 
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Chapter Four introduces the Quick Mild Cognitive Impairment Screen Test 
(Qmci), as one of the key outcome measures for the research. Firstly, it 
introduces the existing cognitive screening instruments. As a new rapid 
cognitive screening test, Qmci is more sensitive in differentiating NC from 
dementia, and more importantly, MCI from dementia than the SMMSE and 
Montreal Cognitive Assessment (MoCA). It is also correlated strongly with 
the SADAS-cog and both were equally responsive to deterioration. This 
chapter also discusses which subtests of Qmci discriminate best between 
normal, MCI and dementia. Finally, this chapter defines the Qmci cut off 
scores, and the cut off scores extent to which these require adjustment for 
age and education. The analysis demonstrating the scientific validity and 
utility of the Qmci is based on the KDD (Knowledge Discovery in 
Databases) process, and assessed by different statistical methods. 
 
Chapter Five reviews the effects of centrally acting Angiotension 
Converting Enzyme Inhibitors (CACE-Is) on the rate of cognitive and ADL 
decline in patients with dementia. Data from two large geriatric medicine 
clinic databases (GAT and DARAD), were pooled together for the more 
robust outcomes. At first, this chapter discusses the association between 
anti-hypertensive agents, especially CACE-Is, and dementia (on cognition 
and function). Three studies were applied to compare the rates of cognitive 
and functional decline in clinic patients with dementia, receiving CACE-Is 
(CACE-I), to those not currently treated with CACE-Is (NoCACE-I). The 
first study (Study One) compares rates of cognitive decline in clinic patients 
with dementia, receiving CACE-Is (CACE-I group), to patients not 
prescribed CACE-Is (NoCACE-I group). The second study (Study Two) 
compares rates of functional and neuropsychological (depression and 
behaviour) decline in dementia, between CACE-I group and NoCACE-I 
group. The third study (Study Three) combines the two databases together. It 
looks at the effects of CACE-Is, especially perindopril, on the rates of basic 
ADLs (Activities Daily Living scores) and instrumental ADLs decline, in 
dementia. 
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Chapter Six summarises all the results and findings of the research. The 
chapter provides a brief overview of the studies, including published work 
based on the results of this research. Then the databases and outcome 
measures used in this research are presented. Contributions to practice and 
theory from the research work are discussed, with potential benefits of the 
studies. Finally, it concludes with recommendations for future work.  
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CHAPTER 2 BACKGROUND 
 
2.1 Introduction 
This chapter discusses the natural history of cognitive impairment (CI), 
including age associated memory loss, mild cognitive impairment (MCI), 
dementia and its subtypes. The prevalence, diagnosis, prognosis, treatment 
and impact, particularly the current use of anti-hypertensives in the 
prevention and management of disease progression are discussed.  
 
Dementia is a term for the loss in mental ability that is severe enough to 
interfere with the person’s ability to perform his/her activities of daily living 
(ADL). It affects a wide range of cognitive functions, including memory, 
attention, language, and problem solving. Dementia normally occurs in 
people aged over 60 and has a 5% - 7% prevalence of case in society in 
most world regions (Prince et al., 2013). As populations age worldwide, the 
prevalence of dementia will increase. Dementia is however, not a single 
disease, but a syndrome that includes many different subtypes, each with 
distinct signs and symptoms. Symptoms are generally present for at least six 
month before a diagnosis can be made4. To date, no agents have been 
developed that prevent, modify or reverse dementia, and available 
treatments for dementia are predominantly symptomatic.  
 
2.2 Prevalence of Dementia  
In both the developed and developing world, populations are ageing. A 
report from the Department of Economic and Social Affairs in the United 
Nations in 2002 stated that, population ageing is an “unprecedented” 
situation, in the history of humanity5. In most European and North American 
societies, population aging is occurring because of three demographic  
                                                        
4 http://www.mdguidelines.com/%20dementia/definition 
5 http://www.un.org/esa/population/publications/worldageing19502050/ 
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trends — a change from high fertility, high mortality rates in Phase One of 
agricultural societies, to relatively high fertility but low mortality rates in 
Phase Two of industrialised societies, to the final stage of low fertility and 
low mortality rates of the post-industrial era (Moody, 2006, Chu, 1997, 
Zhan, 2013). There is also an increase in dependency ratios, with a smaller 
percentage of workers supporting a greater number of people in retirement. 
It will in addition, directly impact upon economic growth. This demographic 
trend is accelerating since the middle of the last century (Uhlenberg, 2013).  
 
By 2050, the number of people aged 60 and above will rise to 1.25 billion, 
and will account for 22 percent of the total world population (Prince et al., 
2013). This rise will cause an increase in the prevalence on dementia. The 
rising numbers have prompted governments to start specific strategies to 
handle the crisis. The probability of developing dementia doubles every five 
years after the age of 60, such that those over 60 have a prevalence of 
between five and eight percent. As age is the greatest risk factor for 
dementia, the prevalence of dementia increases to between 18 to 30 percent 
among those aged over 80 (depending on the geographical region). In 
people aged over 85 years or older, the prevalence on dementia increases to 
about 30% (Salloway et al., 2008). Combining this demographic shift with 
the increasing prevalence of dementia, means that the number of people 
with dementia will double every twenty years (Prince et al., 2013). 
 
Dementia is a general term, to describe any progressive neurodegenerative 
condition that results in loss of cognitive and functional ability, and in the 
end causes a loss of independence (Korczyn et al., 2012). The disease not 
only affects patients and their loved ones, but also impacts upon society and 
governments.  
 
In Canada, where the data analysed as part of this work originated, similar 
demographic trends are evident. In 2011, 747,000 Canadians had cognitive 
impairment, representing 14.9 percent of Canadians aged 65 and above. By 
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2031 that number is expected to reach 1.4 million people6. In the United 
States of America, 4.7 million individuals over 65 years had AD dementia in 
2010; the number with dementia is expected to increase to 13.8 million by 
2050 (Hebert et al., 2013a). 
 
2.3 Cost of Dementia 
One of the problems associated with the increased prevalence of dementia is 
the growing associated economic cost. This financial burden takes a toll on 
governments and families. It is difficult to accurately estimate the cost of 
dementia. Dementia seldom comes alone, but is often associated with other 
diseases. Family provide up to 80% of care, a phenomenon called 
“informal” care. There is little accurate data on the extent of informal care 
provided or the direct and indirect costs of such care (e.g. loss of work due 
to caring duties) (Hurd et al., 2013). The total estimated worldwide costs of 
dementia were 422 billion dollars in 2009, an increase of 34 percent from 
2005, a figure equivalent to one percent of the global gross domestic 
product. The greatest increase in costs were found in developing countries 
(Wimo et al., 2010). A recent study from the USA found that annual costs 
attributed exclusively to dementia were estimated at between 41,000 to 
56,000 dollars per case. The biggest portion of these costs (75 to 84 percent) 
can be attributed to nursing care, followed by the cost of medical treatment. 
The cost of dementia care is one of the biggest contributions to societal 
financial burden (109 billion annually in the US) and dementia costs were 
significantly higher than the direct societal costs of other conditions 
including cancer (77 billion) and heart disease (102 billion) (Hurd et al., 
2013). 
 
                                                        
6 
http://www.alzheimer.ca/en/niagara/Get-involved/Raise-your-voice/A-new-way-of-looking-at-dement
ia 
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2.4 Dementia, AD, Vascular, Mixed Dementia and MCI 
The onset of dementia is slow and usually takes several years (depending on 
the type of dementia) before it is recognised and/or diagnosed. In the early 
stages, it often goes unrecognised as there is enormous variation in 
presentation and the first signs are subtle. Furthermore, the first warning 
signs (e.g. forgetfulness, change in personality, misplacing things) are often 
wrongly associated with other factors (e.g. stress or age) and not every 
doctor is trained to detect these important warning signs (Gauthier et al., 
2006).  
 
Figure 2. 1 Natural History of Cognitive Decline 
 
Figure 2.1 demonstrates the natural history of cognitive decline. The first 
stage occurs as people are getting older, and is associated with normal age 
appropriate memory loss (Christensen, 2001). As we age, neuronal cell loss 
develops. This is “Age Associated Memory Impairment” (AAMI) (Crook et 
al., 1986, O'Brien and Levy, 1992). The next stage is Mild Cognitive 
Impairment (MCI), a common condition that has been recognised as a 
prodrome to dementia (Morris et al., 2001).  
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2.4.1 Mild Cognitive Impairment (MCI) 
MCI is regarded as a precursor of dementia, and is defined as the presence 
of greater cognitive decline than would be expected for an individual at a 
particular age, with an educational level. People with MCI continue to 
function independently and by definition have no functional impairment. 
People with dementia differ in that they usually have more significant 
cognitive deficits and present with impairment in activities of daily 
functioning (Gauthier et al., 2006). The chance of developing Alzheimer’s 
disease (AD), the most common dementia subtype, after a diagnosis of MCI, 
is 11-33% over the next two years (Ritchie, 2004). Using the same clinical 
criteria and taking into account the medical history of memory loss, the 
progression rate can rise from 41% after one year to 64% after two years 
(Geslani et al., 2005). Thus, on average, 10-12 % of patients with MCI 
convert to dementia each year (Bowen et al., 1997, Tierney et al., 1996a, 
Tierney et al., 1996b). If followed over a prolonged period of time, almost 
all will develop dementia within eight years of diagnosis (Morris et al., 
2001).  
 
To diagnose patients correctly with MCI, it is necessary to distinguish 
between normal aging and dementia. As MCI progresses, the risk of getting 
a prompt diagnosis of dementia provides an opportunity to initiate treatment 
early. People with MCI typically complain of memory loss, but have 
relatively normal general cognitive function. They maintain independence in 
instrumental activities of daily living (IADL), e.g. cooking, finances, and 
driving, and some can still function in their occupational activities. Typically, 
a history of memory loss for persons with MCI is corroborated by family 
members (Molloy et al., 2005). If MCI can be reliably diagnosed, it may be 
possible to start interventions that could prevent progression and conversion 
to dementia. Short and simple clinical screening tools to differentiate MCI 
from normal cognition and (or) early dementia, facilitate diagnosis (Molloy 
et al., 2005). A number of these have been developed and are discussed in 
detail below. 
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2.4.2 Types of Dementia 
Dementia can broadly be divided into two different types; cortical and 
sub-cortical dementia. Cortical dementia only affects the outer layers of the 
cortex. The most common types are AD and Creutzfeld-Jacob Dementia7. 
The symptoms generally include short-term memory loss, difficulty with 
word recall and understanding the meaning of words (aphasia). Subcortical 
dementia, on the other hand, affects the structures below the cortex. 
Examples include Parkinson’s disease dementia (PDD) and vascular 
dementia (VaD). Symptoms are different to the cortical dementias, with 
early personality change and slowing in executive and motor function, while 
language and memory are relatively well preserved in the initial stages. 
Figure 2.2 shows the distribution of the different types of dementia. A 
description of the three most common forms and those included in the 
analysis: AD, VaD and mixed (AD-VaD) dementia, is provided below.  
 
Figure 2. 2 Types of Dementia  
 
 
 
 
                                                        
7 http://alzheimers.about.com/od/typesofdementia/a/cortical_sub.htm 
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2.4.2.1 Alzheimer’s Disease (AD) 
The most common form of dementia is AD, accounting for up to 50 percent 
of all dementia cases (Prince et al., 2013). AD is a cortical dementia, 
characterised by degeneration of brain tissue and a progressive loss of 
mental functions8.  
 
Symptoms of the disease progress to a point where the patient is totally 
dependent on the care of others. In the early stages, people find it more 
difficult to remember certain words and to think abstractly. Insomnia, not 
being able to sleep, and a change in the normal behaviour are also often 
early signs. As the disease progresses, it becomes difficult to remember 
recent events (short term memory loss). Normal day-to-day activities are 
increasingly difficult and require help from others. About half of patients 
develop a psychosis, paranoia, delusions and/or hallucinations at some point 
during the condition. By the end-stage of AD, patients usually cannot walk, 
eat or talk anymore and need full-time care. Once this stage is reached, most 
people die within some months9. The exact progression is unpredictable and 
there is a wide variation in the course of the disease, with an average 
duration of six to twelve years (Brodaty et al., 2012). The disease is 
typically diagnosed by a physician, who assesses the symptoms, described 
by the patient and his/her caregivers, performs a physical examination and 
cognitive testing with short screening tests such as the Standardised 
Mini-Mental State Examination (SMMSE). Usually Computerised 
Tomography (CT) or Magnetic Resonance Imaging (MRI) scans and blood 
tests are performed to support the clinical diagnosis and rule out an 
alternative cause. A definite diagnosis of dementia can only be confirmed 
after death, with an analysis of brain tissue. 
 
 
 
                                                        
8 http://alzheimers.about.com/od/typesofdementia/a/cortical_sub.htm 
9 
http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/delirium_and_dementi
a/dementia.html 
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2.4.2.2 Vascular Dementia (VaD) 
VaD is the second most common form of dementia (Prince et al., 2013), and 
frequently co-exists with AD. This condition is called mixed dementia. 
Patients with VaD have neuronal degeneration caused by progressive 
ischaemic secondary to a reduced or blocked cerebral blood supply. A series 
of strokes, large or small, can cause VaD. As small, micro thromboembolic 
strokes are not always clinically evident, VaD can develop silently (Korczyn 
et al., 2012). Unlike AD, where the progression is gradual, VaD can worsen 
suddenly or remain stable for a long time. The symptoms of VaD are similar 
to AD, but generally it does not affect speech and memory to the same 
extent. It is characterised by a change of personality and a slowing of 
thought processes. The symptoms vary depending on where the stroke 
occurred in the brain, and can lead to comorbid symptoms, including loss of 
vision, paralysis of arms or legs and/or depression10. Due to a higher 
comorbidity profile, patients with VaD may have more rapid progression 
with a lower mean survival time, five years compared to seven years for AD 
(Korczyn et al., 2012). The diagnosis of VaD is made in those with 
symptoms of dementia, with prominent cardiovascular risk factors and the 
presence of stroke or stroke like symptoms. While cerebral ischeamic 
changes, ranging from small vessel disease to large vessel territory strokes, 
can be seen on CT or MRI, the diagnosis is never definitive during life.  
 
2.4.2.3 Mixed Dementia 
When the symptoms signs and pathology of both VaD and AD occur 
together this is referred to as “mixed” dementia. A definite diagnosis of 
mixed dementia is difficult due, on the one hand, to unclear diagnostic 
criteria for the disease and, on the other hand, a need to do a post mortem 
examination. The fact that an autopsy is necessary to confirm the diagnosis, 
makes it hard to estimate the exact prevalence and incidence. Mixed 
dementia is much more common than was previously realised, as autopsy 
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studies have shown a prevalence, as high as 54% of cases, suffering from 
dementia (Langa et al., 2004). As with VaD, it might be possible to prevent 
the disease by diminishing the vascular risk factors and preventing strokes. 
Current treatment for mixed dementia uses the same drug therapy as AD, 
including memantine and cholinesterase inhibitors (donepezil, galantamine 
and rivastigmine)11. 
 
2.4.3 Who is at Risk from Dementia 
Table 2. 1 Risk Factors for Vascular Dementia and Alzheimer’s Disease 
(after: Korczyn et al., 2012) 
Risk factors for both VaD and AD Risk factors for AD 
Age Female gender 
Midlife diabetes mellitus   
Midlife hypertension   
Coronary artery disease  
Midlife hypercholesterolaemia Apolipoprotein E status 
High dietary saturated fat and cholesterol Head trauma 
Hyperhomocysteinaemia   
Obesity   
Metabolic syndrome   
Arteriosclerosis   
Smoking   
Poor education  
 
Table 2.1 shows the risk factors that contribute to dementia. There is 
overlap between the risk factors of VaD and AD. In recent years, there is 
growing recognition that VaD and AD may not be two separate entitles, but 
share a lot of disease pathology (Korczyn et al., 2012). 
 
                                                        
11 
http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/delirium_and_dementi
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In general, age remains the strongest risk factor for dementia. Most cases of 
AD are seen in older adults, ages 65 years or above. Between the ages of 65 
and 74, approximately 5% of people have AD. For those over 85, the risk 
increases to 30-50%. While the onset usually starts after 65 years, there are 
rare cases of early-onset AD, starting as early as 30, that account for about 
5% of all AD cases. The exact cause of sporadic AD is unclear, while young 
onset AD is usually familial (Finckh et al., 2000). 
 
There may be a connection between educational level and the risk of 
developing AD. People with fewer years of education seem to be at higher 
risk (Association, 2010). The exact cause for this relationship is unknown, 
but it is theorised that a higher education level leads to the formation of 
more synaptic connections in the brain. This creates a “synaptic reserve” in 
the brain, enabling patients to compensate for the loss of neurons as the 
disease progresses.  
 
There are also several modifiable risk factors for dementia. Type two 
diabetes mellitus, in midlife, and the presence of strokes have been found to 
increase the chance of AD and VaD (Patterson et al., 2007). Higher levels of 
cholesterol during midlife also increases the risk of AD and VaD (Patterson 
et al., 2007), as well as coronary artery disease (arteriosclerosis) (Korczyn et 
al., 2012). When it comes to lifestyle and diet, drinking moderate amounts 
of red wine and eating fish and seafood both are preventive, while a diet full 
of saturated fats can increase the chance of developing dementia (Patterson 
et al., 2007). Physical activity, especially during later stages of the life helps 
delay/prevent AD, possibly because it lowers the rate of obesity, which is a 
risk factor in itself (Cheng et al., 2013). Spending a longer time in formal 
education (more than 15 years compared to 12 years) decreases the chance 
for VaD and AD (Patterson et al., 2007). Smoking may increase the chance 
of dementia, even though this is debated in the literature (Patterson et al., 
2007).  
 
Looking exclusively at AD, females are at a greater risk of developing the 
disease such that over a lifetime 16% of women will develop AD compared 
 28 
to only six percent of men of the same age. The presence of apolipoprotein 
(APO) E2 gene protects against the development of AD, while APOE4 
increase the chance of dementia (Launer et al., 1999). Head trauma also 
contributes to the development of AD, especially in the presence of the 
APOE4 gene (Patterson et al., 2007). 
 
2.5  Treatment of Dementia 
Treatment of dementia can broadly be divided into pharmacological and 
non-pharmacological management. 
 
2.5.1 Pharmacological 
2.5.1.1 Drugs for Symptomatic Control 
Medications in the treatment of dementia can be divided into two groups, 
one targeting disease progression, the other targeting symptoms12.  
 
Cholinesterase inhibitors and N-Methyl D-Aspartamate receptor (NMDA) 
antagonists are the two most widely used medications that target the 
symptoms of dementia. The currently available cholinesterase inhibitors are 
donepezil, galantamine and rivastigmine. These drugs increase the level of 
the neurotransmitter acetylcholine in the brain. The effectiveness of the 
drugs varies between patients, with up to one-third of patients having no 
benefit. In addition, side-effects are common, including nausea, weight loss 
and worsening confusion. NMDA-antagonists, like memantine are used in 
later stages of the disease and can be used in combination with the 
cholinesterase inhibitors (Qaseem et al., 2008).  
 
Antipsychotic drugs (like haloperidol, aripiprazole, risperidone or 
quetiapine) are used to manage the behavioural and psychological 
symptoms of dementia (BPSD) such as agitation, delusions, hallucinations 
                                                        
12 
http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/delirium_and_dementi
a/dementia.html 
 29 
and aggression, especially in the later stages of the disease. These however, 
increase stoke risk and should be used with caution (Douglas and Smeeth, 
2008). Anticonvulsants (like gabapentin or carbamazepine) may also be 
used as mood stabilisers. Their effectiveness however is unclear and 
individual non-pharmacological treatments should be used first (Qaseem et 
al., 2008).  
 
Dietary supplements, such as vitamin B12 pills, lecithin or ginkgo biloba 
extracts have been tried extensively in previous years, but have little value 
in treating dementia13.  
 
2.5.1.2 Disease Modifying Drugs 
The fact that Alzheimer’s takes so long to develop suggests that, it may be 
possible to design drugs that work early in the disease process, to delay 
symptom onset and disability14. For that reason, researchers have been 
testing a number of “disease-modifying” drugs that target the earliest 
biological changes in Alzheimer’s. However, to date, there is no cure for 
dementia and few disease modifying drug treatments have been developed 
to manage dementia patients.  
 
Studies have revealed that the two hallmark brain lesions in Alzheimer’s — 
amyloid deposits and intracellular neurofibrillary tangles (NFTs) — appear 
decades before telltale clinical symptoms such as memory impairment. The 
production of Aβ, which is a crucial step in AD pathogenesis, is the result of 
cleavage of APP (Griffin, 2006). Aβ forms highly insoluble and 
proteolysis-resistant fibrils known as senile plaques. NFTs are composed of 
the tau protein (Galimberti and Scarpini, 2011). Tau is relatively abundant in 
neurons, but is present in all nucleated cells and functions physiologically to 
bind microtubules and stabilise microtubule assembly for polymerisation. 
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The disease-modifying drugs, in development, target much earlier biological 
abnormalities, especially the sequence of events that contribute to the 
development of amyloid plaques. Plaque formation begins when a brain 
protein, amyloid precursor protein (APP), is broken down into peptides by 
various enzymes, known as secretases. The plaques consist of several forms 
of beta-amyloid peptides, some relatively benign, others more toxic. 
 
Usually the most toxic beta-amyloid peptide, Aβ42, makes up less than 5% 
of beta-amyloid load in the brain. However, a combination of genetic and 
environmental factors may tip the balance toward greater Aβ42 production. 
According to a leading theory about Alzheimer’s (Wang et al., 2012), these 
sets of biological events will lead to buildup of toxic beta-amyloid plaque 
around neurons, which effect memory and cognition. 
 
The disease-modifying drugs in development work in different ways, but all 
seek either to decrease production of toxic beta-amyloid peptides or to 
prevent them from accumulating in the brain. The ultimate aim is to find 
whether — by blocking plaque — these drugs can delay cognitive or 
functional decline in people with Alzheimer’s. 
 
The treatment of a dementia depends on the type of dementia the patient has. 
For example, a patient with vascular dementia will be treated to control 
cerebrovascular risk factors, such as high blood pressure and elevated 
cholesterol levels. Alzheimer’s disease, the most common form of dementia, 
can be treated using drugs like acetylcholinesterase inhibitors that increase 
acetylcholine. There are four main acetylcholinesterase inhibitors on the 
market – donepezil (Aricept), galantamine (Razadyne), rivastigmine 
(Exelon), and tacrine (Cognex) (Farlow, 2002). These drugs are used for AD 
and mixed dementias. Donepezil is now also approved for severe AD. 
Tacrine was the first drug approved for AD in 1993, but it is rarely used, due 
to hepatotoxicity (Galimberti and Scarpini, 2011). However, those drugs 
only slightly alleviate symptoms, and do nothing significant to prevent 
 31 
disease progression15.  
 
 A fifth drug used for treating Alzheimer’s disease (usually in moderate to 
severe stages) is Memantine.  Memantine is different than the other group 
of drugs. It works by blocking glutamate, which is produced in excessive 
amounts in brain cells damaged by Alzheimer’s disease. Memantine can be 
used with acetylcholinesterase inhibitors, although the research evidence is 
not convincing about the efficacy of this treatment with some studies yet, 
showing positive side effects while others contradict these findings 
(Reisberg et al., 2003). 
 
2.5.1.2.1 Drugs Interfering with Aβ Deposition 
 Gamma-secretase Inhibitors  
LY450139 is a Gamma-secretase inhibitor for the treatment of Alzheimer's 
disease (Henley et al., 2009). However, LY450139 and other nonselective 
agents may cause serious side effects that would counterbalance any benefit 
for people with Alzheimer’s (Bergmans and De Strooper, 2010). Some 
researchers believe that more selective gamma-secretase inhibitors, in early 
development, may prove to be better options as disease modifiers (Van Dam 
and De Deyn, 2006). Selective Aβ42-lowering agents specifically lower 
Aβ42 levels in the brain. The first drug in this class to reach late-stage 
testing is tarenflurbil (Flurizan). The drug modulates gamma-secretase 
activity by shifting production away from Aβ42, without interfering with 
other proteins. 
 
 Anti-aggregation Agent 
The most studied anti-amyloid aggregation agent is 
tramiprosate (AlzhemedTM, Neurochem Inc.) (Wright, 2006). Tramiprosate 
(Alzhemed) prevents Aβ42 peptides from sticking together (one theory 
being that this is the stage at which they become particularly toxic). 
Although a phase II study generated optimism, researchers announced at the 
Alzheimer’s Association International Conference on Prevention of 
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Dementia in June 2007 (Sullivan, 2007), that results of a phase III study 
were hard to interpret. At the time of writing this thesis, nothing has been 
published about it yet. 
 
 Vaccines 
A few safer Alzheimer’s vaccines are under development. One agent, 
bapineuzumab, a monoclonal antibody, targets and clears beta-amyloid. In 
Europe, 30 participants are also undergoing brain scans to determine 
whether the drug is clearing amyloid plaque deposits16. A phase III study has 
not yet started. Another passive immunisation agent, intravenous 
immunoglobulin, is in phase II trials for Alzheimer’s. Because this 
substance is already FDA-approved to treat people with immune 
deficiencies, its safety profile is well known. Whether it will be effective as 
a disease modifying agent in Alzheimer’s, remains to be seen. Researchers 
are hopeful, however, because intravenous immunoglobulin has both 
anti-amyloid and anti-inflammatory properties, that may be helpful in 
Alzheimer’s. 
 
2.5.1.2.2 Drugs Interfering with Tau Deposition 
By 2050 there will be 600 million people with significant tau pathology but 
not all with AD (Woodward, 2012). Anti-tau therapy could have widespread 
application for those affected, including people with AD, some 
frontotemporal lobar degenerations and mild cognitive impairment (Gong et 
al., 2010). Tau immunotherapy has not progressed beyond animal models, 
but it appears promising and human trials are starting. A tau-blocking 
compound, named methylthioninium chloride (MTC), is being tested 
(TauRx Therapeutics, RemberTM). MTC interferes with tau aggregation by 
acting on self-aggregating truncated tau fragments (Wischik et al., 1996). A 
phase III trial was planned, but the reformulation needs to be studied further. 
 
Several phosphorylation inhibitors, as well as drugs that dephosphorylate 
tau, have been developed. None have undergone extensive human testing. 
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Lithium and memantine affect tau phosphorylation, but have not yet shown 
convincing disease-modifying effects. Metformin induces tau phosphatase 
2A activity, but has not been trialed as a specific dementia therapy 
(Woodward, 2012). 
 
2.5.2 Non-pharmacological Treatment 
Since drug treatments have not proved particularly beneficial and carry the 
risk of side effects, non-pharmacological treatments are an important 
adjunct. Exercise can improve quality of life, although the effectiveness of 
this intervention is not yet proven. Review papers show mixed results with 
little consistent evidence for or against particular intervention strategies 
(Kurz, 2013, O'Neil et al., 2011). The problem is that most studies are 
poorly designed, with small sample sizes or no control groups, making it 
difficult to determine if the success of the intervention is because of a 
increased attention on the patient. The research interventions are also 
usually individually-designed, making it hard to compare the effects 
universally and create practical guidelines (Kurz, 2013).  
 
Interventions can be divided into five main categories:  
 treatments to enhance cognitive performance,  
 to enhance well-being,  
 to improve behavioural symptoms,  
 to improve activities of daily living  
 give support to patients (Kurz, 2013).  
There is increased evidence for greater effectiveness when combining two 
or more interventions together (Karp et al., 2006). Focusing on cognitive 
performance, there is evidence for a slower rate of decline and a decreased 
risk of dementia when elderly patients do cognitive exercises on a regular 
basis (Cheng et al., 2013). The most effective treatments to improve the well 
being of patients with dementia seem to be activity-therapy and 
reminiscence-therapy. Activity-therapy methods stimulating activities in 
their every day life, include activities such as baking, going for walks or 
going shopping etc (Kurz, 2013). Reminiscence therapy includes activities 
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specifically talking about events from the past or listening to music that may 
trigger memories, or writing a biography.  
 
For the management of the BPSD there is evidence that stimulation-oriented 
approaches (e.g. massage therapy, aroma therapy and light therapy) are 
more beneficial than emotional approaches (e.g. animal therapy and 
stimulated care). Exercise therapy, in itself, has not been evaluated in 
clinical trials; however there is evidence that regular exercise increases 
sleeping time and decrease the risk of falls (O'Neil et al., 2011). It increases 
the quality of life for patients with dementia and provides opportunities for 
caregivers and their families to receive training on how to deal with the 
demands of caring for a family member with dementia (Kurz, 2013). In 
summary, it can be concluded that there are some benefit to 
non-pharmacological treatments, although a greater evidence base needs to 
be established.  
 
2.6 Summary 
This chapter describes the background of dementia and its early stage (MCI), 
including the prevalence, risk factors, costs and treatment. Dementia is not a 
single disease, but instead a group of diseases or, in some cases, injury, that 
can cause a change in a person’s intellect, thinking skills, such as memory or 
language, personality or social behaviour. People will often equate dementia 
with Alzheimer’s Disease, but Alzheimer’s is just one type of dementia. The 
onset and course of dementia is dependent upon the type of disease causing 
the symptoms. Some dementias are progressive and primarily managed by 
changes the environment; others can be medically treated and reversed.  
 
Patients with dementia use more healthcare services and typically require 
more expensive care. Using AD as an example, AD progresses gradually 
and can last for decades. There are three main stages of the disease, each 
with its own challenges and symptoms. By identifying the current stage of 
the disease, physicians can predict what symptoms can be expected in the 
future and possible courses of treatment. Each case of AD presents with a 
 35 
unique set of symptoms, varying in severity. 
 
For most dementias, there is no cure, but there are treatments available to 
help slow the progression of disease. Changes to the patient’s environment 
are essential in the management of depression. Maintenance of a healthy 
active lifestyle is also important. One of the main aims of this PhD research 
is to examine the effect of a specific treatment, centrally acting angiotensin 
converting enzyme inhibitors (CACE-Is) in the management of CI and on 
the rate of cognitive, functional and neuropsychological decline in patients 
with dementia. 
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CHAPTER 3 RESEARCH METHODOLOGY: CLINICAL 
DATASETS AND METHODS OF ANALYSIS 
 
3.1 Introduction 
The purpose of this chapter is to introduce the KDD (Knowledge Discovery 
in Databases) process, and data analysis techniques used in this research, 
with regard to the associated technologies and relevant processes. The first 
section describes how KDD can be used to analyse data, while further 
examining the role that data analysis plays in the KDD process. The second 
section explains the principle of data analysis, and the relationship between 
statistics and data mining. The third section describes the three geriatric 
clinical databases, including the clinical characteristics of the patients that 
populate these databases, used as the data source for this PhD research. It 
also discusses the outcome measures used to assess the rate of cognitive and 
functional decline. The last section details the data analysis techniques used 
to examine these databases. 
 
3.2 Knowledge Discovery  
3.2.1 Principles of Knowledge Discovery 
In knowledge discovery, it is important to understand the overall approach, 
before one attempts to extract useful knowledge from data (Klösgen and 
Zytkow, 2002). Simply applying any algorithms or models for data analysis 
is not sufficient for a successful project/study (Elo and Kyngäs, 2008). 
Discovering knowledge should meet the following principles: 
 The outputs must be useful for the user/owner of the data. The ultimate 
result leads to the success of a project/study. Only the application with a 
well-defined process model will at the end of a project/study be valid, 
useful, traceable, and understandable (Cios et al., 1998). 
 A well-defined knowledge discovery model should have a logical 
structure, which can be described to decision makers, in order for them 
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to understand the need and value behind information (Matheus et al., 
1993). 
 Knowledge discovery projects should include careful planning and 
scheduling, instead of directly running a model on the data, especially 
data from the real world (Peng et al., 2008).  
 
A widely used and well-known framework, called KDD (Knowledge 
Discovery in Databases) (c.f. Fayyad et al., 1996b), is often applied to 
formalise the process model. It has attracted a great deal of attention in the 
information industry, due to the need for turning large amounts of data into 
useful information and knowledge. 
 
3.2.2 KDD (Knowledge Discovery in Databases) Definition 
Today, data is being collected and accumulated at a dramatic pace, across a 
wide variety of fields, where it is stored in many different kinds of databases 
and information repositories. There is an urgent need for a new generation 
of techniques to assist people to extract useful information from these 
databases. In order to do this, it is important to follow a theoretical and 
systematic process. Knowledge Discovery in Database (KDD) refers to the 
broad multi-step process of finding knowledge in data, and emphasises the 
high-level application of particular data manipulation and data mining 
methods (Piatetsky-Shapiro, 1991). It provides scientific ways to extract 
implicit, previously unknown, and potentially useful information from raw 
data (Fayyad et al., 1996d). Knowledge discovery uses data mining, 
statistical and machine learning techniques that have evolved through a 
synergy in artificial intelligence, computer science, statistics, and other 
related fields (Mitchell, 1997). The overall goal of the KDD process is to 
extract knowledge from data in the context of large databases.  
 
One of the most popular KDD definitions is: “the nontrivial process of 
identifying valid, novel, potentially useful, and ultimately understandable 
patterns in data” (Fayyad et al., 1996a) (p. 30). It has been widely applied 
to problems across many areas, for example, health care (c.f. Abbott, 2000).  
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3.2.3 KDD Process 
The KDD process is interactive and iterative, involving numerous steps with 
many decisions made by the user. It is an evolutionary process, with its own 
lifecycle and is a means to an end, not an end in and of itself (Holmes, 
2014). Numerous tools exist for this endeavor, many coming from statistics 
and data mining. The overall KDD process (Figure 3.1) includes the 
evaluation and possible interpretation of the “mined” patterns to determine 
which patterns may be considered “new knowledge”.  
 
 
Figure 3. 1 The General KDD Process (after: Fayyad et al., 1996b) 
 
The KDD process is best understood in three phases – the process before 
data analysis, data analysis and the process after data analysis. Han et al. 
(Han and Kamber, 2001) and Tan et al. (Tan, 2007) named the phase before 
data analysis with a more generic term – Data Pre-processing. It gathers all 
the necessary preparation steps before data analysis, including Data 
Cleaning, Data Integration, Data Selection and Data Transformation. 
Similarly, they called the phase after data analysis - Data Post-processing, 
as it includes Visualisation and Pattern Evaluation. While various 
researchers use these various terms in their studies, all of the sub-steps can 
be summarised into the three main phases (see Table 3.1). 
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Table 3. 1 Various Representations of the KDD Process  
      KDD main      
phases 
References 
Data pre-processing Data analysis Data post-processing 
No. of 
Citations 
(Fayyad et al., 
1996a) 
Learning 
Application 
Data 
Selection 
and 
sampling 
Creating a 
target 
dataset 
Data 
cleaning 
Data 
reduction 
and 
transform
ation 
Choosing 
methods 
Applying 
models 
Visualisation Pattern 
Evaluation 
 5,778 
(Han and Kamber, 
2001) 
 
Data 
integration 
Concept 
generation 
Data 
Cleaning 
Data 
reduction 
Data mining Data presentation  20,676 
(Cios et al., 2007) Business 
understanding 
Data understanding Data preparation Modeling  Evaluation Deployment 9 
(Renu et al., 2013)  
Splitting 
Algorithm 
Obtain primary object 
types 
Conversion 
Algorithm 
Data mining  Evaluation  1 
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Even though there are different ways to describe the KDD process, some 
steps within a phase can be merged, based on project and requirements, for 
example, in data pre-processing, data cleaning and data reduction can both 
be forged together, and called data preparation (c.f. Cios et al., 2007). This 
merging activity illustrates the flexibility of the KDD process, but this 
discussion is outside the scope of this research. We use Fayyad’s (Fayyad et 
al., 1996a) model as an example to introduce the KDD steps. The model 
consists of nine steps, which are outlined in Table 3.2. 
 
 41 
Table 3. 2 The Phases in the Knowledge Discovery in Databases (KDD) 
Process (after: Fayyad et al., 1996a) 
Phases Steps Description 
Learning 
application  
Includes relevant prior knowledge and the goals of the application. 
Data selection and 
sampling 
Where data relevant to the analysis task are retrieved from the 
database. 
Creating a target 
dataset 
Includes selecting a dataset or focusing on a subset of variables or 
data samples on which discovery is to be performed. 
Data cleaning 
Includes basic operations, such as removing noise or outliers if 
appropriate, collecting the necessary information to model or 
account for noise, deciding on strategies for handling missing data 
fields, and accounting for time sequence information and known 
changes. Finally, a few more issues need to be decided, such as 
data types, schema, and mapping of missing and unknown values. 
Data 
pre-processing 
Data reduction and 
transformation 
Includes finding useful features to represent the data and using 
dimensional reduction or transformation methods to reduce the 
effective number of variables under consideration or to find 
invariant representations for the data. 
Choosing methods 
Includes selecting method(s) to be used for searching for patterns 
in the data, such as deciding which models and parameters may be 
appropriate and matching a particular data analysis techniques with 
the overall criteria of the KDD process (e.g., the user may be more 
interested in understanding the model than in its predictive 
capabilities). 
Data analysis 
Applying models 
An essential process where intelligent methods are applied in order 
to extract data patterns, including statistics, data mining and 
machine learning methods. 
Visualisation 
Interpreting the discovered patterns and possibly returning to any 
of the previous steps, as well as possible visualisation of the 
extracted patterns, removing redundant or irrelevant patterns, and 
translating the useful ones into terms understandable by the users. 
Data 
post-processing 
Pattern Evaluation 
To identify the truly interesting patterns representing knowledge. 
Pattern evaluation incorporates knowledge into the performance 
system, taking actions based on the information obtained, or simply 
documenting it and reporting it to interested parties, as well as 
checking for and resolving potential conflicts with previously 
extracted knowledge. 
  
As can be seen in Table 3.2, the first five steps comprise the pre-processing 
phase, the steps of choosing the data analysis model and applying models 
represent the data analysis phase. The KDD process can involve iteration 
and/or loops between any two steps (Tan, 2007). The data analysis step may 
interact with the user or a knowledge base. The relevant patterns are 
presented to the user, and may be stored as new knowledge (Han and 
Kamber, 2001). Overall, the largest effort involved and the most important 
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phase in KDD processing is data analysis.  
 
In summary, the KDD process involves using the database along with any 
required selection, cleaning, sampling, and transformations of it; applying 
data analysis methods (algorithms) to enumerate patterns from it; and 
evaluating the outcome (models) to identify the subset of the enumerated 
patterns deemed knowledge. Data analysis is the core phase in KDD, which 
consists of applying different methods (i.e. statistics or data mining) that, 
under acceptable computational efficiency limitations, produce a particular 
enumeration of patterns (or models) over the data. The next section will 
introduce the relationships between statistics and data mining in this data 
analysis phase. 
 
3.3 Data Analysis 
Data analysis is about looking for patterns (Fayyad et al., 1996c). There is 
nothing new about this – people have been seeking patterns for thousands of 
years (Ellis, 1993). Farmers try to find patterns when growing crops, hunters 
seek patterns in animal behaviour, and parents watch for patterns in their 
children, etc. Similarly, a data scientist discovers the patterns from real 
world data, and encapsulates these in theories that can be used for predicting 
what will happen in new situations. Today, vast amounts of data is being 
collected and warehoused, such as web/e-commerce data, purchasing items 
in stores, bank/credit card transactions and so on. These trends are broadly 
known as ‘big data’, and new software, technology and tools are needed to 
cope with the high volume, variety, and velocity of this big data (Howe et al., 
2008). Data mining, as one of the most popular technologies, is about 
solving problems by analysing data already present in databases (Witten and 
Frank, 2005). 
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3.3.1 Statistics as Data Mining Methods 
In theory, KDD refers to the overall process of discovering useful 
knowledge from data. As shown in Table 3.1, data mining is one of the steps 
in the knowledge discovery process, included in the data analysis phase, and 
involves the extraction of hidden information from a dataset. It is a broad 
field that combines techniques from different areas in computer science and 
statistics (Chakrabarti et al., 2004). This term is used mainly by statisticians, 
database researchers, and more recently by Information Systems (IS) and 
business communities (Fayyad et al., 1996b). Data mining assists data 
analysts with finding patterns and relationships in the data (Edelstein, 1999), 
however, it does not tell people the value of the patterns to the organisation. 
Furthermore, the patterns uncovered by data mining must be verified in the 
real world (Edelstein, 1999). 
  
In general, data mining methods can be divided into two categories: 
descriptive and predictive (Han et al., 2006). Descriptive mining tasks 
characterise the general properties of the data in the database. It includes 
Classification, Regression and Deviation, etc. Predictive mining tasks 
perform inference on the current data in order to make predictions. It 
includes Clustering, the Association Rule and Sequential Patterns, etc (see 
Figure 3.2). 
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Figure 3. 2 Data Mining Categories (source: Han et al., 2006) 
 
Prediction Methods use some variables to predict unknown or future values 
of other variables (Tan, 2007). Classification maps a data item into one of 
the predefined classes (Srivathsa, 2011). Classification problems aim to 
identify the characteristics that indicate the group to which each case 
belongs. This pattern can be used both to understand the existing data and to 
predict how new instances will behave. Regression analysis is a statistical 
method that is most often used for numeric prediction (Han et al., 2006). It 
predicts a value of a given continuous variable based on the other variables, 
assuming a linear or nonlinear model of dependency. Deviation Detection is 
also known as Anomaly Detection. It also detects significant deviations from 
normal behaviour (Tan, 2007). The overall goal is to discover all objects that 
are different from the others. 
Data 
Mining  
Prediction 
Methods 
Description 
Methods 
Classification 
 
Deviation 
Detection 
Clustering 
 
Association Rule 
Discovery 
Sequential Pattern 
Discovery 
Regression 
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Descriptive models are the “unsupervised learning” functions (Larose, 
2006). These functions do not predict a target value, but focus more on the 
intrinsic structure, relations, interconnectedness, etc. of the data. The aim is 
to find human-interpretable patterns that describe the data (Tan, 2007). 
Clustering techniques apply when there is no class to be predicted but rather 
when the instances are to be divided into natural groups (Witten and Frank, 
2005). Mining base on the Association Rule finds interesting associations 
and/or correlation relationships among large sets of data items (Rajak and 
Gupta, 2008). To find the rules, it needs to execute the rule-induction 
procedure for every possible combination of attributes, with every possible 
combination of values. Hence, a single association rule often predicts the 
value of more than one attribute (Witten and Frank, 2005). Sequential 
Pattern Discovery is essentially a time-ordered association (Tan, 2007). It is 
the process of extracting previously unknown, valid, and understandable 
information from large databases. 
 
However, some statistical methods are considered part of data mining (Hill 
and Lewicki, 2006). Some, like statistical prediction methods of different 
types of regressions and correlation analysis, are now considered as an 
integral part of data mining research and applications (Piatetsky-Shapiro et 
al., 1996). Another example, comparing classifiers based on ROC curves are 
statistical methods, but also belong to Evaluation of Classification, a type of 
classification method, in data mining (Chakrabarti et al., 2004).  
 
 
Figure 3. 3 Statistics and Data Mining Tasks 
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It can be argued that in the strictest sense, the definition of “statistics” and 
their techniques are not data mining. However, as shown in Figure 3.3, 
statistics consist of two main parts, descriptive and inferential analysis. The 
methodology for organising and summarising the data for the sample is 
called descriptive statistics. When these summaries are attempted to be used 
in order to draw conclusions about an entire population, the employment is 
called statistical inference (Anderson, 1996).  
 
Furthermore, the primary goal of data mining is verification and discovery 
(Xiao, 1998). Like statistics, the data mining verification goal is designed to 
confirm the user’s hypothesis. Data mining of a discovery goal is designed 
to automatically find new patterns for the user. The discovery goal can be 
further subdivided into prediction, where the system finds patterns for the 
purpose of predicting future behaviour of some entities; and description, 
where the system finds patterns to present them to a user in a 
human-understandable form.  
 
In summary, due to the complexity of the stored data, and of the data 
interrelations, in the context of data mining, description tends to be more 
important than prediction. That means that data mining techniques are 
usually not used without the use of statistics, however, data mining 
discovers more than statistics does. Statistics emphasise descriptive analysis 
more than data mining, and they are at the core of data mining - helping to 
distinguish between random noise and significant findings, and providing a 
theory for estimating probabilities of predictions, etc (Piatetsky-Shapiro et 
al., 1996).  
 
3.3.2 Data Analysis in the Medical Area 
The medical area is a knowledge-intensive domain, in which neither data 
gathering nor data analysis can be successful without using knowledge on 
both the problem domain and the data analysis process. Over the last few 
years, the term “knowledge discovery” has been more and more used in 
medical literature (Prather et al., 1997, Bellazzi and Zupan, 2008, Epstein, 
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2010). This means the usefulness of integrating data analysis with decision 
support techniques (Mallach, 2000, Mladenic, 2003) to promote the 
construction of effective decision criteria and models supporting decision 
making and planning in public heath care.  
 
In 2008, a survey was conducted by KDnuggets.com17, one of the most 
influential data mining and KDD websites in the world. See Figure 3.4. The 
most popular method in the medical area was Regression.  
 
Biotech/ Medical: 
1  Regression/ Forecasting  
2  Clustering/ Segmentation 
3  Classification 
4  Association rules 
5  Time sequences 
Figure 3. 4 The Top Five Most Popular Methods in Biotech/Medical in 
2008 
 
Table 3.3 and 3.4 present the results of a literature review exploring the 
types of data analysis techniques most frequently used in the medical area. 
In total 49 articles were reviewed, and 26 were considered applicable to this 
research. All of the articles are in the medical/bioinformatics area and using 
Knowledge Discovery in Databases or data mining techniques. They were 
randomly selected by referring to concepts, like “KDD in medical” or “data 
mining in health care”, in their titles and abstracts. However, some of the 
articles were excluded as they were not an appropriate fit for this research. 
For example, in some instances, they were borrowing the technical 
terminology instead of actually using data analysis techniques. In some 
instances, they were just reporting on the analytical tools they developed, 
and didn’t mention which methods the tools supported. 
 
                                                        
17 http://www.kdnuggets.com/polls/2007/analysis_applications_more_in_2008.htm 
 48 
Data mining methods have been widely applied in medical and 
bioinformatics area. See Table 3.3. The data mining methods in these studies 
were used individually or combined with other methods. For example, Khan 
et al. (Khan et al., 2008) only used decision trees, a data mining model, in 
an oral medicine study (study number 12); yet Ferreira et al. (Ferreira et al., 
2012) used data mining methods (decision trees and Naïve Bayes), and 
statistical methods (ROC curves, Chi-square test and diagnostic tests) to 
improve diagnosis in neonatal jaundice (study number 5). There are six 
studies that applied the KDD process, and data mining methods are used in 
all of these six studies. Overall, there were 18 studies (70%) combining data 
mining and statistical methods. It means that, in data analysis, statistics are 
closely used with data mining methods. In these 18 studies, data were 
described by using statistical methods, during the knowledge discovery 
process. Thus, we could note that data mining can learn from statistics – to a 
large extent, statistics is fundamental to what data mining is really trying to 
achieve. It is also worth mentioning that this literature reviewed focuses on 
generic research studies, which means that these data analysis methods 
could be applied in different areas of medical and bio-informatics research. 
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Table 3. 3 Data Mining and Statistical Methods in Medical and 
Bioinformatics Research 
Study 
No. 
Authors Area of Research 
Contribution 
Focus 
Data 
Mining 
Methods 
Statistical 
methods 
KDD 
study 
1 (Tsumoto et al., 2013) 
Improvement of hospital 
management 
clinic manager √   
2 (Hebert et al., 2013) AD prevalence  geriatrician √ √  
3 (Wong et al., 2013) 
Cardiovascular 
medications 
geriatrician and 
pharmacist √ √  
4 (Hajjar et al., 2012) Drug analysis in dementia 
geriatrician and 
pharmacist √ √  
5 (Ferreira et al., 2012) Diagnosis in neonatal 
clinical  
practitioners 
√ √  
6 (Gagliardi, 2011) Knowledge extraction  
diagnostic 
practitioners √ √ √ 
7 (Zhang et al., 2011) Cognitive impairment geriatrician √ √  
8 (Dong et al., 2011a) Drug analysis in dementia 
geriatrician and 
pharmacist 
√ √  
9 
(Chen and Herskovits, 
2010) 
Dementia  geriatrician √ √  
10 (Smith et al., 2009) Cancer cancer researcher √ √  
11 (Sink et al., 2009) Drug analysis in dementia 
geriatrician and 
pharmacist √ √  
12 (Khan et al., 2008) Oral medicine pharmacist √   
13 (Mullins et al., 2006) 
Introduce a new DM 
approach 
clinical 
researchers √   
14 (Inza et al., 2004) Gene selection  bioinformatician √   
15 (Robles et al., 2004) Protein research bioinformatician √ √  
16 (Weber et al., 2004) 
Analysis of gene 
expression 
bioinformatician √ √  
17 
(Roy Walker et al., 
2004) 
Dementia 
geriatrician and 
bioinformatician √ √  
18 (Tan et al., 2003) 
Improvement of clinical 
practice 
clinical  
practitioners √  √ 
19 (Goodwin et al., 2003) Preterm birth risk 
nursing  
practitioner 
√  √ 
20 (Lee and Abbott, 2003) 
Knowledge discovery for 
nurse researchers 
nurse practitioner √ √ √ 
21 (Mitnitski et al., 2003) Dementia geriatrician √ √ √ 
22 (Ganzert et al., 2002) Respiratory treatment 
clinical  
practitioners √ √  
23 (Tsumoto, 2000) 
Knowledge discovery and 
evaluation  
outpatient clinic √   
24 (Lavrac et al., 2000) 
Intelligent analytical 
methods 
physicians √  √ 
25 (Tierney et al., 1997) Mortality risk  
clinical  
practitioners √ √  
26 (Standish et al., 1996) Cognitive screen test geriatrician √ √  
Sum    26 18 6 
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Table 3. 4 Data Mining and Statistical Method Types in Medical and 
Bioinformatics Research 
Data Mining 
Methods 
Statistical Methods Article 
No. Predictive 
mining 
Descriptive 
mining 
Regression 
Diagnostic 
tests 
Chi-square 
test 
ROC 
curves 
Comparing 
tests 
1  √      
2 √  √     
3 √  √  √   
4 √  √  √   
5 √   √ √ √  
6 √   √    
7 √   √  √  
8 √  √    √ 
9 √  √     
10 √   √    
11 √  √    √ 
12 √       
13 √       
14 √ √      
15 √   √   √ 
16 √  √     
17  √     √ 
18 √       
19 √       
20 √   √  √  
21 √    √   
22 √  √   √  
23  √      
24 √ √      
25 √  √   √  
26 √     √ √ 
Sum 23 5 9 6 4 6 5 
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Of the 26 articles selected, most of the medical studies (n=23) were using 
predictive mining methods, 88%, and five studies used description methods 
(19%). See Table 3.4. Also two studies used both prediction and description 
methods. For those studies using predictive mining methods, there were 14 
studies using a variety of classification methods, and nine studies using 
regression analysis. Classification methods are getting more and more 
popular in medical research. Decision Trees and Bayesian analysis were 
often used as the classification methods. Of these, Decision Trees were 
always combined with other data mining methods, such as Naïve Bayes or 
neural networks etc. Regression analysis is the most popular statistical 
method (n=9) in these studies. This literature review confirmed the survey 
results from KDnuggets, that regression was the most frequently used data 
analysis method in the medical area. Additionally, there were ten geriatrics 
studies in the literature reviewed, which were focused on dementia. All of 
them were using both data mining and statistical methods, as shown in Table 
3.3. The most popular data mining/statistical method was also regression. 
Thus, regression analysis is a key analytical method in this type of research. 
 
However, no matter how much data mining is applied in medical research, 
statistics, especially biostatistics (called medical statistics in UK), has 
played an integral role in modern medicine in everything from analysing 
data to determining if a treatment will work to developing clinical 
trials. Virtually any medical research study uses biostatistics from beginning 
to end. It becomes the foundation of data analysis in medical research. The 
University of North Carolina's Gillings School of Global Public Health 
defines biostatistics as “the science of obtaining, analysing and interpreting 
data in order to understand and improve human health”18.  Statistics help 
researchers make sense of all the data collected to decide whether a 
treatment is working or to find factors that contribute to diseases. This 
research study will apply a variety of data analysis methods, especially 
statistical methods, some of which were used as data mining methods, to 
build models and discover useful information from clinical databases. For 
                                                        
18 http://sph.unc.edu/bios/biostatistics/ 
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example, multivariate regression analysis was used to compare end point 
cognitive and functional scores. The next section will list the data sources 
used in this research – the three main databases and their key instruments, 
and how they were used in each study. 
 
3.4 Clinical Databases 
3.4.1 Introduction 
For the purpose of this research, the data came from three clinical databases: 
the Geriatric Assessment Tool (GAT), the Doxycycline and Rifampin for 
Alzheimer’s Disease (DARAD), and the Qmci Validation databases. These 
data were collected from a variety of geriatric medicine clinics or trials in 
Canada. This section introduces these databases, including their background, 
uses, the variables, and patients’ baseline demographics.  
 
Table 3. 5 The Research Studies Using the GAT, DARAD and Qmci 
Validation Databases  
              Database name 
Studies 
GAT  DARAD  
Qmci 
Validation 
Qmci cut offs √ √ √ 
Qmci subtests   √ 
Qmci vs SMMSE   √ 
Qmci vs SADAS  √  
CACE study in GAT database √   
CACE study in DARAD 
database 
 √  
CACE study in GAT and 
DARAD databases combined 
√ √  
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Table 3.5 demonstrates how the three databases were used in different 
studies for this research. The GAT database was used in the Qmci cut offs 
study along with the DARAD and the Qmci Validation databases for a 
greater sample size. The GAT was also used in comparing the rate of 
cognitive decline between patients taking CACE-Is (Centrally Acting 
Angiotensin Converting Enzyme Inhibitors) and those not currently treated 
with CACE-Is. Combined with the DARAD database, those data were used 
to study the effect of CACE-Is on the rate of cognitive and ADL (activities 
of daily living) decline. The DARAD database was used in the Qmci cut 
offs, and Qmci versus SADAS studies. It was also used in finding the 
differences in the rate of ADL decline between CACE-I and NoCACE-I 
patients. Combined with the GAT database, the DARAD database was used 
in comparing the rate of cognitive and ADL decline for patients taking 
different CACE-I drugs. The data from the Qmci Validation database was 
used in the Qmci cut offs, Qmci subtests, and Qmci versus SMMSE studies. 
 
3.4.2 The Geriatric Assessment Tool (GAT) Database 
3.4.2.1 Overview of the GAT Database 
The GAT is a customised web-based software application that automates a 
clinician’s entire outpatient review, summarising the findings in a discharge 
letter and recording data in a database. GAT data were collected in 
outpatient geriatric medicine clinics in two university hospitals in Ontario, 
Canada between 1999 and 2010. The database contains over 8,000 
individual assessments from 1,749 people, aged 41 to 104 years of age. Of 
these, 1,728 people have diagnosis recorded. It manages patients, 
assessment visits, medications, caregivers, doctors, users and automates the 
doctor’s Geriatric Clinic. Specifically, the GAT records patient visits, 
manages patient records, schedules appointments, manages doctor records, 
manages caregiver records, administers staff, prints consultations 
(eliminating the need for dictation), records potential study candidates, 
billing and more. 
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This database contains observational data, collected in a “real world” setting, 
where treatments were administered on the basis of clinical judgment. It 
includes basic demographic data (age, gender, educational level, medical 
conditions, diagnosis and laboratory findings etc.) and in the case of 
subjects suspected of having memory loss, the results of two cognitive 
screening tests, the Standardised Mini-Mental State Examination (SMMSE) 
(Molloy et al., 1991a) and the Quick Mild Cognitive Impairment screen 
(Qmci) (O'Caoimh et al., 2012a, Molloy et al., 2005). Both tests were 
administered to patients by trained raters (clinic nurses), blind to the 
diagnosis, and prior to each assessment to monitor progression. A Quick 
Activities of Daily Living Score (Qadl) test is also available in GAT, for 
patients assessed from 2001 to 2009.  
 
The GAT database includes patients with possible or probable AD, VaD, 
mixed dementia (AD-VaD), Lewy Body Dementia (LBD), frontotemporal 
dementia (FTD), Parkinson Disease (PDD), normal cognition (NC), MCI, 
patients with depression (with and without comorbid CI), alcohol, 
post-traumatic dementia (PTD), PTD with depression, and post anaesthesia 
dementia (PAD). The majority of the dementia patients in the GAT database 
have AD, vascular and mixed dementia. The distribution of these diagnoses 
is shown in Figure 3.5. In this research, AD, vascular and mixed dementia 
were included (yellow tagged in Figure 3.5), as they have the similar 
symptoms. Although the database contains data on patients with a wide 
variety of dementia subtypes, only individuals with subjective memory loss, 
such as possible or probable Alzheimer’s Disease (AD), vascular and mixed 
dementia subtypes were included in this analysis, as those diagnoses have 
similar symptoms.  
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Figure 3. 5 Distribution of Diagnoses in the GAT Database 
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3.4.2.2 Demographics of Patients in the GAT Database 
Each subject included in the GAT database underwent a comprehensive 
work-up, including physical history, examination and laboratory 
investigations, and each was diagnosed as having either NC, MCI or 
dementia with or without comorbid depression. Dementia was diagnosed by 
a consultant physician using National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS) (McKhann et al., 1984) 
and Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
criteria (Association and DSM-IV., 1994). MCI was defined by clinical 
criteria where subjects presented with subjective and corroborated memory 
loss, without loss of function. The results of cognitive testing were not used 
to confirm the diagnosis. Controls were subjects presenting with subjective 
memory loss with NC. Depression was also diagnosed clinically and 
screened using the Geriatric Depression Scale (score > 7) (Brink et al., 
1982). 
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Table 3. 6 Baseline Demographics and Outcome Measure Scores for 
GAT Patients 
 Total Dementia MCI Normal Depression 
Number 1728 817 235 181 137 
Age (mean + SD) 75.3 +9.8 77.9 +8.1 74.7 +9.3 73.9 +10.3 68.9 +11.3 
Male (%) 46.7% 50.3% 48.5% 47.2% 29.4% 
Education  
(mean + SD) 
11.4 +4.1 10.9 +4.0 11.4 +4.2 13.3 +4.3 12.5 +4.1 
Systolic BP in mmHg 
(mean + SD) 
133.3 +17.7 133.7 +17.9 135.6 +19.2 131.5 +14.4 133.1 +19.3 
Diastolic BP in 
mmHg (mean + SD) 
71.6 +10.8 71.8 +11.0 72.0 +10.2 71.5 +10.7 71.1 +10.6 
SMMSE median 
baseline score (IQR) 
25 (7) 22 (7) 28 (3) 29 (2) 29 (3) 
Qmci median baseline 
score (IQR) 
49 (27) 38 (22) 57 (15) 69 (18) 64 (18) 
Qadl median baseline 
score (IQR) 
4 (15) 10 (19) 0 (2) 0 (9.5) 2 (4) 
 
Table 3.6 shows the baseline characteristics and outcome measure scores, 
for patients included from 1,728 total patient numbers and divided 
according to diagnosis. There was no significant difference on age, gender, 
education, blood pressure in dementia, MCI, normal and depression groups. 
SMMSE and Qmci, the cognitive outcome measures, are scored out of 30 
and 100 respectively, with higher scores suggesting greater cognition. The 
functional outcome measure, Qadl (Quick activities of daily living test), is 
scored out of 90, with higher scores suggesting worse independence.  
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3.4.3 The Doxycycline and Rifampin for Alzheimer’s Disease 
(DARAD) Trial Database 
3.4.3.1 Overview of the DARAD Database 
The DARAD was a multi-centre, blinded, randomised, 2x2 factorial control 
trial conducted in Canada between 2006 and 2010. The DARAD database 
included subjects with mild to moderate AD, recruited from 14 Canadian 
centres, including Toronto, Hamilton, Halifax and Edmonton, on the basis of 
National Institute of Neurological and Communicative Disorders and Stroke 
criteria. All patients were aged over or equal to 50 years old, Standardised 
Mini-Mental State Examination (SMMSE) score from 14 to 26, having 
sufficient English literacy to complete standardised testing, and having a 
consenting caregiver to monitor the patient and report on their behaviour. 
These subjects received detailed work-up and had cognitive assessments 
performed every three months for one year (Molloy et al., 2012). 
 
The original objective of the DARAD trial was to compare two antibiotics, 
rifampacin and doxycycline to placebo, over a one-year period. Cognition, 
function, mood and behaviour were scored. The primary outcomes were a 
measure of cognition, the SADAS-cog (Standish et al., 1996) and a measure 
of global function – the Clinical Dementia Rating (CDR) (Hughes et al., 
1982). Secondary outcomes included the Standardised Mini-mental State 
Examination (SMMSE) (Molloy et al., 1991a), Quick Mild Cognitive 
Impairment Test (Qmci) (Molloy et al., 2005, O'Caoimh et al., 2012a), 
activities of daily living (ADL) function measured by the Lawton Scale 
(Self-maintenance, 1969), behaviour measured by the Dysfunctionsal 
Behaviour Rating Scale (Molloy et al., 1991b), the Cornell Scale for 
Depression in Dementia (CSDD) (Alexopoulos et al., 1988), and depression 
measured by Geriatric Depression Scale (Yesavage et al., 1983, Shiekh and 
Yesavage, 1986). The DBRI has two sub-tests, behavioural frequency and 
difficulty/response (DBRIF and DBRIR). These tests are described briefly 
in Section 3.5. 
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The SADAS-cog, CDR-SB, Qmci, Lawton-Brody ADL Scale and DBRI 
scores were available at one, three, six, nine and twelve months (end-point). 
The SMMSE score was recorded at screening and end-point, the GDS score 
at baseline and end-point and the CSDD score at baseline, six-months and 
end-point only. 
 
3.4.3.2 Patients Demographics in DARAD 
An initial power calculation estimated that 500 patients would be sufficient 
to detect a three points difference in the SADAS-cog with significance level 
0.05, assuming a standard deviation of change of 9.8, allowing for 10% 
dropout. In total, 406 patients with mild to moderate AD (SMMSE scores 
between 14 and 26) were included in the DARAD study, conducted from 
2006 to 2010. All patients were aged 50 years or more, and met the National 
Institute of Neurological Disorders and Stroke (NINCDS) criteria for AD. 
Not all the patients took all the nine tests. Patients were stratified on centre, 
age, gender, SMMSE score, use of cholinesterase inhibitors, site and NMDA 
agonists, using a computer randomisation programme. Patients returned for 
interval assessment at three, six, nine and twelve months and were contacted 
by phone once per month.  
 
Physical exams and laboratory screening were carried out and 
patient/caregiver reports were elicited at each visit to monitor patient safety. 
Adverse events (AE) were assessed at each visit by asking the patient and 
caregiver about any sickness or untoward physical event the patient had 
experienced since the previous visit. When patients reported adverse events, 
the local investigator assessed the probability of the relationship of the AE 
to the study medication based on the patient’s medical history, family 
reports, the chronology related to the study and the known safety profiles of 
doxycycline and rifampin. The investigator made this determination blinded 
to the treatment allocation. Serious adverse events (deaths, hospitalisations, 
cancer, etc.) were reported to the local research ethics boards as well as to 
the central monitoring site. Regular safety reports were also submitted to the 
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Data Monitoring Committee (DMC) which operated at arms-length from the 
research group and had access to the treatment allocation via the unblinded 
medication manager. Table 3.7 presents the baseline demographics, baseline 
and end point scores for each outcome measures for patients included in the 
DARAD trial. 
 
Table 3. 7 Baseline Demographics, Baseline (BL) and End-Point (EP) 
Scores for DARAD Patients  
Number 406 Age 77.8 (7.1) Male % 50.7% 
Education 12.3 
(3.5) 
BP systolic 134.3 
(16.0) 
BP diastolic 73.1 
(10.2) 
BL 39 (19) BL 51 (9) BL 5.5 (4) 
Qmci  
EP 33 (22) 
ADL  
EP 47 (12) 
CDR-SB 
EP 8 (6) 
BL 3 (4) BL 4 (10) BL 13 (11) 
CSDD 
EP 4 (5) 
DBRIF 
EP 5 (16) 
DBRIR 
EP 14.5 (15) 
BL 1 (3) BL 20 (10) BL 23 (5) 
GDS 
EP 1 (3) 
SADAS 
EP 24.5 (17) 
SMMSE 
EP 21 (7) 
 
The patients in the DARAD database had mild to moderate AD. There were 
no significant difference between their age, gender, education and blood 
pressure. In outcome measures, Qmci, ADL and SMMSE with higher scores 
suggest better condition; CDR-SB, CSDD, DBRIF, DBRIR, GDS and 
SADAS with higher scores suggest worse condition. 
 
3.4.4 Qmci Validation Database 
3.4.4.1 Overview of Qmci Validation Database 
The Qmci database includes patients recruited from four memory clinics in 
Ontario Canada, (Hamilton, Paris, Niagara Falls and Grand Bend). The 
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assessments were done on patients and families during clinic. This was a 
highly selected population, created to validate the Qmci (O'Caoimh et al., 
2012a, O'Caoimh et al., 2013a). It only included subjects aged 55 years or 
more, referred for assessment of cognition. Subjects with LBD, PDD and 
depression were excluded. Normal controls in this database included 
caregivers and families attending with patients. Those with subjective 
memory loss, but normal cognition or with alternative causes of memory 
loss such as hypothyroidism, were excluded.  
 
3.4.4.2 Patient Demographics in Qmci Validation Database 
This database contained 965 patients, recording their age, gender, education, 
diagnosis, stages of dementia and three cognitive tests (Qmci, SMMSE and 
ABCS135). There were mainly three diagnosis types in this database. 
Normal controls were selected by convenience sampling. All caregivers, or 
those attending with the subjects, were asked if they themselves had 
memory problems. Those without memory problems were invited to 
participate as normal controls. A diagnosis of MCI was made by a 
consultant geriatrician if patients had recent, subjective but corroborated 
memory loss, without obvious loss of social or occupational function. A 
diagnosis of dementia was based on NINCDS (McKhann et al., 1984) and 
DSM-IV criteria (First, 1994). Dementia severity was correlated with the 
Reisberg FAST scale (Reisberg, 1987). Dementia patients were divided into 
three sub-groups, based on stages: mild, moderate and severe dementia. The 
baseline demographics are presented in Table 3.8. 
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Table 3. 8 Patients Demographics in Qmci Validation Database 
Group N Mean 
Age 
Gender 
(% male) 
Mean 
Education 
(years) 
Median 
Qmci 
(IQR) 
Median 
SMMSE 
(IQR) 
Median 
ABCS135 
(IQR) 
Normal 630 67.4 40.3% 13.8 76 (14) 29 (2) 116 (12) 
MCI 154 73.6 50% 12.2 62 (15) 28 (2) 102 (17) 
Dementia 
Total 
181 78.1 46.1% 11.0 36 (22) 22 (2) 70 (38) 
Mild 
dementia 
129 78.3 44.3% 11.2 40 (17) 23 (5) 75 (27) 
Moderate 
dementia 
31 76 48.5% 10.4 17 (27) 15 (9) 37 (51) 
Severe 
dementia 
7 75.3 71.4% 10.3 3 (7) 8 (4) 8 (23) 
 
Table 3.8 shows the baseline characteristics and three cognitive test scores. 
There was no significant difference in age, gender, and education between 
the dementia, MCI, and normal groups. Qmci, SMMSE and ABCS135, the 
cognitive outcome measures, are scored out of 100, 30 and 135 respectively, 
with higher scores suggesting greater cognition. The majority (78%) of 
dementia cases were mild (n = 141). Removing moderate and severe cases 
did not affect sensitivity (O'Caoimh et al., 2012a). These cognitive tests 
were performed in random order, by trained raters, blind to the diagnosis 
and prior to the assessment. 
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3.5 Key Instruments in the Three Clinical Databases 
3.5.1 Introduction 
This section introduces all the key instruments/measures for dementia 
patients used in this research; they are contained in the GAT, DARAD and 
Qmci Validation databases. These instruments measured cognition, function, 
depression, and behaviour profiles in the dementia patients: SADAS-cog 
(Standish et al., 1996), SMMSE (Molloy et al., 1991a), and Qmci (Molloy et 
al., 2005, O'Caoimh et al., 2012b) were the measurements for cognition; 
Lawton-Brody ADL (ADL) (Self-maintenance, 1969) and Qadl were the 
measurements for function; GDS (Yesavage et al., 1983, Shiekh and 
Yesavage, 1986) and CSDD (Alexopoulos et al., 1988) were the 
measurements for depression; DBRI (Molloy et al., 1991b) measured 
behaviours on patients’ frequency and response to each behaviour as 
caregivers’ burden; CDR (Hughes et al., 1982) was used as a scale to 
quantify the severity of dementia. Table 3.9 describes these instruments in 
the three databases. 
 
Table 3. 9 Key Instruments in the Three Clinical Databases 
              Database name 
Instruments 
GAT  DARAD  
Qmci 
Validation 
CDR  √  
SADAS-cog  √  
SMMSE √ √  
Qmci √ √ √ 
GDS √ √  
ADL/ Qadl √ √  
DBRI  √  
CSDD  √  
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The databases also include the subtest scores for these instruments. Most of 
these instruments are widely employed in clinics today. Some of them, like 
SADAS-cog, are the accepted gold standard for measuring cognition in 
dementia (Rosen et al., 1984). All of the screening tools are attached in 
Appendix. 
 
3.5.2 Clinical Dementia Rating Scale (CDR)  
The Clinical Dementia Rating Scale (CDR) is a clinician-rated instrument 
that stages dementia, tracking the progression of cognitive and functional 
decline. It measures memory, orientation, judgment and problem solving, 
community affairs, home and hobbies, and personal care. The CDR may be 
scored in two ways: the global CDR scored our of three points (Morris, 
1993), and the CDR sum of boxes (CDR-SB) technique (Ferris et al., 1997). 
In this study, the CDR-SB scores ranged from 0 - 18 (most severe), with a 
score of zero indicating no impairment, scores of 0.5-4.0 denote possible 
impairment, and 4.5-9.0, 9.5-15.5 and 16.0-18.0 suggest mild, moderate and 
severe impairment respectively. CDR was performed at baseline and 
follow-up. The CDR has excellent inter-rater reliability (0.89) and correlates 
significantly with the Short Portable Mental Status Questionnaire (0.74) and 
the Blessed Dementia Scale (0.84) cognitive tests (P < 0.0001) (Davis et al., 
1990). 
 
3.5.3 Standardised Alzheimer’s Disease Assessment 
Scale-Cognitive Subscale (SADAS-cog)  
The Alzheimer’s Disease Assessment Scale-cognitive section (ADAS-cog) 
(Rosen et al., 1984) is the accepted standard for measuring cognition in 
clinical trials in dementia. It has 11 domains measuring word recall, object 
naming, command following, construction and ideational praxis, orientation, 
word recognition, language, speech comprehension, word finding and recall. 
Total scores range from 0 to 70 with higher scores (>18) suggesting greater 
cognitive impairment. The minimal important change has been determined 
to be approximately four points, representing a change at six month period. 
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Many regulatory authorities, including the US Food and Drug 
Administration, require evidence of such change at six months to confirm 
the benefit of any new medication (McKhann et al., 1984, Matthews et al., 
2000, Aisen et al., 2003). 
 
The ADAS-cog, although comprehensive and useful at different stages of 
dementia, has limitations. It is long, requires training, and there are concerns 
about the instruments’ inter-rater reliability (Connor and Sabbagh, 2008). It 
also has a ceiling effect, limiting usefulness in the initial stages of dementia 
(Mohs et al., 1997). To overcome these problems, the Standardised 
Alzheimer’s Disease Assessment Scale-cognitive section (SADAS-cog) was 
created with clearly defined administration and scoring guidelines, which 
showed improved inter-rater reliability (Standish et al., 1996). It can be 
administered in approximately 45 minutes (O'Caoimh et al., 2013b).  
 
3.5.4 The Standardised Mini-Mental State Examination 
(SMMSE)  
This is a widely used short mental status instrument that scores cognition 
and includes orientation, registration, concentration, short-term memory, 
language and visual-spatial ability, taking approximately 10 minutes to 
administer. Originally MMSE was developed by Folstein, et al. (Folstein et 
al., 1975) to distinguish depression from dementia. The SMMSE has 
explicit guidelines for administration and scoring and improved inter rater 
reliability, compared with the traditional MMSE (Molloy et al., 2005). It is 
used extensively as a reliable measure of dementia severity. The test/retest 
reliability is 0.89 and the inter rater reliability is 0.83. The scale is 
responsive to change and correlates well (0.70-0.90) with other cognitive 
screening instruments (Kane et al., 2000). Table 3.10 presents the scoring of 
the different domains in the SMMSE.  
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Table 3. 10 SMMSE Scoring Table 
SMMSE test Score 
Orientation 5 
Registration 5 
Concentration 5 
Short-term recall 6 
Naming familiar items 2 
Repeating a common expression 1 
The ability to read and follow written 
instructions 
1 
Write a sentence 1 
Construct a diagram 1 
Follow a three step verbal command 3 
Total 30 
 
The SMMSE is scored out of 30 points. People who are well-educated, have 
normal cognition, complain of memory loss, or have diagnosed MCI will 
usually score above 26 (Molloy et al., 1991a, Molloy et al., 2005). Mild, 
moderate and servere dementia patients will usually score between 20 – 25, 
10 – 19, 0 – 10, respectively (Vertesi et al., 2001).  
 
3.5.5 The Quick Mild Cognitive Impairment (Qmci) Screen  
The Qmci is a short (three to five minutes) cognitive screen with six subtests 
measuring five cognitive domains: orientation (five questions), registration 
(five-word registration), delayed recall, visual-spatial ability (clock 
drawing), verbal fluency (naming animals in one minute) and logical 
memory (immediate verbal recall of a short story). It is scored out of 100 
points, with higher scores suggesting greater cognitive abilities. Table 3.11 
presents the points weightings of the six subtests. The Qmci is sensitive to 
early cognitive changes and was developed specifically to differentiate 
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between normal cognition, MCI and dementia. The Qmci shows a 
statistically significant difference between normal cognition and MCI. This 
difference is significant regardless of patients’ age or education. The Qmci 
has superior accuracy for detecting MCI compared to the SMMSE 
(O'Caoimh et al., 2012a).  
 
Table 3. 11 Qmci Scoring Table 
Qmci subtests Score 
Orientation 10 
Registration 5 
Clock drawing 15 
Delayed recall 20 
Verbal fluency 20 
Logical Memory 30 
Total 100 
 
Qmci cut offs are sensitive to patients’ age and education. For all patients, 
the optimal cut-off score for identifying cognitive impairment is ≤60; 
sensitivity of 89%, specificity 86%, and area under the curve (AUC) 0.95. A 
score ≤50 has 84% sensitivity, 79% specificity, AUC 0.89 for detecting 
dementia (O'Caoimh et al.).  
 
3.5.6 Geriatric Depression Scale (GDS)  
The Geriatric Depression Scale (GDS) (Yesavage et al., 1983) is a 
clinician-administered measure of depression. It has two accepted forms, the 
long form with 30 questions, and a short form with 15 questions. The 
GDS-30 was originally validated with standard research diagnostic criteria 
for depression. With a cut off point of 11/30, it has a sensitivity of 84% and 
specificity of 95% for depression. Test retest reliability is satisfactory with a 
correlation of 0.85. The 15 GDS-SF item was used in DARAD, scored from 
0 to 15 with a score ≥5 suggesting depression (Marc et al., 2008). While the 
performance of the GDS is compromised by severe cognitive impairment 
(approximately 20 or less out of 30 on the MMSE), this scale is considered 
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suitable as a brief screen for depression in patients with mild to moderate 
patients with dementia (da Costa et al., 2008). 
 
3.5.7 Lawton-Brody Scale (ADL) and Qadl 
Lawton-Brody Scale is a well established instrument for measuring the 
performance of instrumental and basic activities of daily living (ADLs) 
(Spilker, 1990, Lawton, 1970). It combines both basic (Physical 
Self-Maintenance Scale) and instrumental (Lawton Scale) ADLs, covering 
14 subtests, scored from 14 to 65 points, with higher scores suggesting 
greater independence. It consists of items that may be performed by either 
women or men (ability to use telephone, toileting, feeding themselves, 
dressing, grooming, walking, bathing, shopping, food preparation, 
housekeeping, laundry, mode of transportation, medication administration 
and handling finances). Administration is either by self report 
(Self-maintenance, 1969) or by a caregiver. The inter rater reliability is 0.85, 
and the coefficient of reliability is 0.96 for men and 0.93 for women. 
 
The Qadl test is a shortened version of the Lawton-Brody ADL scale. It 
contains 10 subtests, scored by patients’ caregivers, indicate how the patient 
manages his/her “activities of daily living”, and how s/he functions every 
day. It also includes how s/he manages medications, handles money (pay 
bills, shop, etc), uses the telephone, prepares food, grooms (hair, shaving, 
nails, etc.), bathes (bath, shower), walks, toilets (urine/feces), transfers (e.g 
bed to chair), and feeds themselves (eat and drink). Each subtest has two 
questions: what is the level of care required, and how much of a problem 
this is. Each “level of the care” question is scored from zero to five points, 
with higher scores suggesting more dependence. Each question for 
“problem” is scored from zero to four, with higher scores suggesting worse 
problem. The Qadl has excellent inter-rater reliability (Caoimh et al., 2012).  
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3.5.8 Dysfunctional Behaviour Rating Scale (DBRI)  
The Dysfunctional Behaviour Rating Scale (DBRI) measures 25 behaviours 
according to their frequency (DBRI frequency, from ‘never’ to ‘greater than 
five times per day’) and scores caregiver burden for each behaviour (DBRI 
reaction, impact from ‘no problem’ to ‘great deal of a problem’). The 
questions are answered by a caregiver or other informant, who is familiar 
with the patient. The inter-rater reliability of the DBRI is 0.75. Validity of 
the DBRI as compared to the Behavioural Problem Checklist (BPC) total 
score is 0.71. The DBRI is a specific, reliable and valid caregiver-reported 
measure of dysfunctional behaviour in cognitively impaired elderly patients 
living in the community. 
 
3.5.9 Cornell Scale for Depression in Dementia (CSDD)  
CSDD was specifically developed to assess signs and symptoms of major 
depression in patients with dementia. It has 19 items that use the 
information from an interview with patient and caregiver. CSDD ratings are 
significantly related to clinical diagnoses of depression in elderly people, 
with or without dementia (Vida et al., 1994, Ownby et al., 2001). It has a 
19-item scale, range of 0-39: normal <6, probable depression 10-17, definite 
depression ≥18. 
 
3.6 Analytical Methods 
This section focuses on the analytical methods used in the core part of KDD 
process (data analysis), within the medical area. It explains how to use 
descriptive statistics to understand and report on medical data, and 
introduces the statistical methods used in this research across the various 
studies. 
 
3.6.1 Data Analysis in Medical Research  
Nowadays, clinical medicine is facing the challenge of interpreting a 
growing volume of data recorded as part of clinical practice. Large clinical 
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and administration databases are now common, as hospital information 
systems become more sophisticated, capturing patient case mix. Enormous 
amounts of information are collected continuously by monitoring 
physiological parameters of patients (Tan et al., 2003) and can be used for 
medical research and to improve hospital management. The analysis of 
medical data will be a keystone to planning future healthcare (Auffray et al., 
2009). Data analysis of quantitative and qualitative research must be 
performed and reported according to scholarly conventions. The purpose of 
this section is to introduce the concepts of data analysis in medical research. 
 
3.6.1.1 Experimental Design (Obtaining Data) 
Data collection is one of the key parts in the research process. The collection 
methods will directly impact on data analysis at a later stage (Peacock and 
Peacock, 2010). Research questions determine which variables are needed 
for analysis. During the design of collection forms, variables associated with 
the outcomes should be considered. Coding allows non-numerical or 
numerical data in categories to be used in analysis. Some data analysis 
packages can analyse non-numerical data, but it is easier to assign a number 
to each category. Hence, the coding should be designed at the time when 
form is made, so that it can be built into the form. A special code is used for 
missing data or not-applicable (n/a) value. For example, for a yes/no 
question, number one represents yes, zero represents no, and nine could be 
used to indicate a missing value. It is not allowable to fill in a casual number 
like 999 or 222 for an unknown answer, as those numbers are also 
representing an amount. One variable should not contain two or more kinds 
of data types. For the last example, if number one is chosen to represent yes, 
and zero represents no, then the missing value should be represented by a 
number, e.g. “9”, not a character, such as “blank”. 
 
3.6.1.2 Descriptive Statistics (Exploring, Summarizing and 
Presenting Data) 
In statistics, a population is studied, and usually the set of observations 
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represents a sample from the entire collection of possible data known as a 
population (Peacock and Peacock, 2010). It is important that the population 
being sampled is well-defined to ensure that the sample drawn will be 
representative and useful to describe it. Summarising data is helpful in 
checking data quality as well as for presenting findings to others. The first 
step in analysing data should begin by presenting and describing the 
information contained in it. This is completed by employing a set of 
techniques more commonly known as descriptive statistics or exploratory 
data analysis (Hartwig, 1979). These tools are primarily concerned with 
summarising and exploring data to detect errors and assess patterns. 
Generally, this involves ordering and presenting the collected measurements 
in the form of tables; graphs such as pie charts, bar charts and histograms; 
and numerical summaries.  
 
3.6.1.3 Tests of Statistical Significance 
A significance test uses data from a sample to show the Likelihood that a 
hypothesis about a population is true. If the hypothesis being tested is not 
true, then the opposite hypothesis must be true. A measure of the evidence 
for/against the hypothesis is provided by a p value. The null hypothesis 
(Fisher, 1935) is the basic hypothesis which usually is expanded in the form 
‘there is no difference’ or ‘there is no association’. The corresponding 
alternative hypothesis is that ‘there is a difference’ or ‘there is an 
association’. For example, for the question of “if a new treatment can reduce 
blood pressure better than the existing one”, the null hypothesis means that 
blood pressure is the same between the two groups; the alternative 
hypothesis means that blood pressure is different in the two groups. In 
scientific and medical research, null hypothesis play a major role in testing 
the significance of differences in treatment and control groups. A p value < 
0.05 indicates statistical significance (means that there is less than a 5% 
chance that this difference was due to chance), which is an integral part of 
hypothesis testing used as an important value judgment. In statistics, a result 
is considered significant, because it has been predicted as unlikely to have 
occurred by chance alone, not because it is important or meaningful (Wilcox, 
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1996). 
 
3.6.2 Statistical Methods 
The purpose of this section is to introduce the different statistical methods 
used in this research. Table 3.12 presents the list of the tests. 
 
Table 3. 12 The List of the Statistical Tests Used in the Research 
Types of methods Test names 
Distribution tests for normality The Shapiro-Wilk Test 
Two-Sample t-Test 
Parametric methods 
Paired t-test Comparing test 
Non-parametric methods Mann-Whitley U test 
Pearson’s Correlation 
Coefficient 
Correlation Coefficient 
Spearman’s Rank Correlation 
Coefficient 
Simple Linear Regression 
Measure of associations 
Chi-Square Test 
One-way Analysis of variance 
(one-way ANOVA) 
Analysis of variance 
Multivariate analysis of 
variance (MANOVA) 
Receiver Operating 
Characteristic (ROC) curve 
Diagnostic tests 
Youden’s index and 
Likelihood ratios 
 
The tests listed in Table 3.12 were the methods applied in this research, 
some of the other tests for the similar purpose, for example, the 
Kolmogorov-Smirnov test for normality distribution, will not be considered. 
The next sections will introduce the theory of the tests, and the conditions 
where they could be applied.  
 
 
 73 
3.6.2.1 Distribution Tests for Normality 
The normal distribution is the most important and most widely used 
distribution in statistics for quantitative data. Data needs to be determined as 
normal distributed or non-normal distributed, before parametrical or 
non-parametrical tests are executed. Parametric methods are often used 
while the data are normal distributed, and where they are not true of the raw 
data, which usually are not normal distributed. There are situations in which 
even transformed data may not satisfy the assumptions of normal, however, 
and in these cases it may be inappropriate to use traditional (parametric) 
methods of analysis. Non-parametric methods (Noether, 1967) provide an 
alternative series of statistical methods that require no or very limited 
assumptions to be made about the data. There is a wide range of methods 
that can be used in different circumstances, but some of the more commonly 
used are the non-parametric alternatives to the t-tests (Whitley and Ball, 
2002). 
 
Sometimes, the normal distribution is called the "bell curve", although the 
tonal qualities of such a bell would be less than pleasing. The normal curve 
was discovered by de Moivre in 1753 (Gaddum, 1945) and developed as a 
useful mathematical tool. Figure 3.6 presented the Standard Normal 
Distribution with percentages for every half of a standard deviation, and 
cumulative percentages.  
 
 
Figure 3. 6 Standard Normal Distribution Curve 
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The hypotheses used in testing data normality are as follows: 
H0: The distribution of the data is normal. 
Ha: The distribution of the data is not normal. 
 
The normal distribution is characterised by the following mathematical 
function: 
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Where x is the co-ordinate on the x-axis. The expected value of a normal 
distribution is μ. It can take on all real values. The variance is σ2, which can 
only take on positive values. 
 
If a test does not reject normality, this suggests that a parametric procedure 
that assumes normality (e.g., a t-test) can be safely used. Non-normal data 
distributions are skewed distributions which are non-parametric, with a tail. 
Figure 3.7 a) and b) represent the positively and negatively skewed data 
distributions respectively. If the longer tail occurs on the right, that is, if 
there are more extreme values on the right, it is said to be positively skewed 
or right-skewed. If the longer tail occurs on the left with more extreme 
values on the left of the distribution, it is said to be negatively skewed or 
left-skewed. 
 
Figure 3. 7 a) Positively Skewed Distributions. b) Negatively Skewed 
Distributions 
 
If data are not normally distributed, do not report the mean for the data. 
Describe distinctly non-normal data with the median and range or 
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interquartile range (Lang et al., 1998). Another way to report this type of 
data is by using a five-number summary consisting of the minimum, 25th 
percentile, 50th percentile, 75th percentile, and maximum. These five 
numbers are based on the boxplot. 
 
 The Shapiro-Wilk Test for Normality 
The Shapiro-Wilks test (Shapiro and Wilk, 1965) for normality is one of the 
general normality tests designed to detect all departures from normality.  It 
calculates a W statistic that tests whether a random sample, x1, x2, ..., 
xn comes from (specifically) a normal distribution . Small values of W are 
evidence of departure from normality and percentage points for 
the W statistic. The W statistic is calculated as follows: 
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where the x(i) are the ordered sample values (x1 is the smallest) and the ai are 
constants generated from the means, variances and covariances of the order 
statistics of a sample of size from a normal distribution (Pearson and Hartley, 
1972).  
 
The test rejects the hypothesis of normality when the p-value is less than or 
equal to 0.05.  Failing the normality test allows you to state with 95% 
confidence the data does not fit the normal distribution.  Passing the 
normality test only allows you to state no significant departure from 
normality was found. Shapiro-Wilks test was used on every study in this 
research for testing the normality of data, in order to choose whether 
parametric or non-parametric tests should be applied in the later analysis. 
 
3.6.2.2 Comparing Test 
Testing for comparison can be separated into parametric and non-parametric 
methods, based on the distributions of data. Methods that use distributional 
assumptions are called parametric methods (Altman and Bland, 2009), i.e. t 
test. Alternative methods, such as Mann-Whitney test, and rank correlation, 
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do not require the data to follow a particular distribution.  Methods which 
do not require us to make distributional assumptions about the data are 
called non-parametric methods (Altman and Bland, 2009). 
 
 Two-Sample t-Test (Parametric methods) 
The two-sample (independent groups) t-test (Seize, 1977) is used to 
determine whether the unknown means of two populations are different 
from each other based on independent samples from each population. It is 
based on the sampling distribution of the difference of two sample means 
(normal distributed continuous data). Hence, a normality test for the t-test 
need to be run when the data has small sample size. If it is not, a similar 
non-parametric t-test should be used. Another consideration that should be 
addressed before using the t-test is whether the population variances can be 
considered to be equal. If they are different, the Satterthwaite approximation, 
available in some statistical programs, may be used (Peacock and Peacock, 
2010).  
 
The null hypotheses for the comparison of the means in a two-sample t-test 
is that, the two samples come from populations are the same.  
 
The means of two samples can be tested for difference by the following 
formula: 
 (Phillips, 1999) 
 
Where 1x , 2x  are the means, Sp is the pooled standard deviation 
calculated from the groups standard deviations.  
 
 Paired t-test (Parametric methods) 
The paired t-test (Seize, 1977) is a methods for data in which the two 
samples are paired in some way. It analyses mean difference and confidence 
interval for the difference in a paired sample, as in a two treatment 
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randomised block design. It also used to compare two means that are 
repeated measures for the same participants - scores might be repeated 
across different measures or time. Similar with two sample t-test, it is based 
on the sampling distribution of the mean difference (normal).  
 
The null hypothesis for the comparison of the means in a paired t-test is that, 
the population mean of the differences is zero.  
 
The means of two paired samples can be tested for difference by the 
following formula: 
t = 
nS
d
d /
 (Phillips, 1999) 
Where if xi1 – xi2 = di, then the mean of the difference di is d . Sd is the 
standard deviation of the difference, and n is the sample size. 
 
 Mann-Whitley U test (non-parametric methods) 
The Mann-Whitley U test (Wilcoxon, 1945, Mann and Whitney, 1947) is 
similar with the two-sample t-test without the normality or equal variance 
assumption. However, the data must meet the requirement that the two 
samples are independent (Elliott and Woodward, 2007). Unlike the 
parametric test, The Mann-Whitley U test uses ranks or ordering of the data 
instead of the raw data values. Hence, in another word, it is designed to 
compare groups’ medians, not means. In addition, it also can compare 
ordinal data from two independent groups. 
 
The logic behind the Mann-Whitney test is to rank the data for each 
condition, and then see how different the two rank totals are. If there is a 
systematic difference between the two conditions, then most of the high 
ranks will belong to one condition and most of the low ranks will belong to 
the other one. As a result, the rank totals will be quite different. On the other 
hand, if the two conditions are similar, then high and low ranks will be 
distributed fairly evenly between the two conditions and the rank totals will 
be fairly similar. The Mann-Whitney test statistic "U" reflects the difference 
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between the two rank totals. The smaller it is (taking into account how many 
participants you have in each group) then the less likely it is to have 
occurred by chance. Note if there have small samples, the Mann-Whitney 
test has little power. In fact, if the total sample size is seven or less, the 
Mann-Whitney U test will always give a p value greater than 0.05, no matter 
how much the groups differ (Kruskal, 1957). 
 
See the following calculation of U value. Both samples (having 
sizes N and M) are combined into one array which is sorted in ascending 
order. Information had been kept about which sample the element had come 
from. After sorting, each element is replaced by its rank (its index in array, 
from 1 to N+M). Then the ranks of the first sample elements are 
summarised and the U-value is calculated: 
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The null hypothesis of the Mann-Whitney U test is that, observations from 
one group do not tend to have a higher or lower ranking than observations 
from the other group. 
 
3.6.2.3 Measure of Associations 
This section describes measures and tests of associations between two 
categorical variables and between two numerical variables. Of these, 
correlation coefficient and regression (simple linear regression) are used to 
investigate the relationship between two variables. Chi-square test is used in 
sampling distribution of the test statistic. 
 
 Pearson’s Correlation Coefficient (Correlation Coefficient) 
A Correlation Coefficient test is used to measure the strength of relationship 
or degree between two variables, of a supposed linear association between 
them. A correlation coefficient is always between -1 and +1, where -1 
indicates that the points in the scatter-plot of the two variables all lie on a 
line that has negative slope, and a correlation coefficient of +1 indicates that 
 79 
the points all lie on a line that has positive slope. Hence, in general, a 
positive correlation between two variables indicates that, as one of the 
variable increase, the other variable also tends to increase. On the contrary, 
if the correlation coefficient is negative, then as one variable increases, the 
other one tends to decrease. If there is absolutely no linear relationship then 
the correlation coefficient is zero.  
 
The correlation coefficient should be employed as a descriptive measure 
only when scatter plot indicates that a linear relationship exists between the 
two variables of interests. Pearson’s Correlation Coefficient (Society, 1894) 
measures the strength of the linear relationship between two numerical 
variables. It is appropriate for data that attain at least an interval level of 
measurement. It is independent of the scale used to measure the variables. 
 
The hypotheses for testing the statistical significance of a Pearson’s 
correlation coefficient are the following: 
 
H0: There is no linear relationship between the two variables. 
Ha: There is a linear relationship between the two variables. 
 
The following test statistic is used for calculating Pearson’s Correlation 
Coefficient: 
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Where r is the sample correlation coefficient and n is the sample size. Under 
the null hypothesis of no correlation, this test statistic will follow a t 
distribution with n-2 degrees of freedom. The t distribution is used to carry 
out the desired hypothesis test.  
 
 Spearman’s Rank Correlation Coefficient (Correlation Coefficient) 
If the data consists of rank (ordinal data) or there are serious reservations 
about the underlying assumption of bivariate Normality, the Spearman’s 
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Rank Correlation Coefficient (Spearman, 1904) should be used. It is the 
nonparametric equivalent of the parametric Spearman’s Rank Correlation 
Coefficient, and it measures the strength of linear relationship between two 
categorical variables. As for Pearson’s correlation coefficient, the sign of the 
correlation indicates the direction of the relationship while its absolute value 
indicates the strength of the linear association. It has the same null 
hypothesis with Pearson’s correlation coefficient.  
 
To compute the Spearman’s Rank Correlation Coefficient, the raw scores 
will be substituted by their ranks, and perform the usual Pearson’s 
correlation coefficient on the ranks. The way to calculate the rank of 
Spearman’s Rank Correlation Coefficient is: 
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Where d means the difference between two ranks, and n represents the 
simple size. 
 
 Simple Linear Regression 
Simple linear regression (Legendre, 1805, Gauss, 1809) is a statistical 
method used to examine the nature of linear relationship between one 
predictor (independent variable) and a single quantitative response 
(dependent) variable, where one predicts the outcome and the other is 
regarded as the outcome. In general, simple linear regression analysis 
produces a regression equation that can be used in prediction. A typical 
linear regression expression/equation involves observing a sample of paired 
observations in which the independent variable (X) may have been fixed at a 
variety of values of interest, and the dependent variable has been observed. 
This resulting set of observations is sometimes referred to as a training 
sample. It gives the equation of the best straight line through the observed 
data: 
cbXaY   
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Where Y is the outcome, a is the intercept, b is the slope of the line, X is the 
predictor variable, and c is an error term with zero mean and constant 
variance. The equation can be used to predict the dependent variable given a 
value of the independent variable. In this PhD research, simple linear 
regression was used to determine if the linear model fit the data for 
correlation coefficient analysis. 
 
 Chi-Square Test 
The term Chi-Square (Pearson, 1900) has two distinct meanings in statistics. 
One meaning is, it is used to refer to a particular mathematical distribution. 
Another meaning of the term is, it is used to refer to a statistical test whose 
resulting test statistics is distributed in approximately the same way as the 
Chi-Square distribution (Fisher, 1924). 
 
In general, Chi-Square Test tests for an association between two categorical 
variables, where each variable having only two categories is equivalent to 
the z test for two proportions. It is based on the Chi-Square distribution with 
n degrees of freedom, where n is given by (no. of rows -1) * (no. of columns 
-1). The Chi-Square distribution is not symmetrical. It climbs to its highest 
point rapidly and comes down to the horizontal axis more slowly. It is 
skewed to the right, starts at zero on the horizontal axis, and extends 
indefinitely to the right approaching the horizontal axis as it does so. There 
are an infinite number of Chi-Square distributions – one for each degree of 
freedom. As the degree of freedom increase, the shape of the Chi-Square 
distribution looks increasing like the normal distribution. 
 
The Chi-Square test is always testing the null hypothesis, which states that 
there is no significant difference between the expected and observed 
result. If the data consists of two categories on the row and two categories 
on the column (2x2 table), then it is allowed to compare two proportions. 
The null hypothesis (Ho) that there is no association between the row and 
column variables can be restated in terms of proportions. The test statistic is 
given by following formula: 
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Where O is the observed frequency in a given cell, and E is the expected 
frequency in the given cell if the null hypothesis is true. The way to 
calculate E, the expected frequency, is as following: 
 
E = 
sizeSample
totalcolumnxtotalRow
 
 
3.6.2.4 One-way Analysis of Variance (one-way ANOVA) 
ANOVA (Fisher, 1925) is used to assess the statistical difference between 
the means of two or more groups. The term “one-way” is used when there is 
only one independent variable. One-way ANOVA is an extension of the 
two-sample t-test used to determine where there are differences among more 
than two group means.  
 
Differences between the group means are examined with the F-test instead 
of the t-test when ANOVA are used. To do so, the total variance is 
partitioned into two forms of variation and they are compared. One is the 
variation within the groups and the other is the variation between the 
groups. The F-distribution is the ratio of these two forms of variance and 
can be calculated as follows: 
 
F = variance between groups (VB) / variance within groups (VW) 
 
When the variance between the groups relative to within the groups is larger, 
then the F value is larger. Larger F value indicates significant differences 
between the groups and a high likelihood the null hypothesis will be 
rejected. The null hypothesis for the comparison of the means in a one-way 
ANOVA is that, the population means of the all groups are the same. 
 
One-way ANOVA test works on continuous data, and the measurement 
variable is normally distributed within each group. Another assumption is 
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that the within-group variances are the same for each of the groups. 
 
3.6.2.5 Multivariate Analysis of Variance (MANOVA) 
MANOVA (multivariate analysis of variance) (Bartlett, 1939) is a statistical 
procedure to determine if a set of categorical predictor variables can explain 
the variability in a set of continuous response variables. It is also possible to 
include continuous predictor variables either as covariates or as true 
independent variables in the design. It is related to within-subject ANOVA 
in that both of these analyses examine multiple measurements from each 
case in data.  
 
The primary purpose of MANOVA is to show that an independent variable 
has an overall effect on a collection of continuous dependent variables. If 
there are a large number of dependent variables in data, a MANOVA should 
be performed to see if there is any effect of the independent variables, taking 
into account the number of different dependent variables of examining. 
 
If there were multiple dependent variables in data, an ANOVA could be 
used on each variable to examine the effect of the independent variable. 
However, if performing these multiple tests would increase the error rate 
were concerned, a MANOVA would be useful, as it is a single test of the 
independent variable’s influence on the collection of dependent variables. In 
other words, MANOVA can act as protection against an inflation of error 
rate from performing a large number of analysis investigating the same 
hypothesis. If there is a significant effect of the independent variable in the 
MANOVA, one could then follow up that MANOVA with univariate 
ANOVAs (ANOVAs with a single dependent variable) (Rencher and 
Christensen, 2012). 
 
Performing a MANOVA is not the same as looking for an effect on the 
average of the dependent variables. Therefore, it is also different from 
looking for a main effect of a between subjects variable within a repeated 
measures analysis. In truth, the dependent variables are never combined 
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together in MANOVA. MANOVA separately considers the effect of the 
independent variables on the dependent variables. It actually produces a 
matrix of results, which separately contains the influence of the independent 
variables on each of the dependent variables. 
 
3.6.2.6 Diagnostic Tests 
A diagnostic test or procedure is used in clinical practice to determine if a 
patient is likely to have a particular disease or situation. A diagnostic test is 
used in preference to a definitive 'gold standard' test, when this definitive 
test is expensive, or/and time-consuming, and impractical for use in routine 
clinical practice. It can classify individuals into two categories, such as 
positive or negative, diseased or non-diseased, high or low risk, etc. 
Diagnostic tests won’t always give the 'correct' answer, it’s important to be 
able to quantify how accurate a particular test is. There is no single 
statistical measurement that can summarise the accuracy, since a test result 
may either fail to detect a case (false negative) or falsely identify a case 
(false positive).  
 
Sometimes it is not possible to determine the true diagnosis without invasive 
procedures, which would be harmful to the patient, so the 'gold standard' is 
the best diagnosis possible. There are four commonly used measures to 
summarise a test’s performance: sensitivity (Altman and Bland, 1994a), 
specificity (Altman and Bland, 1994a), positive predict value (PPV) 
(Altman and Bland, 1994b), negative predict value (NPV) (Altman and 
Bland, 1994b). 
 
Sensitivity is the proportion of true positives that are correctly identified by 
the test. Oppositely, specificity is the proportion of true negatives that are 
correctly identified by the test. See Table 3.13. 
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Table 3. 13 Positive and Negative Distribution Matrix for Diagnosis 
Tests 
Disease status 
  Positive Negative Total 
Positive a b a + b 
Negative c d c + d 
Test 
Total a + c b + d n 
 
Assuming that the diagnostic tests can either be positive and negative, 
indicating the presence or absence of a disease. The numbers a, b, c, d, and 
n represent the amounts of true positive, true negative, false negative, true 
negative, and total simple size respectively. The sensitivity and specificity 
can be represented as follows: 
 
Sensitivity = a/(a+c) 
Specificity = d/(b+d) 
 
Sensitivity refers to the proportion of true positives who are test positive, 
and specificity refers to the proportion of true negatives who are test 
negative. However, sensitivity and specificity are characteristics of the test, 
but they do not help a clinician to interpret the results of the test. PPV and 
NPV are useful in a clinical setting as they give the probabilities that an 
individual subject is truly positive given that they tested positive, or truly 
negative given that they tested negative. PPV and NPV depend on the 
prevalence of the disease (Peacock and Peacock, 2010) in the population 
being tested. The definition of prevalence of disease is as follows: 
 
Prevalence of disease = (a+c)/n 
 
Prevalence of disease indicates the proportion of all individuals who have 
the disease. If the sensitivity and specificity for a test are known, but the test 
intends to be used on different population from the one it was developed in, 
the PPV and NPV can be calculated using the following standard formulae 
based on Bayes’ theorem (Todhunter, 1865, Pearson, 1907, Fisher, 1922).  
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PPV indicates the proportion of test positives who are true positive, and 
NPV indicates the proportion of test negatives who are true negative.  
 
 Receiver Operating Characteristic (ROC) Curve 
Receiver Operating Characteristic (ROC) curves (Green and Swets, 1966) 
are a useful way to interpret sensitivity and specificity levels and to 
determine related cut scores. ROC curves are a generalisation of the set of 
potential combinations of sensitivity and specificity possible for predictors 
(Pepe et al., 2004). ROC curve analyses not only provide information about 
cut off scores, but also provide a natural common scale for comparing 
different predictors that are measured in different units, whereas the odds 
ratio in logistic regression analysis must be interpreted according to a unit 
increase in the value of the predictor, which can make comparison between 
predictors difficult (Pepe et al., 2004). An overall indication of the 
diagnostic accuracy of a ROC curve is the area under the curve (AUC). It is 
widely recognised as the measure of a diagnostic test's discriminatory power 
(Worster et al., 2006). AUC values closer to one indicate the screening 
measure reliably distinguishes among students with satisfactory and 
unsatisfactory reading performance, whereas values at .50 indicate the 
predictor is no better than chance (Zhou et al., 2011). As a graphical method, 
the AUC of ROC curve can be used to compare the sensitivity and 
specificity for all possible cut off scores. This allows the most appropriate 
cut-off to be chosen for the particular context. 
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Figure 3. 8 An Example of ROC Curve 
 
An example of ROC curve obtained by plot at different cut-offs is shown in 
Figure 3.8. The ROC curve is a graph of sensitivity (y-axis) vs. 1 - 
specificity (x-axis). It offers a graphical illustration of these trade-offs at 
each "cut-off" for any diagnostic test that uses a continuous variable. Ideally, 
the best "cut-off" value provides both the highest sensitivity and the highest 
specificity, easily located on the ROC curve by finding the highest point on 
the vertical axis and the furthest to the left on the horizontal axis (upper left 
corner). However, it is rare that this ideal can be achieved, so that, for 
example, one may opt to choose a higher sensitivity at the cost of lower 
specificity. It will depend on the requirement of study. 
 
 Youden’s index and Likelihood ratios 
The Youden’s index (J) (Youden, 1950), a function of sensitivity and 
specificity, is a commonly used measure of overall diagnostic effectiveness 
(Zou et al., 1997, Barkan, 2001). It is one of the oldest measures for 
diagnostic accuracy. It is used for the evaluation of overall discriminative 
power of a diagnostic procedure and for comparison of this test with other 
tests.  
 
The Youden's index is the difference between the true positive rate and the 
false positive rate. This index ranges between zero and one, with values 
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close to one indicating that the biomarker’s effectiveness is relatively large 
and values close to zero indicating limited effectiveness. Maximising this 
index allows to find, from the ROC curve, an optimal cut-off point 
independently from the prevalence. Figure 3.9 shows that, J is the vertical 
distance between the ROC curve and the first bisector (or chance line). J is 
defined by  
 
}1)()(max{  cyspecificitcysensitivitJ  (Youden, 1950) 
 
Where c refers to the overall cut-off points,  c .  
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Figure 3. 9 ROC Curve 
 
If risk of disease is an increasing function of the marker level, sensitivity 
decreases and specificity increases with rising c. Thus, there is a penalty, 
decreased specificity for increasing sensitivity too far. J occurs at the 
optimal cut-point for calling a patient diseased, maximising the number of 
correctly classified individuals (Hilden and Glasziou, 1996).  
 
Youden’s index is not affected by the disease prevalence, but it is affected 
by the spectrum of the disease, as are also sensitivity, specificity and 
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Likelihood ratios. However, Youden's index is not sensitive for differences 
in the sensitivity and specificity of the test, which is its main disadvantage. 
The consequences of a positive or negative test result may be quite different 
and the loss from missing a case may be greater than from overcalling a 
control. For example, a test with sensitivity (0.9) and specificity (0.4) has 
the same Youden’s index (0.3) as another test with sensitivity (0.6) and 
specificity (0.7). If one is to assess the discriminative power of a test solely 
based on Youden's index, it could be mistakenly concluded that these two 
tests are equally effective. Hence, Likelihood ratios (Neyman and Pearson, 
1931) is used to verify the results. 
 
As an alternative statistics for summarising diagnostic accuracy, which have 
several particularly powerful properties that make them more useful 
clinically than other statistics, Likelihood ratios (LR) is defined as the ratio 
of expected test result in subjects with a certain state/disease to the subjects 
without the disease. Each test result has its own Likelihood ratio, which 
summarises how many times more (or less) likely patients with the disease 
are to have that particular result than patients without the disease. It is the 
ratio of the probability of the specific test result in people who do have the 
disease to the probability in people who do not (Deeks and Altman, 2004). 
 
As discussed, Likelihood ratios directly link the pre-test and post-test 
probability of a disease in a specific patient. It shows how many times more 
likely particular test result is in subjects with the disease than in those 
without disease. When both probabilities are equal, such test is of no value 
and its Likelihood ratio equals one. A Likelihood ratio greater than one 
indicates that the test result is associated with the presence of the disease, 
whereas a Likelihood ratio less than one indicates that the test result is 
associated with the absence of disease. The further Likelihood ratios are 
from one the stronger the evidence for the presence or absence of disease. 
Likelihood ratios above 10 and below 0.1 are considered to provide strong 
evidence to rule in or rule out diagnoses respectively in most circumstances 
(Oxman et al., 1994). When tests report results as being either positive or 
negative the two Likelihood ratios are called the positive Likelihood ratio 
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(LR+) and the negative Likelihood ratio (LR-). 
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LR+ values should be greater than one, LR- values should be positive 
fractions between zero and one. However if the LR+ was less than one and 
the LR- was greater than one, the definitions of a positive and negative test 
result would be reversed. A benefit of using Likelihood ratios over a test’s 
predictive values is that, unlike predictive values, the Likelihood ratio 
depends only on sensitivity and specificity, and not on disease prevalence. 
Consequently, the Likelihood ratios from one study are applicable to some 
other clinical setting, as long as the definition of the disease is not changed. 
If the way of defining the disease varies, none of the calculated measures 
will apply in some other clinical context. 
 
3.6.3 The Use of Data Analysis Methods 
Table 3.14 shows how these methods employed in difference studies. It lists 
nine frequently used statistical (e.g. ROC curve) and data mining (e.g. 
Simple Linear Regression) methods in clinical studies. Each study applies a 
verity methods. Of these, distribution tests for normality, comparison 
methods (parametrical and non-parametrical), and Chi-Square Test are 
usually used for descriptive analyses in statistics. The other methods are 
usually used as inferential analysis in statistics. 
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Table 3. 14 The Use of Statistical Methods in the Studies of this Research 
 
          
Methods 
 
 
Studies 
Distribution 
tests for 
normality 
Parametric 
methods 
for 
comparison 
Non-parametric 
methods for 
comparison 
Correlation 
Coefficient 
Simple 
Linear 
Regression 
Chi-Square 
Test 
Multivariate 
Analysis of 
Variance 
(MANOVA) 
Receiver 
Operating 
Characteristic 
(ROC) curve 
Youden’s 
index and 
Likelihood 
ratios 
Qmci cut offs 
(O’Caoimh et al.) 
√  √   √  √ √ 
Qmci subtests 
(O’Caoimh et al., 
2013a) 
√  √ √ √ √  √  
Qmci vs SMMSE 
(O’Caoimh et al., 
2012a) 
√  √   √  √  
Qmci vs SADAS 
(O’Caoimh et al., 
2013b) 
√  √ √ √ √    
CACE study in 
GAT database (Gao 
et al., 2013a) 
√  √   √ √   
CACE study in 
DARAD database 
(O’Caoimh et al., 
2014) 
√ √ √   √ √   
CACE study in the 
GAT and DARAD 
databases 
combined (Gao et 
al.) 
√  √   √ √   
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Shapiro-Wilks test, Mann-Whitney U test, and Chi-square test are widely 
used in all studies in this research. Shapiro-Wilks test is used for testing the 
normality of data, to choose whether parametric or non-parametric tests 
should be applied in the later analysis. Mann-Whitney U test is always used 
in the demographic analysis for comparing differences in the baseline 
characteristics between two groups in those studies. Chi-square test is used 
for testing the differences in baseline characteristics, for example, the 
comparison on gender, age or education levels between two groups, for 
verifying the baseline differences. 
 
In the Qmci subtest study (O’Caoimh et al., 2013a), the reliability of the test 
was demonstrated by measuring the Qmci on two separate occasions. 
Pearson’s correlation coefficient showed good test–retest correlation. In 
Qmci vs SADAS study (O’Caoimh et al., 2013b), the correlations between 
the Qmci and the SADAS-cog were calculated using the data collected at 1, 
3, 6, 9, and 12 months. This showed that Qmci correlated strongly with the 
SADAS-cog and both were equally responsive to change over time. In this 
PhD research, simple linear regression was always jointly applied with 
correlation coefficient analyses, to verify if the model is linear to fit with the 
data in these analyses. 
 
In The CACE studies on GAT (Gao et al., 2013a), DARAD (O’Caoimh et 
al., 2014), that used two databases combined (Gao et al.), multivariate 
analysis of variance was used to compare end point cognitive and functional 
scores (SMMSE, Qmci and ADL), adjusted for the baseline scores and 
characteristics (age, years of education, duration of follow-up and BP) 
between groups. 
 
In the Qmci subtests study (O’Caoimh et al., 2013a), ROC curves were 
constructed to determine the sensitivity and specificity of the Qmci subtests. 
Area under the curve (AUC) was calculated for each subtest, and analysed 
for age and years of education. In the Qmci cut-off study (O’Caoimh et al.), 
the area under the curve (AUC) was calculated to determine the 
performance of the Qmci for the total sample and each subgroup to classify 
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patients as normal cognition, MCI or dementia. Youden’s index and 
Likelihood ratios were also used in the Qmci cut off study. Cut-off scores 
were calculated using Youden’s Index for each possible outcome based upon 
ROC curves. To provide clinical relevance to the cut-offs, Likelihood ratios 
of the probability of having normal cognition and CI were determined. The 
positive Likelihood ratio (LR+) describes how the probability of disease 
shifts when the finding is present.  
 
3.7 Conclusion 
The first part in this chapter explains the KDD definition and process, which 
refers to the overall process of determining useful knowledge from 
databases. It includes three main phases: data pre-processing, data analysis, 
and data post-processing. Data pre-processing transforms raw data into an 
understandable format. It prepares the real world (raw) data for further 
processing. Data analysis is the core phase in KDD, which applying data 
analysis methods (algorithms) to enumerate patterns from it. This part 
presents two main data analytical approaches: data mining and statistics. 
They are closely connected and employed together during analysis. Data 
post-processing evaluates the extracted knowledge, visualizes it, or merely 
documents it for the end user.  
 
Then this chapter introduces the data sources used in this research – the 
three clinical databases: the Geriatric Assessment Tool (GAT), the 
Doxycycline and Rifampin for Alzheimer’s Disease (DARAD), and the 
Qmci Validation databases. The key instruments of these databases, and the 
studies they were used are also presented. The last section in this chapter 
describes the specific analytical methods used in the research. The key 
concepts of data analysis in medical research are introduced. These methods 
built the core part (data analysis) for the KDD process in the research. They 
are not only used in the studies of the research, but also the popular data 
analytical methods in general medical area, especially the geriatrics research. 
The next two chapters, Chapter Four and Five will present and discuss those 
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studies, describe how the methods were applied, and present the 
interesting/significant findings from the analysis outcomes. 
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CHAPTER 4 QUICK MILD COGNITIVE IMPAIRMENT 
(Qmci) 
 
4.1 Introduction 
This chapter provides a review of the different short cognitive screens that 
were in the research. Along with the Standardised Mini-Mental State 
Examination, the Quick Mild Cognitive Impairment (Qmci) screen is the 
other cognitive outcome measure that will be analysed in this work. It then 
presents a comprehensive description of the Qmci screen, detailing the 
rationale for developing the test and explaining its evolution in recent 
studies, from a previous version called the AB Cognitive screen 135. This 
chapter also explains the process whereby usable cut-off scores for the Qmci 
were developed in order to be able to use this test in subsequent analyses.  
 
This chapter will initially present data that we used to establish the 
sensitivity and specificity of the Qmci for differentiating MCI from normal 
cognition and dementia. It was also compared with the SMMSE and its 
predecessor, the ABCS 135 (O'Caoimh et al., 2012a). Finally, it will explore 
the development of cut-off scores between normal, MCI and dementia, and 
the methods employed as part of this work to develop these cut-off scores. 
The analysis demonstrating the scientific validity and utility of the Qmci is 
based on the KDD (Knowledge Discovery in Databases) process, and 
assessed by different statistical methods. These will be described in detail. 
 
4.2 Research Motivation 
Adults with memory loss present a challenge to clinicians, who must 
determine if memory changes are part of normal aging or are consistent with 
cognitive impairment (CI), mild cognitive impairment (MCI) or dementia. 
Screening for CI is important to allow clinicians to identify reversible 
causes and initiate treatment so that patients and caregivers may plan for the 
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future (Boise et al., 1999). Screening for CI is limited, by a lack of sensitive 
and specific cognitive screening tests to differentiate normal cognition (NC) 
and MCI from dementia (Winblad et al., 2004). The effects of age and 
education further complicate this. Few tests are sensitive or specific in 
patients with low education (Cordell et al., 2013). Clinicians need 
standardised scoring formats that can measure changes over the full 
spectrum of cognitive decline from early (high ceiling) through to the later 
stages of dementia (low-floor). Given this, there is a need for short cognitive 
screening instruments that can differentiate NC from MCI and dementia, 
and accurately describe transition over the full spectrum of cognitive 
decline. 
 
As discussed in Chapter Two, MCI represents a heterogeneous group of 
disorders of memory impairment (Petersen, 2004). Individuals with MCI 
have variable and often subtle cognitive changes, making accurate diagnosis 
difficult. Although many go on to develop dementia, the rate of progression 
varies from person to person, mainly due to variability in the definitions 
used (Fisk et al., 2003) and in the diagnostic methods employed.  
 
4.3 Existing Cognitive Screening Instruments 
Several cognitive screening tests are currently used in clinical practice 
including the Alzheimer’s Disease Assessment Scale-cognitive section 
(ADAS-cog) (Rosen et al., 1984), the Mini-Mental State Examination 
(MMSE) (Folstein et al., 1975), the SMMSE (Molloy and Standish, 1997b), 
the Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) and 
the original version of the Qmci, the AB Cognitive Screen 135 (ABCS 135) 
(Standish et al., 2007). This section will explore the psychometric properties 
of the different tests used. As the Alzheimer’s Disease Assessment 
Scale-cognitive section (ADAS-cog) and the Standardised Mini-Mental 
state Examination (SMMSE) have been introduced in Chapter 3, we will not 
describe them again at here. 
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4.3.1 Mini-Mental State Examination (MMSE) 
The Folstein Mini-Mental State Examination (MMSE) (Folstein et al., 1975) 
is one of the most widely employed cognitive screening tools for dementia 
patients, who present with cognitive impairment. It is used primarily to 
screen patients with cognitive impairment and quantifies cognitive deficits. 
It is useful in identifying dementia and in following cognition over time. 
The Standardised Mini-Mental State Examination (SMMSE) was developed 
to improve the accuracy of the MMSE. The SMMSE has explicit 
administration and scoring guidelines, and improved inter-rater reliability 
than the MMSE (Molloy et al., 1991a, Molloy and Standish, 1997b). Both 
the MMSE and SMMSE have a limited role in identifying MCI (Mitchell, 
2009), as they lack sufficient accuracy to differentiate between NC and MCI, 
especially in patients with high levels of education (Crum et al., 1993). 
These factors limit the MMSE and SMMSE as useful screening tools. 
 
4.3.2 Montreal Cognitive Assessment 
The Montreal Cognitive Assessment (MoCA) is another cognitive screening 
tool that has grown in popularity in recent years. Unlike the MMSE, it is 
highly sensitive and specific at differentiating MCI from NC and dementia 
(Nasreddine et al., 2005). Originally validated against the MMSE 
(Nasreddine et al., 2005), it has since been externally validated against 
different cognitive tests in different cognitive disorders (Gill et al., 2008, 
Videnovic et al., 2010, Wong et al., 2009). It takes longer than the MMSE, 
at least 10 minutes (Nasreddine et al., 2005) and has floor effects, limiting 
its use in those with advanced dementia (O'Caoimh et al., 2013c). It has a 
high sensitivity but a relatively low specificity at its recommended cut-off 
score (<26) (Smith et al., 2007). It was originally published in 2005 and was 
not available for analysis in any of the databases used in this work. 
 
4.3.3 The AB Cognitive Screen 135 
The AB Cognitive Screen 135 (ABCS 135) was also developed to improve 
the accuracy of diagnosing MCI and mild dementia. The ABCS 135 has five 
 98 
domains: orientation, registration, clock drawing, delayed recall (DR) and 
verbal fluency (VF) (Molloy et al., 2005). It is administered in three to 
five minutes and is more sensitive in differentiating NC from MCI and 
dementia than the SMMSE (Molloy et al., 2005). Verbal fluency and 
delayed recall subtests in the ABCS135 were best at distinguishing between 
MCI and NC (Standish et al., 2007). Both subtests have a tendency to floor 
when administered to patients in the later stages of dementia. Orientation 
and registration are not sensitive to early cognitive change, but they decline 
at a linear rate through the later stages, providing a measure of change in 
established dementia. Clock drawing is useful to differentiate MCI from 
early dementia and to chart progression. Age and education affect both the 
ABCS135 and SMMSE (Molloy et al., 2005).  
 
Although, the ABCS 135 is quick to use and accurate (Molloy et al., 2005), 
subsequent analysis of its domains suggested that much of the test may be 
redundant (Standish et al., 2007). Analysis had suggested that although all of 
the domains differentiate NC and MCI from dementia, orientation, 
registration and clock drawing did not enhance the ability of the test to 
differentiate NC from MCI. For this reason, the Quick Mild Cognitive 
Impairment (Qmci) screen was developed, to enhance the sensitivity of the 
ABCS 135, particularly for MCI. 
 
4.4 Developing the Quick Mild Cognitive Impairment 
screen (Qmci) 
4.4.1 Initial development of the Qmci 
The Qmci has the same basic structure as the ABCS 135 except that it 
contains an additional subtest called logical memory (LM) giving it a total 
of six subtests, covering five domains: orientation, registration, clock 
drawing, delayed recall (DR), verbal fluency (VF) (naming animals) and 
LM. LM tests immediate verbal recall of a short story (Wechsler, 2008) and 
is not affected by age or education (Lichtenberg and Christensen, 1992). 
With the addition of LM, the ABCS 135’ scoring was also reweighted, with 
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its total point score reduced from 135 points to 100 points (see Table 4.1).  
 
Table 4. 1 Comparison of the ABCS 135 and the Qmci Screening Test 
ABCS 135 Score Qmci Score 
Orientation 25 Orientation 10 
Registration 25 Registration 5 
Clock drawing 30 Clock drawing 15 
Delayed recall 25 Delayed recall 20 
Verbal fluency 30 Verbal fluency 20 
  Logical memory 30 
 
Previous analysis of the ABCS 135 domains found that DR and VF, were 
more sensitive at differentiating MCI from NC than orientation, registration 
and clock drawing (Standish et al., 2007). Given this, these three domains 
were reduced by a factor of 2.5, 5 and 2, respectively. The relative weighting 
of VF and DR were also increased relative to the other domains. The Qmci 
tool and scoring guidelines are presented in appendix. 
 
4.4.2 Validation of the Qmci 
To validate the Qmci, we previously compared the sensitivity and specificity 
of the newly developed Qmci with its predecessor the ABCS 135 and the 
SMMSE to distinguish individuals with NC from those with MCI and 
dementia (O'Caoimh et al., 2012a). In summary, subjects were analysed 
from the Qmci database that contained data from patients attending four 
memory clinics in Ontario, Canada (Hamilton, Paris, Niagara Falls and 
Grand Bend). In the Qmci database, data were available for 965 subjects. 
Normal controls were selected by convenience sampling. Caregivers, or 
those attending with the subjects, without memory problems were invited to 
participate as normal controls. Dementia was based on NINCDS (McKhann 
et al., 1984) and DSM-IV criteria (First, 1994). A diagnosis of MCI was 
made by a consultant geriatrician in patients who had recent, subjective but 
corroborated memory loss, without loss of social or occupational function. 
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Subjects under 55 years, unable to communicate verbally in English, 
diagnosed with depression, Parkinson's disease or Lewy-body dementia, and 
those without collateral were excluded. Each subject had the SMMSE and 
the Qmci administered. The ABCS 135 was reconstituted from the Qmci 
data by removing the LM domain and reweighting to a total of 135 points. 
The Shapiro–Wilk test was used to test normality and found that the 
majority of data were non-parametric. This data were analysed using the 
Mann–Whitney U test. Student's t-tests compared scores for parametric data. 
Data were also analysed using Receiver operating characteristics (ROC) 
curves. Pearson Chi-squared tests were used to compare distributions when 
it was not possible to analyse differences in medians. Each of the Qmci 
domains were subsequently analysed and compared with the SMMSE to 
investigate the psychometric properties of the individual parts of the test and 
how these contribute to the workings of the test as a whole (O'Caoimh et al., 
2013a). 
 
In the 965 participants included, there were 551 females (57%) and 414 
males (43%). Of the total included, 630 subjects had NC (65%), 154 had 
MCI (16%) and 181 (19%) had dementia. The median age of the total 
population was 70.5 years. Subjects with normal cognition had a median 
SMMSE score of 29, those with MCI a score of 28 and those with dementia 
score of 22, compared with a median Qmci score of 76, 62 and 36 
respectively. The results and demographics are summarised with 
inter-quartile range (IQR) in Table 4.3. 
 
While all three tests distinguished dementia from MCI, the Qmci had greater 
accuracy in differentiating MCI from NC and MCI from dementia. Although 
the Qmci, ABCS 135 and the SMMSE were able to distinguish MCI from 
NC, the Qmci was more sensitive with an area under the curve (AUC) of 
0.86 compared with 0.83 for the ABCS 135 and 0.67 for the SMMSE. The 
Qmci was also more sensitive at differentiating MCI from dementia, AUC of 
0.92 versus 0.91 for the ABCS 135 and 0.91 for the SMMSE (O'Caoimh et 
al., 2012a). The results from this initial work showed that the Qmci was 
more sensitive than the SMMSE and the ABCS 135 in differentiating MCI 
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from NC, while all three are able to distinguish NC from dementia, the 
Qmci was a valid test to use in subsequent analyses of the databases in this 
work. The median Qmci, SMMSE and ABCS 135 scores, along with the 
median scores for the Qmci domains, for subjects with either MCI and NC 
or MCI and dementia are presented in Table 4.2.  
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Table 4. 2 The Total Qmci, SMMSE, ABCS 135 and Qmci Subtest Median Scores with IQR (Q1 = 1st Quartile, Q3 = 3rd Quartile) 
by Diagnosis 
Item 
NC  
median (Q3-Q1 = 
IQR)  
(n = 630) 
MCI  
median  
(Q3-Q1 = IQR)  
(n = 154) 
Dementia 
median  
(Q3-Q1 = IQR)  
(n = 181) 
P-value of 
the median 
diff between 
MCI-NC 
P-value of the 
median diff 
between 
MCI-Dementia 
Area under  
the Curve 
 (95% CI) 
NC from MCI 
Area under the 
Curve 
 (95% CI) 
MCI from D 
Qmci total 76 (83–69= 14) 62 (68–53=15) 36 (45–23 = 22) P < 0.001 P < 0.001 0.86  0.92  
SMMSE total 28 (29–27 = 2) 28 (29–27 = 2) 22 (25–18 = 7) P < 0.001 P < 0.001 0.67  0.91  
ABCS 135 116 (121–109=12) 102 (111–94 = 17) 70 (84–46 = 38) P < 0.001 P < 0.001 0.82  0.91  
Qmci subtests (score out of)   
Orientation (10)  10 (10–10 = 0) 10 (10–9 = 1) 7 (9–5 = 4) P < 0.001 P < 0.001 0.57 0.88 
Registration (5)  5 (5–5 = 0) 5 (5–4 = 1) 5 (5–3 = 2) P < 0.001 P = 0.002 0.56 0.64 
Clock drawing 
(15)  
15 (15–15 = 0) 14 (15–13 = 2) 11 (14–2 = 12) P < 0.001 P < 0.001 0.67 0.76 
Delayed recall 
(20)  
16 (20–12 = 8) 12 (16–8 = 8) 0 (8–0 = 8) P < 0.001 P < 0.001 0.73 0.84  
Verbal fluency 
(20)  
11 (13–9 = 4) 7 (9–6 = 3) 4 (6–2 = 4) P < 0.001 P < 0.001 0.77 0.83 
Logical 
memory(30)  
20 (24–16 = 8) 12.5 (16–10=6) 8 (10–2 = 8) P < 0.001 P < 0.001 0.80(0.77-0.84) 0.82(0.77-0.86) 
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Results suggested that LM was the most accurate domain for separating 
MCI from NC with an AUC of 0.80, higher than the ABCS 135 (0.80) and 
SMMSE (0.67). The other domains, VF (0.77), and DR (0.73) registration 
for words (0.56), orientation (0.57) and clock drawing (0.66) were the less 
accurate. The ability of the tests to differentiate MCI from dementia, 
including the ability of the Qmci domains is also presented in Table 4.3. 
 
In summary, the Qmci (total), ABCS 135, SMMSE and LM had similar 
ability to differentiate MCI from dementia, suggesting that no single test is 
superior in the assessment of patients with established CI. Each of the 
domains of the Qmci accurately distinguished MCI from dementia, although 
the best performing test was now orientation (AUC of 0.88) suggesting that 
different domains have different utilities depending on whether one is trying 
to differentiate MCI from NC or MCI from dementia. 
 
4.5 Developing the Qmci Cut Offs 
4.5.1 Rationale for Developing Cut-offs for the Qmci 
The utility of screening instruments depends upon their sensitivity and 
specificity in the diagnosis of the condition being sought. For short 
cognitive screens, cut-off scores for transition points between different 
cognitive states are required. Cognitive tests provide a range of scores which 
mean that clinicians must select cut-off scores to optimize sensitivity and 
specificity. Useful screening instruments should be responsive to change 
across the cognitive spectrum, from normal cognition to MCI and dementia. 
Additionally, there are no published cut-offs for the Qmci. In order to use 
the test in subsequent analyses, we performed a study to define cut-off 
scores for the Qmci. 
 
4.5.2 Methods for Developing the Cut-off Scores 
In this study, we pooled three databases the Qmci validation database, the 
GAT (Geriatric Assessment Tool) database, and the DARAD (Doxycycline 
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And Rifampacin for Alzheimers Disease) trial database (Molloy et al., 2012), 
to try to develop the cut-off scores between normal, MCI and dementia. 
Subjects were included if their Qmci scores, diagnosis, age and educational 
level were available. Inclusion and exclusion criteria were similar to the 
Qmci Validation Database (O'Caoimh et al., 2012a). Table 4.3 presents the 
baseline demographic data for patients included from the three databases.  
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Table 4. 3 Baseline Demographics for Qmci Patients in GAT, DARAD, and Qmci Validation Databases 
Database 
No of 
Patients 
Available 
No of 
assessments 
included 
NC 
(n=x) 
MCI 
(n=x) 
Dementia 
(n=x) 
Age 
(Mean+/-SD) 
Gender 
(% male) 
Education 
(Mean+/-SD) 
Qmci score 
(Mean+/-SD) 
DARAD 413 1,697 0 0 381 77.6 +/-7.0 49.5% 12.2+/-3.5 35.9+/-14.5 
GAT 1,034 1,894 114 163 414 77.7 +/- 7.9 53.6% 11.9+/-3.9 45.7+/-20.2 
Qmci 
(validation) 
965 940 624 149 167 70.2+/-9.8 42.8% 13.1+/-3.6 65.6+/-19.6 
Total 2,412 4,531 738 312 962 76.1+/-8.6 49.8% 12.2+/-3.7 46.2+/-21.1 
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Figure 4. 1 Flow Chart Demonstrating the Recruitment of Patients from 
the Three Databases 
 
The Qmci is scored out of 100 points. Pooled data were grouped by age and 
education, and the Qmci cut-offs were analysed for each subgroup. The 
cut-off for age was 75 years, as this provided the best balance in numbers 
between the four subgroups. Age 75 also represents the accepted age cut-off 
for CI using the MMSE (Ylikoski et al., 1992), above which scores must be 
adjusted to account for age. The cut-off for education was 12 years, as the 
average length of formal schooling in North America (United States and 
Canada) is 12 years, equivalent to leaving education after high school, 
between 16 and 17 years of age19. The population was divided according to 
age and education, to create four subgroups: age ≤ 75 with education ≥ 12 
years, (n=1176); age ≤ 75 with education < 12 years (n=611), age > 75 with 
education < 12 years, (n=1234); and age > 75 with education ≥ 12 years, 
(n=1510). Table 4.4 provides the total number, gender, mean age, education 
and Qmci scores for the total sample and the four subgroups. 
 
                                                        
19 http://www.nationmaster.com/country-info/stats/Education/Average-years-of-schooling-of-adults 
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Analyses were conducted using SPSS 18.0. The Shapiro–Wilk test assessed 
normality, the Mann–Whitney U test compared non-parametric data, and 
student's t-tests compared parametric data. The Kruskal-Wallis test for 
comparisons between two or more groups. Youden’s Index was used to 
estimate the best balance sensitivity and specificity at each cut-off for the 
Qmci. The area under the curve (AUC) was calculated to determine the 
performance of the Qmci for the total sample and each subgroup to classify 
patients as normal cognition, MCI or dementia. 
 
4.5.3 Developing Cut-off Scores 
Cut-off scores were calculated using Youden’s Index (Youden, 1950) for 
each possible outcome based upon receiver operating characteristics (ROC) 
curves. These Cut-off scores were chosen to give the best balance between 
sensitivity and specificity. Priority was given to sensitivity, aiming for a 
minimum sensitivity of 85% and if possible, a specificity of 85%. We tried 
to balance sensitivity and specificity to maximize both, choosing scores to 
stretch out the point differences between the different diagnoses, 
maximizing the range for MCI.  
 
To provide clinical relevance to the cut-offs, Likelihood ratios of the 
probability of having normal cognition and CI were determined. The 
positive Likelihood ratio (LR+) describes how the probability of disease 
shifts when the finding is present. A score of two to five suggests a small 
chance, five to ten moderate and >10 a large chance. The negative 
Likelihood ratio (LR-) describes how the probability of disease shifts when 
it is absent (McGee, 2002). A score of 0.2-0.5 suggests a small chance, 
0.1-0.2 moderate and <0.1 a large chance. 
 
4.5.4 Results for the Qmci Cut-off Scores 
Baseline demographic data are provided in Table 4.4. After excluding 
patients with missing data, 2,012 subjects, representing 4,531 assessments, 
were available for analysis. Of these, 853 had NC, 703 MCI and 2975 
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dementia, (Figure 4.1). The median age at the time of assessment was 78 
years, interquartile range (IQR) 11. The median Qmci score for normal 
cognition was 75 (IQR 15) points, for MCI 57 (IQR 20) and dementia 37 
(IQR 23). The scores were significantly different in the three groups, 
p<0.001. Based upon Youden’s Index, a cut-off score of 60/100 provided the 
best balance between sensitivity and specificity for the overall population 
for CI, and 50/100 for dementia. At these cut-offs of the Qmci had a 
sensitivity of 89% and specificity of 86% for CI (AUC 0.95, 95% 
confidence interval 0.94-0.95), and a sensitivity of 84% and specificity of 
79% for dementia (AUC of 0.89, 95% confidence interval 0.88-0.90). The 
cut off scores for overall population and subgroups were presented in Table 
4.4. 
 
Table 4. 4 Qmci cut-off Scores with Sensitivity and Specificity Grouped 
by Age and Education Comparing Patients with NC to CI and those with 
Dementia Compared to the Rest 
 
Optimal 
Cut-off 
Sensitivity Specificity 
NC vs CI 60 89% 86% 
Overall 
D vs rest 50 84% 79% 
NC vs CI 57 84% 82% Age ≤ 75 
Edu < 12 D vs rest 47 85% 80% 
NC vs CI 67 86% 89% Age ≤ 75 
Edu ≥ 12 D vs rest 53 93% 81% 
NC vs CI 54 85% 81% Age > 75 
Edu < 12 D vs rest 42 80% 62% 
NC vs CI 56 87% 81% Age > 75 
Edu ≥ 12 D vs rest 47 82% 71% 
 
Table 4.4 provides cut-off scores and sensitivity and specificity levels for 
NC, the threshold for CI (NC from MCI and dementia), and dementia 
(dementia from NC and MCI), for the overall population and four subgroups, 
divided according to age and education, selected using the Youden’s Index. 
The optimal cut-off for identifying CI for older subjects (>75) with less time 
in formal education (<12) fell from 62 to 54 points. Sensitivity and 
specificity for detecting CI were highest for younger (≤ 75) subjects with 
more education (≥ 12), at 88% and 87% respectively and lowest for the 
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oldest subjects (>75) with less formal education (<12), at 85% and 81% 
respectively. This subgroup also had the lowest sensitivity and specificity 
for detecting dementia, 80% and 62%, at a cut-off of 42. The Qmci was 
most accurate at separating CI from NC for younger subjects (≤75), with 
more time in formal education (≥12), AUC of 0.95. The Qmci was least able 
to differentiate CI from NC (AUC of 0.89) and dementia (AUC of 0.81), in 
older subjects (>75) with less (<12) formal education, with sensitivities and 
specificities falling correspondingly. The points range between NC and 
dementia cut-offs, was wider for younger subjects with more formal 
education, 67 to 53, (14 point spread), and narrowest for older subjects with 
less education, 56 to 46, (nine points). The distribution of Qmci cut-offs for 
the population overall and each subgroup is illustrated in Figure 4.2. 
 
 
Figure 4. 2 Distribution of the Qmci Cut-off Scores for all Patients and 
Four Subgroups Stratified by Age and Education, Based on Sensitivity 
and Specificity of each Score 
 
Likelihood ratios were calculated for the cut-off scores for the total 
population and each subgroup. Those at or below 60, the cut-off that 
provided the best balance between sensitivity and specificity for the 
presence of CI, had a moderate chance of having CI (NLR 0.17). Above 60, 
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there was a moderate chance of having NC (PLR 7.88). Above 65 there was 
a large chance (PLR >10) of having NC whereas at or below 65 the chance 
of having NC was small (NLR 0.23). Those at or below 50, the optimal 
cut-off score for detecting dementia, had moderate chance of having 
dementia (PLR 5.0) while above 50 there was a small chance of having 
dementia (NLR 0.28). Likelihood ratios also confirmed the choice of cut-off 
scores for each subgroup. For example, the cut-off above which younger 
subjects (≤75) with more formal education (≥12) had a large chance of 
being normal was 70. At or below 70, the chance of not being normal was 
also small, confirming that the optimal cut-off (≤67), lies below this. 
 
4.5.4 Discussion of the Qmci Cut-off Scores 
Thus, cut-off scores for the Qmci screen, adjusted for age and education 
were now available for subsequent analysis of the databases. In summary, a 
cut-off score of ≤60 points, provided the best balance between sensitivity 
and specificity for the Qmci. At this cut-off, it had an 89% sensitivity and 
86% specificity for CI comparing well with other short cognitive tests such 
as the widely used MoCA which has a similar sensitivity of 90% 
(Nasreddine et al., 2005) but a lower specificity (Luis et al., 2009, Smith et 
al., 2007) at its recommended cut-off of ≤26 (Nasreddine et al., 2005). 
However, it must be remembered that cut-off scores, simply indicate 
transition points and should be interpreted with caution as cognitive 
performance is affected by individual variations in age and educational level 
(Crum et al., 1993). Placing emphasis on cut-offs rather than clinical 
assessment, could be misleading (Cullen et al., 2007). Obviously if 60 were 
a cut-off and a person scored 59 or 61, then a diagnosis is less certain than a 
person who scored 57 or 67. The closer a person scores to the cut-off, the 
less certain the diagnosis is. And clinicians know this and will rely on other 
factor in making a diagnosis clinically. 
 
In summary, this section provides usable cut-off scores for the Qmci based 
upon large numbers of patients presenting with memory loss across both 
clinical and research settings. It shows that the Qmci can differentiate MCI 
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from NC and dementia and suggests superior sensitivity and specificity over 
other short cognitive screens such as the SMMSE and MoCA. This analysis 
also provided cut-off scores adjusted for age and education that while not 
used directly in subsequent analysis provide an important part of the 
development of any short cognitive screening test. Based upon this analysis, 
a cut-off score of <60 for CI (either MCI or dementia), a range of 59 to 51 
for MCI, and <50 points for dementia. Thus, the Qmci is a useful tool in the 
clinic to screen for CI and to differentiate between normal cognition, MCI 
and dementia.  
 
4.6 Comparison of the Qmci with Other Cognitive Tests  
Apart from its validation against the SMMSE and its predecessor, the ABCS 
135, the Qmci has also been compared with other cognitive and functional 
outcome measures. These include the MoCA (O'Caoimh et al., 2013c), the 
SADAS-cog, the Clinical Dementia Rating (CDR) scale and the 
Lawton-Brody activities of daily living scale (O'Caoimh et al., 2014). The 
recently developed MoCA is widely validated in the detection of early CI 
(Nasreddine et al., 2005), but although it has excellent sensitivity for CI, 
particularly for MCI and early dementia, its specificity has been questioned 
in older adults, especially those with lower levels of formal education. 
Comparison of the Qmci with the MoCA showed that the Qmci was more 
accurate with shorter administration times (O'Caoimh et al., 2013c). 
Specifically the Qmci was more accurate than the MoCA in differentiating 
MCI from those with normal cognition, area under the curve (AUC) of 0.82 
versus 0.74. It also had superior accuracy in differentiating MCI from 
dementia, AUC of 0.96 versus 0.91. At the recommended cut-off scores for 
each test, the Qmci (<60) had greater sensitivity (88%) and specificity (88%) 
for cognitive impairment, compared with 96% and 41% respectively for the 
MoCA (<26). Median administration times are 4.52 minutes for the Qmci 
compared with 9.52 minutes for the MoCA.  
 
We have also compared the Qmci with other direct and indirect cognitive 
screens including the SADAS-cog, a marker of ADLs, the Lawton-Brody 
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scale and a global test of dementia, the CDR scale. By comparing rates of 
change, over the one year of follow-up in a clinical trial, the DARAD, we 
showed that the Qmci had strong and significant correlation with the 
SADAS-cog and moderate significant correlation with ADLs and the CDR 
scale (O'Caoimh et al., 2014).   
 
4.7 Conclusion and Rationale for Using the Qmci 
Multiple short cognitive screens are in currently available to clinicians 
(Cullen et al., 2007), the most widely used of which is the MMSE (Folstein 
et al., 1975) and its standardised form, the SMMSE. There are however, 
several well-established difficulties with using these in clinical practice, 
particularly where screening for MCI and early dementia (Mitchell, 2009) 
and especially among older adults with high educational attainment (Crum 
et al., 1993). Using the cut-off scores described in section 4.5, recent 
research has shown that the Qmci has superior accuracy for identifying MCI 
from NC in older adults attending a memory clinic, compared with the 
SMMSE and the MoCA, the same population as will be assessed in this 
work. Although both the Qmci and MoCA differentiated MCI from NC and 
dementia, the Qmci was more accurate and has a shorter administration time. 
The MoCA had a low specificity for CI and a high rate of false positives, 
suggesting that it is less clinically useful among older adults.   
 
Overall, the Qmci is a short screening test for cognitive impairment, 
developed as a rapid, valid and reliable tool for the early detection and 
differential diagnosis of mild cognitive impairment (MCI) and dementia 
(O'Caoimh et al., 2012a).  The Qmci includes a selection of domains that 
while useful have different accuracy at different stages of disease 
progression. The Qmci has six domains: orientation, registration, clock 
drawing, delayed recall, verbal fluency (naming animals) and logical 
memory (LM), an immediate verbal recall of a short story. It is scored out of 
100 points and has a median administration time of 4.24 minutes (O'Caoimh 
et al., 2013a). The Qmci was derived from the ABCS 135 by reweighting its 
subtests and adding LM (O'Caoimh et al., 2012a). It has superior sensitivity 
 113 
and specificity for differentiating MCI from normal cognition and dementia 
compared to the SMMSE and the AB Cognitive screen 135 (O'Caoimh et al., 
2012a). It also correlates with the SADAS-cog, CDR scale and the 
Lawton-Brody activities of daily living scale (O'Caoimh et al., 2013b). In 
the next chapter, Qmci will perform as a key cognitive measurement with 
SMMSE in the studies, which explore the effects of centrally acting ACE 
inhibitors in dementia. 
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CHAPTER 5 DRUG ANALYSIS 
 
5.1 Introduction 
There is growing evidence that antihypertensive agents, particularly 
centrally acting ACE inhibitors (CACE-Is), that cross the blood–brain 
barrier, are associated with a reduced rate of cognitive decline. This chapter 
describes how CACE-Is, one of the first anti-hypertensives to be studied, are 
associated with reduced rates of cognitive and functional decline in 
dementia, measured with Qmci, SMMSE and ADL tests, as the key outcome 
measures.  
 
The centrally acting ACE inhibitors in this PhD research 
included perindopril, coversyl, aceon, ramipril, altace, tritace, lisinopril, 
captopril, capoten, co-zidocapt, capozide, fosinopril, monopril, zestril, 
prinivil, trandolapril, mavik and Tarka. Of these, perindopril, coversyl and 
aceon were in the perindopril group, the other centrally acting ACE 
inhibitors were in the “other CACE-I” group. Patients who were not 
currently prescribed CACE-Is were called NoCACE-I group. 
 
This chapter discusses the association between anti-hypertensive agents, 
especially CACE-Is, with dementia, on cognition and function. There were 
three studies examined the effect of CACE-Is, on cognitive and functional 
rate of decline in patients with dementia. The data analyses in those studies 
were based on a KDD (Knowledge Discovery in Databases) process. The 
sections for these three studies (Section 5.3 - 5.5) rely on the data 
pre-processing, data analysis and data post-processing (results) procedures. 
The first study used the GAT (Geriatric Assessment Tool) database. We 
compared rates of cognitive decline in clinic patients with dementia, 
receiving CACE-Is (CACE-I group), to NoCACE-I group, and to those who 
started CACE-Is, during their first six months of treatment (NewCACE-I 
group). The second study used the Doxycycline and Rifampin for 
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Alzheimer’s Disease (DARAD) database. The aim of this study was to 
compare rates of cognitive, functional and neuropsychological (depression 
and behaviour) decline in dementia patients receiving CACE-Is (CACE-I) to 
those not currently treated with CACE-Is (NoCACE-I). The third study 
pooled the GAT and DARAD databases together. We subdivided CACE-I 
group into perindopril and other CACE-I subgroups, and compared the rates 
of functional and cognitive decline in patients with established dementia 
between those groups. To examine the impact of CACE-Is on ADLs, we 
also separated ADLs into basic ADLs (BADLs) and instrumental ADLs 
(IADLs) to compare the rate of functional decline in subjects with dementia, 
who were receiving CACE-Is or not treated with CACE-Is (NoCACE-I). 
 
5.2 Background 
5.2.1 Anti-hypertensive Agents for Cognition in Dementia  
As the worldwide populations aged, the incidence of dementia will increase. 
By 2040, approximately 81 million people worldwide will have dementia 
(Ferri et al., 2005). To date, no agents have been identified that prevent, 
modify or reverse dementia, and available treatments for dementia are 
predominantly symptomatic (Sloane et al., 2002). There is growing 
recognition of the role of cardiovascular risk factors, especially in mid-life, 
in the development and progression of mild cognitive impairment and 
dementia (Whitmer et al., 2005, Breteler et al., 1994, Rozzini et al., 2008).  
 
Blood pressure (BP) control, in particular, is associated with both a reduced 
incidence of cognitive impairment and rate of cognitive decline (Duron et al., 
2009, Ligthart et al., 2010, Collaborative et al., 2003, Oveisgharan and 
Hachinski, 2010). Varieties of anti-hypertensives improve cognition in older 
adults with elevated BP (Fogari et al., 2003, Fogari et al., 2004) and have 
potential as therapeutic agents in dementia (Kehoe and Passmore, 2012, 
Fournier et al., 2009, Davies et al., 2011). Results are however inconsistent 
(Staessen et al., 2011, Poon, 2008, Sink et al., 2009) with some 
observational studies even suggesting harm (Kehoe et al., 2013). 
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5.2.1.1 Anti-hypertensive Agents and Dementia 
Several anti-hypertensive agents are associated with a reduced risk of 
developing dementia, including calcium channel blockers (CCBs) (Tollefson, 
1990, Kennelly et al., 2012), diuretics (Collaborative et al., 2003), 
angiotensin receptor blockers (ARBs) (Hajjar et al., 2012b, Li et al., 2010, 
Lithell et al., 2003), and angiotensin converting enzyme inhibitors (ACE-Is) 
(Ohrui et al., 2004, Rozzini et al., 2006).  
 
Angiotensin Converting Enzyme Inhibitors, (ACE-Is) and Angiotensin 
Receptor Blockers (ARBs) may lower dementia risk or slow progression, 
independent of their BP lowering properties (Davies et al., 2011, Li et al., 
2010, Hajjar et al., 2009, Hajjar et al., 2012c). Prescription of ARBs and 
ACE-Is is also associated with reduced incidence of both vascular dementia 
(VaD) and mixed dementia subtypes (Hanes and Weir, 2007, Davies et al., 
2011). Results of clinical trials investigating the potential role of 
anti-hypertensives are limited and conflicting (Poon, 2008). The Perindopril 
Protection against Recurrent Stroke Study (PROGRESS), demonstrated that 
a combination of Perindopril (ACE-I) and indapamide (diuretic) was 
associated with a significant reduction in the incidence of stroke and in 
cognitive decline, compared to placebo (Collaborative et al., 2003). The 
Systolic Hypertension in Europe (Syst-Eur) study, found that the 
combination of enalapril (ACE-I), nitrendipine (CCB), and/or 
hydrochlorothiazide (diuretic), reduced the incidence of dementia by 55%, 
compared to placebo (Staessen et al., 1997, Forette et al., 2002). 
Mono-therapy with the ARB, candesartan, in the Study on Cognition and 
Prognosis in the Elderly (SCOPE), also showed modest effects (Lithell et al., 
2003). Not all studies have shown cognitive benefits with anti-hypertensive 
agents; some implicate them in the worsening of cognition (Maxwell et al., 
1999). The ONTARGET and TRANSCEND trials, two parallel studies 
involving more than 25,000 patients, found that ACE-Is did not have any 
measurable effects on cognition (Teo et al., 2004). Although the evidence is 
limited, treatment with anti-hypertensives has been associated with reduced 
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rates of cognitive (Mielke et al., 2007, Bellew et al., 2004) and functional 
decline (Rosenberg et al., 2008a) in those with established AD. 
 
ACE-Is were one of the first anti-hypertensives to be studied, particularly in 
Alzheimer’s disease (AD), the most prevalent form of dementia 
(Brunnström et al., 2009). Patients with AD have abnormal cleavage of 
amyloid precursor protein (APP) resulting in a pathological accumulation of 
amyloid beta (Aβ), a key neuropathological hallmark of AD (Hardy, 2009). 
The relationship between angiotensin converting enzyme (ACE) and the 
accumulation of Aβ is complex and different polymorphisms have been 
postulated to either increase (Kehoe et al., 1999), or decrease (Lehmann et 
al., 2005), the risk of developing AD. ACE activity is increased in AD, 
proportional to the Aβ load (Miners et al., 2007).   
 
5.2.1.2 Centrally-acting ACE–Is and Cognition 
Centrally acting ACE-Is (CACE-Is), a sub-group of ACE-Is, that cross the 
blood-brain barrier, are associated in observational studies, with a reduced 
incidence of mild cognitive impairment (MCI) (Solfrizzi et al., 2011, 
Rozzini et al., 2006) and dementia (Sink et al., 2009), and slower rates of 
cognitive decline in Alzheimer’s disease (AD), relative to non-centrally 
acting ACE-Is (Ohrui et al., 2004, Gao et al., 2013a).  The CACE-I 
perindopril when administered to mouse models, showed a significant 
protective effect (Dong et al., 2011b) and reversed cognitive impairment 
more than the non-centrally acting imidapril and enalapril (Yamada et al., 
2010). Patients receiving CACE-Is have a reduced rate of cognitive decline 
compared to both non-centrally acting ACE-Is and CCBs (Ohrui et al., 
2004). The Cardiovascular Health Study demonstrated no reduced risk in 
incident dementia in those taking CACE-Is, compared to other classes of 
anti-hypertensives (Fried et al., 1991). Those prescribed CACE-Is, had a 
reduced rate of cognitive decline and less impairment in instrumental 
activities of daily living (IADL’s), compared to those taking non-centrally 
acting agents (Sink et al., 2009).  
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The strongest pre-clinical evidence to date for the utility of ACE-Is in 
affecting cognitive decline is for the CACE-Is, perindopril. Perindopril 
reversed Aβ induced cognitive impairment (Yamada et al., 2010), inhibited 
brain ACE activity, elevating extra cellular acetylcholine levels in mice 
(Yamada et al., 2011), while two non-centrally acting ACE-Is, did not. 
Perindopril, but not other ACE-I’s, significantly inhibited hippocampal ACE, 
and prevented cognitive impairment in mouse models of AD (Dong et al., 
2011b, Tota et al., 2012). Clinically, the Cardiovascular Health Study 
reported observational data that perindopril, rather than non-centrally acting 
ACE-Is and calcium channel blockers, decreased the rate of decline in 
patients with mild to moderate AD (Sink et al., 2009). Results however are 
inconsistent. Secondary analyses of randomized trials have failed to detect 
an effect of ACE-Is (Teo et al., 2004) or ARBs on cognition (Staessen et al., 
2011, Lithell et al., 2003). Furthermore, a small placebo controlled clinical 
trial in non-demented offspring of AD patients showed no effect on 
cognition (Wharton et al., 2012).  
 
Outside of clinical trials, there is little data on the effects of CACE-Is on the 
rate of cognitive decline in patients with dementia. Given this, and the 
growing evidence for anti-hypertensive agents, particularly CACE-Is, in 
reducing the incidence and rate of cognitive decline, in Chapter 5.3, we 
compared the rates of decline in patients taking CACE-Is (CACE-I), to 
those not currently prescribed CACE-Is (NoCACE-I), in patients with 
established dementia, attending a memory clinic, based on GAT database. In 
that section, we also examined whether patients started on CACE-Is while 
attending clinic (NewCACE-I), behaved differently during their first six 
months of treatment, compared to the NoCACE-I group, and those already 
established on CACE-Is. 
 
5.2.2 Anti-hypertensive Agents and ADL Function in Dementia 
Impaired activities of daily living (ADL) affect functional independence and 
patient quality of life (Liu et al., 1991). Changes in ADLs represent the 
hallmark characteristic of progression from mild cognitive impairment 
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(MCI) to dementia (Patterson et al., 2007), and signal onset of progressive 
cognitive decline in patients with established dementia (Mortimer et al., 
1992). Loss of instrumental ADLs (IADLs), such as shopping or cooking, 
usually occur before the loss of basic ADLs (BADLs), like dressing or 
toileting (Pérès et al., 2008). Hypertension is highly prevalent in older adults, 
including in those with cognitive impairment (CI) (Igase et al., 2011).  
 
 Hypertension, ACE inhibitors and Activities of Daily Living 
Hypertension may increase the risk of decline in ADLs in patients with 
dementia (Stuck et al., 1999). This has been found for IADLs but not 
BADLs (Caskie et al., 2010). Although few studies have assessed the effects 
of anti-hypertensive agents on rates of functional decline in patients with 
established dementia, data from recent observational studies suggests that 
beta-blockers (Rosenberg et al., 2008b) and ACE-Is may slow functional 
decline in patients with mild to moderate Alzheimer’s disease (AD) 
(O'Caoimh et al., 2014). Available evidence suggests that ACE-Is are 
associated with improved physical function (exercise tolerance), increased 
muscle strength  and lower falls risk (Sumukadas et al., 2007, Wong et al., 
2013), in older adults with normal cognition. Furthermore, the 
discontinuation of ACE-Is in those with AD is associated with increased 
rates of functional decline (Regan et al., 2006). For example, vascular 
dementia has been associated with a condition called amyloid angiopathy, in 
which amyloid plaques accumulate in the blood-vessel walls, causing them 
to break down and rupture.  
 
ACE-Is may slow functional decline by reducing inflammation, improving 
endothelial function and increasing muscle blood flow and glucose delivery 
to skeletal and cardiac muscle (Onder et al., 2002). Contradicting this, other 
observational studies suggest that exposure to ACE-Is is associated with 
increased dependency in ADLs (Sink et al., 2009), and studies investigating 
ACE genotypes, some of which might mimic or have comparable biological 
ACE activity to ACE-Is, had conflicting results on functional decline in 
older adults, with both increased (Seripa et al., 2011)and decreased 
disability (Kritchevsky et al., 2005) observed. Hence, Chapter 5.4 compared 
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rates of decline in patients with Alzheimer’s disease (AD) receiving 
CACE-Is to those not currently treated with CACE-Is (NoCACE-I) in 
patients with mild to moderate AD, in the DARAD database. 
 
To date, few studies have investigated whether ACE-Is affect ADLs, and to 
our knowledge, none if they differentially affect IADLs or BADLs. Given 
this, and the recent, albeit often conflicting data favoring CACE-Is in 
reducing the incidence and rate of cognitive decline, in Chapter 5.5, we 
pooled the GAT and DARAD databases together, and compared the rates of 
cognitive and functional decline (including IADLs and BADLs) in 
community dwelling older adults with established dementia taking CACE-Is 
(CACE-I), to those not currently prescribed CACE-Is (NoCACE-I). 
 
5.3 Effects of CACE-Is on the Rate of Cognitive Decline 
in Dementia (Study One: CACE Study in GAT Database) 
5.3.1 Introduction 
The first study investigated whether patients with dementia, receiving 
CACE-Is, had slower rates of cognitive decline compared to others, who 
were not receiving CACE-Is (NoCACE-Is), irrespective of blood pressure 
readings or diagnosis of hypertension, based on Geriatric Assessment Tool 
(GAT) database. We also examined whether patients started on CACE-Is, 
while attending clinic (NewCACE-I), behaved differently in the first six 
months of treatment compared to the average change in those taking 
CACE-Is over a longer period of time. 
 
This database includes two cognitive screening test score, the Standardised 
Mini-Mental State Examination (SMMSE) (Molloy et al., 1991a, Molloy 
and Standish, 1997b) and the Quick Mild Cognitive Impairment (Qmci) 
screen (O'Caoimh et al., 2012a, O'Caoimh et al., 2013a). These tests were 
scored by nurses in the clinic prior to the assessment, who were test-blind to 
the diagnosis. Cognitive assessments were performed to assist in diagnosis, 
treatment effects and to follow progression.  
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5.3.2 Data Pre-processing – Subjects Selection 
A consultant geriatrician diagnosed the patients with dementia using 
NINCDS (McKhann et al., 1984) and the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition (DSM-IV) criteria (First, 
1994). Patients with AD, vascular or mixed dementias (Alzheimer's/vascular) 
were included in the analysis. Patients with Lewy body dementia, 
Parkinson's disease dementia, frontotemporal dementia, alcohol-related 
dementia, post-trauma and post-anaesthetic dementia, were excluded, as 
there is little evidence that antihypertensive medications affect these 
dementia subtypes. Patients with normal cognition, n=181, MCI, n=235 and 
depression, n=397 were also excluded. Participants with depression (n= 397) 
were excluded: 260 with CI and comorbid depression, and 137 with normal 
cognition and depression, as there is little evidence that ACE-Is affect 
comorbid depression (Rogers and Pies, 2008), while the results of cognitive 
testing are negatively affected by depression (Porter et al., 2003).  Patients 
were also excluded from the analysis if they did not have the results of 
either the Qmci or SMMSE available at both the baseline and end point (last 
visit). In total, 456 (56%) dementia patients with only one cognitive test 
record were excluded. In order to facilitate comparisons, changes between 
the baseline and end-point scores were standardised at six months, between 
all groups. There was no significant difference in baseline SMMSE (p=0.06) 
or Qmci scores (p=0.51), using regression analysis, adjusting for baseline 
characteristics (age, gender, education and BP) between participants without 
follow-up and those included. Figure 5.1 graphically presents the process of 
patient selection.  
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Figure 5. 1 Flow Chart Demonstrates the Breakdown of the Patients 
Who were Included in the GAT Database 
 
The CACE-I group included patients currently prescribed the centrally 
acting ACE inhibitors. NoCACE-I included patients who were not currently 
receiving centrally acting ACE inhibitors, irrespective of the BP readings, 
diagnosis of hypertension or whether they were receiving other 
antihypertensive medications. 
 
5.3.3 Data Analysis 
Baseline Qmci and SMMSE scores (the time-point when cognitive scores 
were first available for each subject) were compared to end-point scores (the 
time-point when cognitive scores were last available), between subjects 
taking CACE-Is and NoCACE-Is, and between those newly started on 
CACE-Is during a clinic visit (NewCACE-Is) and all other CACE-Is 
 123 
subjects. The goal was to determine whether there were differences in their 
rates of cognitive decline. Average rates of decline in cognitive scores were 
initially calculated for each subject, per month. Given that regulatory 
authorities, including the Food and Drug Authority, require evidence of 
change in cognitive tests over six months, to confirm the benefit of new 
medications, longitudinal outcomes were changes measured from baseline, 
expressed on a six monthly basis (Matthews et al., 2000), according to the 
formula: Rate of decline = (Baseline score – End-point score)/ Duration in 
months.  
 
Data were analysed using SPSS V.18.0. Normality was tested using the 
Kolmogorov-Smirnov and Shapiro-Wilk tests. Mann-Whitney U test was 
used to compare the non-normally distributed data. Categorical data were 
analysed with χ2 tests. Multivariate regression was used to compare rate of 
change between the three groups (CACE-I, NoCACE-I and NewCACE-I), 
adjusted for the baseline cognitive scores and characteristics (age, years of 
education, duration of follow-up and BP). Data were presented as median 
and interquartile range (IQR), as most of them were non-parametric. 
 
5.3.4 Results 
5.3.4.1 Baseline Characteristics 
Table 5.1 and 5.2 present demographics, medication use, baseline and 
end-point Qmci and SMMSE scores for subjects taking CACE-Is, 
NoCACE-Is or NewCACE-Is. There were 817 subjects, in total, with 
dementia, who were divided into CACE-Is, (n=248) and NoCACE-Is 
(n=569). The mean age of the total sample was 77.9, with a SD of + 8.1 
years. The mean age of subjects taking CACE-Is, was 77.2, compared to 77 
for the NoCACE-Is group. There were no significant differences in age 
profiles between the two, p=0.57. The total sample was 50.3% male. 
Subjects receiving CACE-Is were 51.8% male, compared to 49.6% of 
NoCACE-Is subjects, and again there was no significant difference between 
both groups, p=0.12. There were no differences in use of cholinesterase 
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inhibitors or mean-time between subjects taking CACE-Is, NoCACE-Is or 
NewCACE-Is.  
 
Table 5. 1 Baseline Characteristics of CACE-I, NoCACE-I and 
NewCACE-I Patients 
Groups CACE-I NoCACE-I NewCACE-I 
Number 85 276 30 
Age (mean ± SD) 77.2 ± 6.4 77.0 ± 7.6 77.3 ± 8.2 
Male (%) 44 (51.8 %) 137 (49.6%) 15 (50%) 
Education  
(mean ± SD) 
10.6 ± 3.8 11.4 ± 4.0 12.1 ± 3.9 
Systolic BP in mmHg 
(mean ± SD) 
133.4 ± 21.2 135.5 ± 16.9 141.1 ± 16.2 
Diastolic BP in mmHg 
(mean ± SD) 
70.1 ± 12.6 72.5 ± 11.5 78.1 ± 17.0 
Cholinesterase 
Inhibitor use (%) 
75 (88.2%) 228 (82.6 %) 24 (80%) 
Memantine use (%) 23 (27.1 %) 72 (26.1 %) 8 (26.7%) 
 
There were 147 participants who had both SMMSE and Qmci scores at 
baseline and end point; 206 participants had SMMSE scores only, and 8 had 
Qmci scores alone. The median duration of follow up between baseline and 
end-point are presented in Table 5.2. The mean SMMSE score at baseline 
was 21.6 (+ 5.6); the mean score at end-point was 18.1 (+ 8.0). The mean 
Qmci scores were 36.8 (+ 13.6) and 31.3 (+ 18.3) at baseline and end-point, 
respectively. There were 83 subjects taking CACE-Is and 270 NoCACE-I 
who had SMMSE scores available at both baseline and end-point. For 
CACE-I subjects, the median baseline SMMSE was 22 (6), similar to 
NoCACE-I 23 (7), p=0.943. Qmci scores were available for 41 subjects 
taking CACE-Is and 114 NoCACE-I and again, there was no significant 
difference between Qmci median scores, at baseline between CACE-I, 36 
(11) and NoCACE-I, 38 (20), p=0.39. There were no significant differences 
in the baseline SMMSE and Qmci scores between the three groups (CACE-I, 
NoCACE-I and NewCACE-I), adjusted by the baseline characteristics (age, 
education, duration of follow-up and BP). 
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Table 5. 2 Baseline and End-Point (Last Visit) SMMSE and Qmci Scores 
 N Baseline  
Mean(±SD) 
Age 
Gender 
(male,%) 
Median 
Duration of 
follow-up in 
months 
Baseline 
Median 
(Q3-Q1) 
Score 
End-point 
Median 
(Q3-Q1) 
Score 
CACE-I 83 77.3 (± 6.6) 53.0% 17 (34-7) 22 (25-19) 20 (25-14) 
NoCACE-I 270 77.1(± 7.6) 49.3% 18 (31-9) 23 (26-19) 20 (25-13) 
SMMSE 
NewCACE-I 30 77.3 (± 8.2) 50% 6 (7-4) 23 (27-18) 24 (27-19) 
CACE-I 41 78.9 (± 6.1) 56.1% 16 (31-7) 36 (44-23) 29 (49-15) Qmci 
NoCACE-I 114 78.0 (±7.6) 49.1% 11 (24-6) 38 (47-27) 32 (45-17) 
 
Within the CACE-I group, 30 subjects had recently (median six months) 
been started on CACE-Is (NewCACE-I) while attending clinic. The median 
SMMSE score for NewCACE-I was 23 (9), mean Qmci score 35.6 (+/-18.0). 
There was no significant difference between the baseline scores for 
NewCACE-I with the other two subgroups.  
 
There were no differences in use of cholinesterase inhibitors (CholEI) or 
memantine between patients taking CACE-Is, NoCACE-Is or NewCACE-Is. 
Eight subjects taking NewCACE-Is were co-administered other medications 
that are associated with improvement in cognitive scores: CholEI (n=5), a 
diuretic (n=1), CCB (n=1) and L-thyroxine (n=1), while three had such 
medications discontinued: CholEI (n=1) and diuretic (n=2).  
 
5.3.4.2 Rate of Decline 
For the total sample, the median rate of cognitive decline, between baseline 
and end-point, measured by the SMMSE, was 0.69 points per six months 
(IQR of 2). The median changes in SMMSE scores were 0.8, 1.0 and −1.2, 
respectively, for the CACE-I, NoCACE-I and NewCACE-I groups, per six 
months. The median change for Qmci was two points per six months, while 
the median Qmci score differences for the CACE-I and NoCACE-I groups 
were 1.8 and 2.1, respectively, per six months.  
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The differences were examined using both one tail and two tail tests, the 
results were the same. Using the two tail test as an example, the difference 
in the SMMSE median rate of decline over six months for CACE-I patients, 
was small but non-significant, compared to NoCACE-I patients. The median 
rates of decline between CACE-I and NoCACE-I in Qmci scores, reached 
borderline significance, p=0.049. The median decline on SMMSE score was 
−1.2 points for the NewCACE-I group, per six months, significantly less 
than for the CACE-I group (median 0.8); p=0.003 and NoCACE-I group 
(median 1.0), p=0.001. The numbers on Qmci score for the NewCACE-I 
group were too small to compare. These results are presented in Table 5.3. 
After adjusting for baseline cognitive scores, (SMMSE and Qmci) and 
patient characteristics (age, education, duration of follow-up and BP), 
multivariate regression analysis was used to compare the end-point 
SMMMSE and Qmci scores. Significant differences were seen in end-point 
scores on the SMMSE (p=0.002) scores between CACE-I, NoCACE-I and 
NewCACE-I groups. There was no significant difference between the 
CACE-I and NoCACE-I groups, (p=0.172), for the Qmci. 
 
Table 5. 3 Comparison of Differences in Qmci and SMMSE Scores 
between Baseline and End-Point 
 Groups 
Mann-Whitney 
U test (two tail) 
Mann-Whitney 
U test (one tail) 
MANOVA test 
CACE-I (53)      vs   NoCACE-I (102) Changes  
in Qmci median*=1.8 median*=2.1 
p = 0.049 P=0.02 P=0.172 
CACE-I (113)    vs    NoCACE-I (240) 
median*=0.8 median*=1.0 
p = 0.77 P=0.06 
NewCACE-I (30)   vs   NoCACE-I 
(240) 
median*= - 1.2 median*= 1.0 
p = 0.001 P<0.001 
NewCACE-I (30)   vs   CACE-I** (83) 
Changes  
in SMMSE 
median*= - 1.2 median*= 0.8 
p = 0.003 P=0.002 
P=0.002 
*Median score is for the change in six months for CACE-I, NoCACE-I and NewCACE-I 
** CACE-I group excluding NewCACE-I subjects. 
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5.3.5 Conclusion 
A small reduction was demonstrated in this study in the rate of cognitive 
decline, in patients receiving CACE-Is compared to the NoCACE-I group, 
measured with the Qmci and SMMSE There was a small but statistically 
significant difference in the changes in Qmci scores over six months. The 
changes in SMMSE scores were not significant, but it suggested a possible 
slower progression in the CACE-I group. A median improvement was 
showed in NewCACE-I patients, rather than a decline in SMMSE scores, 
compared to the CACE-Is and NoCACE-Is groups, over the first six months 
of treatment. The findings of an association between a reduced rate of 
cognitive decline and the initiation of treatment were confirmed between the 
use of CACE-Is, during the first six months of treatment.  
 
Compared to those already established on maintenance treatment, this is the 
first study to demonstrate that cognitive scores improve in patients starting 
on CACE-Is. Better medication compliance, increased cerebrovascular 
perfusion after initial treatment or the effects of improved BP control.54 55 
may relate to this.  
 
There are several strengths to this study. It includes different (AD, vascular 
and mixed) dementia subtypes in large numbers. The effects of CACE-Is 
were investigated in an unselected clinic sample of older adults, whose 
mean age approached 80 years. It also has a number of limitations.  This 
study is an analysis of observational study. The data were collected in a ‘real 
world’ setting, where based on clinical judgment treatments were 
administrated, including antihypertensive agents. Observational studies like 
this are subject to bias in that those who receive treatment may be 
systematically different from those who do not.  It means that the baseline 
demographic characteristics of the groups were similar, and few 
NewCACE-I subjects received other medications that could have accounted 
for the differences observed. Compliance with antihypertensive treatment, 
which has been shown to reduce with time (Chapman et al., 2005, Conlin et 
al., 2001), may have accounted for the improvement in the NewCACE-I 
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group, and could also have been a confounding factor. Similarly, for the 
CACE-I and NoCACE-I groups, in this retrospective analysis, it was not 
possible to establish the duration of treatment with antihypertensive 
medications, prior to attending clinic.  
 
Most patients’ Qmci or SMMSE records were in the database. However, a 
large proportion lacked results at the baseline or end point, limiting the 
numbers included in the analysis. The results would possible have differed 
with more complete data on all patients. However, the baseline cognitive 
scores were similar between those included and excluded, because of 
missing data. As this is the accepted time scale to show evidence of benefit 
in clinical drug trials, changes over the first six months of treatment were 
analysed, and used to compare the subgroup scores (Matthews et al., 2000). 
Although a shorter interval with a small percentage (9%) between the 
baseline and end-point scores exists, the duration of follow-up was 
standardised at six months to facilitate comparisons. ADAS-cog is the 
accepted standard for measuring cognitive change (Rosen et al., 1984). In 
this observational study, in a clinic setting, only the Qmci and the 
commonly used SMMSE were available. Of these, the Qmci has been 
shown to be as sensitive to change as the SADAS-cog (O'Caoimh et al., 
2013b). Significant differences on SMMSE, could not be replicated with the 
Qmci, between NewCACE-I and the other groups’ scores, as the numbers 
were too small to analyse. 
 
To sum up, an association between the use of CACE-Is and reduced rates of 
cognitive decline was demonstrated in this study, in the first six months of 
treatment, in an unselected sample of clinic patients with dementia. This 
supports the increasing evidence for the use of ACE-Is and other 
antihypertensive agents in dementia management (Poon, 2008). Even 
though there are small and uncertain clinical significant differences, if 
sustained over years, the compounding effects may well have significant 
clinical benefits. This is supported by recent evidence suggesting that 
ACE-Is, could contribute to increased amyloid burden (Hu et al., 2001, 
Kehoe and Passmore, 2012, Fournier et al., 2009), by interfering with 
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degradation of Aβ, which potentially increases rates of cognitive decline and 
dementia severity (Sink et al., 2009). Indeed, mortality in patients with CI 
may be raised by ACE-Is, suggesting that if ACE-Is are proven to be 
beneficial in dementia, not all patients will benefit (Kehoe et al., 2013). The 
next study is going to use the similar process to compare the rate of 
functional and neuropsychological decline in CACE-I and NoCACE-I 
patients with dementia, in DARAD database. We explored if these findings 
could be replicated in a different dementia database. 
 
5.4 Effects of CACE-Is on Functional Decline in Patients 
with Alzheimer’s Disease (Study Two: CACE Study in 
DARAD Database) 
5.4.1 Introduction 
The aim of the second study, was to compare rates of cognitive, functional 
and neuropsychological decline, in patients with AD receiving CACE-Is 
(called CACE-Is) to those not currently treated with CACE-Is (NoCACE-I). 
This study conducted a secondary analysis of data from the Doxycycline 
and Rifampin for Alzheimer’s Disease (DARAD) trial (Molloy et al., 2012). 
DARAD was a multi-centre, blinded, randomized 2x2 factorial controlled 
trial. Patients were recruited from 2006 to 2010, comparing doxycycline and 
rifampicin to placebo, to investigate if these can slow down the progression 
of AD (Molloy et al., 2012). There were eight outcome measures: the 
Standardised Alzheimer’s Disease Assessment Scale – Cognitive Subscale 
(SADAS-cog) (Standish et al., 1996), the Clinical Dementia Rating 
scale-Sum of the Boxes (CDR-SB) (Schafer et al., 2004), the Standardised 
Mini-Mental State Examination (SMMSE) (Molloy et al., 1991a, Molloy 
and Standish, 1997b), Quick Mild Cognitive Impairment screen (Qmci) 
(O'Caoimh et al., 2012a), the Geriatric Depression Scale (GDS) (Yesavage, 
1988), Cornell Scale for Depression in Dementia (CSDD) (Alexopoulos et 
al., 1988), Lawton-Brody ADL Scale (Self-maintenance, 1969), and the 
Dysfunctional Behaviour Rating Instrument (DBRI), frequency (DBRIF) 
and reaction (DBRIR), subscales (Molloy et al., 1991b, Molloy et al., 1997).  
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5.4.2 Data Pre-processing – Subjects Selection 
In total, there were 406 mild to moderate AD (SMMSE scores between 14 
and 26) patients included from 14 geriatric outpatient clinics in Canada. It 
included patients aged 50 or over, and who met the National Institute of 
Neurological Disorders and Stroke (NINCDS) criteria for AD (McKhann et 
al., 1984). In this study, patients were separated into two groups:  CACE-I 
group, which included patients currently taking centrally acting ACE-Is: 
ramipril (n=57), perindopril (n=21), lisinopril (n=9), trandolapril (n=3), and 
fosinopril (n=1) (Sink et al., 2009, Solfrizzi et al., 2011), and NoCACE-I 
group, who were not currently receiving CACE-Is, irrespective of BP 
readings, diagnosis of hypertension or receipt of other anti-hypertensives.  
 
5.4.3 Data Analysis 
The difference between baseline and 12-month scores were compared 
between CACE-I and the NoCACE-I group, for the average 12-month rate 
of change. Those changes were calculated as the baseline minus the 
12-month score, for the Qmci, CSDD, GDS, Lawton-Brody ADLs scales. 
The changes for SADAS-cog, CDR-SB, DBRIF and DBRIR scales were 
calculated as month 12 score minus the baseline score. In this way, positive 
change represented improvement, irrespective of the scoring instructions. 
Data were analysed in SPSS 20.0. Non-normally distributed numerical data 
were presented as medians with interquartile range. Chi-square tests were 
used for categorical data. Multivariate regression was used to compare rates 
of change between the three groups (CACE-I, NoCACE-I and NewCACE-I), 
adjusted for the baseline cognitive scores and characteristics (age, years of 
education, and blood pressure). Multivariate regression was also used to 
compare the rate of decline between the subgroups, for each measure. 
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5.4.4 Results 
5.4.4.1 Baseline Demographics 
There were in total 365 patients available for all outcome measures at 12 
months. Overall, 41 patients were excluded because of refusal (n=14), death 
(n=13), withdrawal from the trial (n=5), adverse events (n=6) and for other 
reasons (n=3). Patients' baseline characteristics are presented in Table 5.4. In 
the 365 patients, 91 were receiving CACE-Is: 21 were taking perindopril 
and 70 other CACE-Is (see Figure 5.2). There was no difference in baseline 
scores between the CACE-I and NoCACE-I groups. However, there was a 
marginal statistically significant difference in baseline characteristics for 
gender (p=0.05), cholinesterase inhibitor use (p=0.03) and SADAS-cog 
scores (p=0.04), between the CACE-I subgroups (perindopril and other 
CACE-Is) and the NoCACE-I group. 
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Table 5. 4 Differences in Baseline Demographic Characteristics and 
Outcome Measures between CACE-I Group to NoCACE-I Group 
 
CACE-I  
(n = 91) 
Median (IQR)
NoCACE-I 
(n = 274) 
Median (IQR)
Perindopril 
(n = 21) 
Median (IQR) 
Other CACE-I
(n = 70) 
Median (IQR) 
P-value¹ P-value² 
Age  79 (8) 78 (10) 78 (9) 79 (10) P=0.90 P=0.72 
Gender (male %) 45.1% 51.1% 23.8% 51.4% P=0.46 P=0.05 
Education 
(years) 
12 (4) 12 (5) 12 (5) 12 (3.5) P=0.06 P=0.15 
BP systolic  138 (19) 134 (22.5) 140 (19) 135.5 (17.25) P=0.41 P=0.45 
BP diastolic 70 (14) 72 (14) 70 (11) 70 (12.5) P=0.41 P=0.66 
Cholinesterase 
Inhibitor use (%) 89.0% 92.3% 76.2% 92.9% P=0.32 P=0.03 
Memantine use 
(%) 
15.4% 15.3% 14.2% 15.7% P=0.64 P=0.99 
SMMSE 23 (4.5) 22.5 (5) 24 (2) 23 (5) P=0.14 P=0.22 
Qmci 39.5 (18) 39 (19) 40 (12) 39 (20) P=0.74 P=0.90 
SADAS-cog 18 (12) 21 (11) 16 (9) 19 (12) P=0.05 P=0.04 
Lawton-Brody 
ADL 
51 (10) 52 (10) 52 (9) 51 (11) P=0.34 P=0.57 
CDR-SB 5 (4) 5 (4) 4.5 (4) 6 (4) P=0.74 P=0.23 
CSDD 3 (5) 3 (4) 4 (8) 3 (5) P=0.09 P=0.23 
GDS 1 (2) 1 (3) 2 (2) 1 (2) P=0.74 P=0.82 
DBRIF 4 (13) 5 (10) 3 (11) 4 (13) P=0.61 P=0.88 
DBRIR 11 (12) 13(11) 12 (16) 11 (12) P=0.45 P=0.75 
¹ P-values are provided for independent samples median test (numerical data) or Chi-square test 
(categorical data) for comparison between CACE-I and NoCACE-I groups. 
² P-values are provided for independent samples median test (numerical data) or Chi-square test 
(categorical data) for comparison between perindopril, Other CACE-Is and NoCACE-I groups. 
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Figure 5. 2 Flow Diagram for CACE-I and NoCACE-I Patients in 
DARAD Database 
 
5.4.4.2 Rate of Decline 
The rates of decline were examined using both one tail and two tail tests, the 
results were the same. Using the two tail test as an example, a median 
decline of three points (IQR six) in ADL scores was seen in CACE-I 
patients, between baseline and 12 months, compared to a median decline of 
four points (IQR seven) in the NoCACE-I group (p=0.024). There was no 
statistically significant difference in decline for the other outcome measures 
in the analysis. In particular, CACE-I patients demonstrated a median 
decline in Qmci scores, four (IQR 12) versus five (IQR 13) points, in the 
NoCACE-I group (p = 0.15). The rate of decline in CDR-SB and CCSD 
scores was also smaller in the CACE-I group than the NoCACE-I group, 
even though the differences were not statistically significant (see Table 5.5). 
A significant difference in ADL scores was confirmed after adjusting for age, 
education, gender and BP (p=0.034). Another significant one point 
difference was seen in the rate of decline in the CSDD scores, between 
CACE-I and NoCACE-I groups, using the same adjusted analysis (p=0.001, 
see Table 5.5).  
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Table 5. 5 Comparison of the Rate of Decline, from Baseline to One Year, 
between CACE-I and NoCACE-I Patients 
Variable CACE-I 
Median (IQR) 
NoCACE-I 
Median (IQR) 
P-value1 P-value2 P-value3 
BP (systolic) 0(30) 1.5(24) P=0.38 P=0.13 P=0.69* 
BP (diastolic) 0(20) 0(18) P=0.69 P=0.25 P=0.71* 
SADAS-cog 2(9) 4(8) P=0.41 P=0.19 P=0.86 
CDR-SB 2(4) 1.5(3.5) P=0.83 P=0.40 P=0.84 
Qmci 4(12) 5(13) P=0.15 P=0.20 P=0.49 
Lawton-Brody (ADL) 3(6) 4(7) P=0.024 P=0.01 P=0.034 
CSDD 0(3) 1(4) P=0.13 P=0.03 P=0.001 
GDS 0(2) 0(2) P=0.95 P=0.37 P=0.94 
DBRIF 0(9) 0(8) P=0.50 P=0.26 P=0.24 
DBRIR 4(13) 2(11) P=0.50 P=0.32 P=0.44 
¹ P-values are provided for unadjusted comparison between CACE-I and NoCACE-I groups, using two tail 
Mann-Whitney U test. 
2 P-values are provided for unadjusted comparison between CACE-I and NoCACE-I groups, using one tail 
Mann-Whitney U test. 
3 P-values are provided for multivariate regression (adjusted for age, gender, education and blood pressure, 
BP) for comparison between the CACE-I and NoCACE-I groups. 
* Adjusted for age, gender and education. 
 
There was a significant median reduction in the rate of decline in ADLs 
(p=0.01), comparing perindopril to NoCACE-I group, one point compared 
to four points. The CDR-SB had a borderline significant reduction for the 
perindopril compared to the NoCACE-I group (p=0.04), and perindopril 
compare to other CACE-I group (p=0.05). There was a median decline 
shown in patients receiving other CACE-Is in ADL scores, of three points 
(IQR seven), compared to one point (IQR six) for perindopril (p=0.09).  
 
5.4.5 Conclusion 
In this study, a small (25%, three versus four points) reduction was found in 
the rate of decline in ADL scores, over a 12-month period, in patients taking 
CACE-Is compared to those not currently receiving CACE-Is, measured 
with the Lawton-Brody ADL Scale. Although only changes in ADL and 
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CSSD scores were statistically significant, other outcomes measures 
generally demonstrated a decreased progression for the CACE-I, compared 
to the NoCACE-I group. In particular, the Qmci screen scores declined 20% 
less (four versus five points respectively), in the CACE-I group over one 
year. These data are consistent with the other studies demonstrating a slower 
rate of cognitive decline in patients with dementia receiving CACE-Is 
(Ohrui et al., 2004, Gao et al., 2013a, Hanes and Weir, 2007). 
 
To our knowledge, a reduced rate of decline in ADLs has not been 
demonstrated previously, for subjects with established dementia, receiving 
CACE-Is, although the effect has been shown with beta-blockers 
(Rosenberg et al., 2008b). Given the non-significant changes in blood 
pressure, over the 12-month follow-up period, it is unlikely to be an 
anti-hypertensive effect.  There are a number of other plausible 
mechanisms by which CACE-Is could preferentially impact upon ADLs. 
Perindopril improves exercise tolerance in older adults, with normal 
cognition, with (Henriksen and Jacob, 2003) and without heart failure 
(Sumukadas et al., 2007). Potential explanations for this include the ability 
of ACE-Is to improve endothelial function and to reduce inflammation, 
increasing muscle blood flow and glucose delivery (Onder et al., 2002), to 
skeletal as well as cardiac muscle, thereby improving exercise tolerance and 
capacity. Benefits have been demonstrated in the previous trials, equivalent 
to six months of training, with four weeks exposure to ACE-Is (Sumukadas 
et al., 2007). These effects appear to be unique to ACE-Is, when compared 
to other anti-hypertensive agents (Montgomery et al., 1999), again 
suggesting that they are independent of the drugs’ BP lowering properties. 
In addition, individuals with polymorphisms resulting in low ACE activity, 
have a better response to training (Montgomery et al., 1999). The 
association between treatments with either ARBs and/or ACE-Is, and with a 
lower incidence of falls, also supports the theory that these medications may 
produce effects on physical functional activities (Wong et al., 2013). Thus, 
one year of ACE-I treatment could result in improvements in function and 
muscle strength, sufficient to alter the rate of decline in ADLs, theoretically.  
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In this study, perindopril was associated with a slower rate of decline in 
measures of ADLs, global function (CDR-SB) and cognition (SADAS-cog 
and Qmci), compared to other CACE-Is, although only the CDR-SB reached 
statistical significance. The potential benefits of perindopril on exercise 
tolerance, has been reported previously (Hutcheon et al., 2002), over other 
ACE-Is, with most studies reporting positive findings using perindopril 
(Henriksen and Jacob, 2003, Sumukadas et al., 2007) and negative findings 
using other classes such as quinapril (Zi et al., 2003) or fosinopril 
(Hutcheon et al., 2002). 
 
There were minimal or no effects of CACE-Is, on mood or the BPSD, in this 
study. Both the CACE-I and NoCACE-I groups appeared to demonstrate 
little difference in rates of decline in their GDS, CSDD and DBRI scores 
over the year of follow-up. Although more subjects in the CACE-I group, 
compared to the NoCACE-I group, showed improvement in CSDD scores 
(57% versus 47%) over one year, baseline CSDD scores were significantly 
higher in the CACE-I group at baseline. This is reflective of the current 
evidence base, which suggests the ACE-Is, in general, have little effect on 
mood and depression (Deary et al., 1991, Rogers and Pies, 2008).  
 
The strength of the study lies in the fact that these data came from a clinical 
trial, with rigorous interviewer training and quality checks. Moreover, the 
DARAD trial had good compliance with measurements throughout and 
relatively low loss to follow-up (Molloy et al., 2012). Other strengths 
include measurement of a wide variety of outcomes over one year, the large 
numbers and regular assessments (Molloy et al., 2012).  
 
There are a number of limitations to this study. The subjects who had 
established dementia, median SMMSE of 23, and may have been taking 
CACE-Is for many years. As this was a secondary analysis of data from a 
randomised control trial (RCT), it was not possible to identify duration or 
previous history of anti-hypertensive treatment. Overall 41% of patients in 
the NoCACE-I group were not taking any anti-hypertensive treatment. 
Lower blood pressure is associated with slower progression of functional 
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and cognitive impairment (Rosenberg et al., 2008b). These medications may 
have caused bias from confounding by indication, favouring those currently 
receiving them. However, baseline characteristics, including BP were 
similar between the CACE-I and NoCACE-I groups, and did not affect rates 
of decline. Hence, most anti-hypertensive drugs may have associated with 
reduced rates of cognitive and or functional decline (Davies et al., 2011, Li 
et al., 2010, Sink et al., 2009). There were borderline significant differences 
between the three groups (CACE-I, NoCACE-I and perindopril) in gender, 
SADAS-cog scores and cholinesterase inhibitor use. However, after 
adjustment for these variables, the difference in deterioration in ADL 
remained.  In addition, even though the Lawton-Brody ADL Scale score is 
not a gold standard outcome measure, it is still a widely used instrument to 
score both basic and instrumental activities of daily living (Lawton, 1970, 
Sheehan, 2012). Like most instruments measuring ADLs, limitations include 
potential bias arising from self or informant reporting rather than a 
demonstration of ability, and insensitivity to small changes in function. 
Compliance with anti-hypertensive treatment, which has been shown to 
reduce with time, may also have been a confounder. Small effects may 
reflect that this analysis was conducted in patients with more advanced 
disease. Therefore greater effects might be gained from longer treatment 
periods in patients with early stages of cognitive impairment (e.g. MCI) or 
with less advanced pathology (Solfrizzi et al., 2011, Rozzini et al., 2006). 
 
In summary, this study demonstrates the benefit of CACE-Is compared to a 
group not currently treated with CACE-Is, in dementia patients, across a 
range of outcome measures, particularly ADLs. The most notable finding is 
the reduced rate of progression in ADL disability. The progress reduction in 
ADLs is small, and if real, of uncertain significance and with an unclear 
mechanism. If such an effect were sustained over years, patient may benefit 
greatly by these effects. These findings provide positive support for 
CACE-Is, and perhaps perindopril in particular, in that it slows functional 
reduction in patients with dementia. At present there have been no 
anti-hypertensive agents licensed for the treatment of dementia. These data 
support the need for further study. The next study combined the GAT and 
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DARAD databases together, and expands ADLs into basic and instrumental 
ADLs, to explore the effect on CACE-I. It incorporated previous studies to 
determine if greater numbers would allow for more detailed analysis on the 
outcome measures. 
 
5.5 CACE-Is and Functional Decline in Dementia: Do 
They Affect Instrumental or Basic ADLs (Study Three: 
CACE Study in GAT and DARAD Databases Combined) 
5.5.1 Introduction 
The third study expanded on the results of the previous two studies. This 
analysis was conducted on the data from two databases: the GAT (Geriatric 
Assessment Tool), a geriatric medicine outpatient clinic database and the 
DARAD (Doxycycline and Rifampacin for Alzheimers Disease) study, a 
clinical trial (Molloy et al., 2012). All patients had been diagnosed with 
Alzheimer’s disease, vascular or mixed dementias. Patients were included if 
baseline and end-point scores were available on the three outcome measures: 
Standardised Mini-Mental State Examination (SMMSE), Quick Mild 
Cognitive Impairment screen (Qmci), and a modified Lawton-Brody ADL 
Scale (ADLs). The ADL score was divided into basic and instrumental 
ADLs. The aim of this study was to confirm if centrally acting angiotensin 
converting enzyme inhibitors (CACE-Is) are associated with reduced rates of 
cognitive and possibly functional decline in dementia. 
 
In this study, the outcome measures were the SMMSE, Qmci and a 
shortened version of the Lawton-Brody ADL scale. The original 
Lawton-Brody ADL scale (Self-maintenance, 1969), scored out of 64 points, 
includes 14 categories; higher scores denote greater independence. It was 
used as an outcome measure in the DARAD trial. However, due to time 
limitations in busy clinics, not all subtests of the Lawton-Brody ADL scale 
were recorded in the GAT. Therefore, this study included a modified 
Lawton-Brody ADL scale. Of these available subtests, bathing, walking, 
grooming, feeding, and toileting are BADLs; using the phone, finances, 
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medication administration, and food preparation are IADLs. This modified 
ADL scale was scored from 9 to 39 points, with higher scores denoting 
greater independence. 
5.5.2 Data Pre-processing – Subjects Selection 
The National Institute of Neurological Disorders and Stroke (McKhann et 
al., 1984) criteria were used to diagnose patients with dementia. Only 
patients with AD, vascular or mixed dementias (Alzheimer’s-vascular), aged 
50 years or more, were included. There were in total 1223 patients with 
dementia available, 406 from the DARAD database and 817 from the GAT 
database. Of the GAT patients, 439 patients were excluded, as they did not 
have either Qmci, SMMSE or ADL scores, available at both baseline and 
end-point. Of the DARAD patients, 41 were excluded because of missing 
data. Figure 5.3 graphically presents the patient selection. In this study, 
patients were subdivided into CACE-I group, those currently receiving 
Centrally Acting ACE-Is, and NoCACE-I group, who were not currently 
receiving CACE-Is, irrespective of diagnosis of hypertension, BP readings 
or receipt of other anti-hypertensives. The CACE-I group were then 
separated into two sub-groups: Perindopril and an ‘other CACE-I’ group.  
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Figure 5. 3 Flow Chart for Patients in GAT and DARAD Databases 
 
5.5.3 Data Analysis 
We examined differences in the rate of change in Qmci, SMMSE and ADL 
scores, from baseline to end-point, between those in the CACE-I, 
perindopril, other CACE-I and NoCACE-I groups. Given that regulatory 
authorities, like the United States Food and Drug Administration, require 
evidence of change in cognitive tests over six months, to confirm benefit 
from new medications, the change scores were calculated from baseline, on 
a six monthly basis, using the formula: Rate of decline = (Baseline score – 
End-point score) x 6/ Duration in months. We also used multivariate 
regression to compare end-point cognitive (SMMSE and Qmci) and ADL 
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scores, adjusted for baseline cognitive scores and characteristics (age, years 
of education, duration of follow-up and BP), between the three groups 
(perindopril, other CACE-I and NoCACE-I). Data were analysed using 
SPSS 18.0. Kolmogorov-Smirnov and Shapiro-Wilk tests were used to test 
for normality. Non-normally distributed data were compared with the 
Mann-Whitney U test. Categorical data were analysed with Chi-squared 
tests. 
 
5.5.4 Results 
5.5.4.1 Baseline Characteristics 
There were totally 743 dementia patients, with either a Qmci, SMMSE or 
ADL score available at both baseline and end point included in the analyses, 
including 378 from the GAT databases, and 365 from the DARAD. Of these, 
187 were receiving CACE-Is and 556 were not. Within the CACE-I group, 
33 were taking perindopril (excluding seven patients who started on 
CACE-Is while attending clinic), and 154 patients were taking other 
CACE-Is. The mean age of those included (n=743) was 77.4 years. Half 
(49.6%) were men, and the mean time spent in education was 11.7 years. 
There were no significant differences in gender between the CACE-I and 
NoCACE-I groups (p=0.83), nor between the perindopril, other CACE-I and 
NoCACE-I groups (p=0.06). The perindopril group had more females (75%) 
compared to other CACE-I group, p<0.001. The mean systolic and diastolic 
BP for the total sample was 134.1mmHg and 72.5mmHg, respectively. Most 
of the population were receiving cholinesterase inhibitors (ChEI), a smaller 
percentage were taking memantine. No significant differences were seen in 
the distribution of ChEI (p=0.73) or memantine (p=0.79) use between the 
CACE-I and NoCACE-I groups. Table 5.6 demonstrates the baseline 
characteristics, including baseline and end-point SMMSE, Qmci and ADL 
scores, for the CACE-I, perindopril, other CACE-I and NoCACE-I groups. 
In total, the mean SMMSE, Qmci and ADL scores at baseline and end-point 
were 21.9 (SD ± 4.5) and 19.5 (SD ± 6.6), 38.2 (SD ± 13.1) and 32.7 (SD ± 
16.2), and 32.7 (SD ± 4.6) and 29.8 (SD ± 5.9), respectively. There were no 
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significant differences in baseline SMMSE, Qmci and ADL scores between 
the perindopril, other CACE-I and NoCACE-I groups, after adjusting for 
baseline characteristics (age, gender, education, duration of follow-up and 
BP). 
 
Table 5. 6 Baseline Characteristics for CACE-I, Perindopril, Other 
CACE-I and NoCACE-I Patients (BP=blood pressure) 
 
CACE-I NoCACE-I Perindopril 
Other 
CACE-I 
Number 187 556 33 154 
Age (mean + SD) 78.0 + 6.5 77.2 + 7.4 75.6 + 7.5 78.5 + 6.2 
Gender (male %) 49.0% 49.8% 30.3% 52.9% 
Education (mean + SD) 11.0 + 3.5 11.9 + 3.8 12.0 + 4.1 10.8 + 3.4 
BP systolic (mean + SD) 135.2 + 16.4 133.8 + 16.4 136.6 + 14.3 134.8 + 16.9 
BP diastolic (mean + SD) 71.2 + 9.9 72.9 + 10.8 70.7 + 10.4 71.4 + 9.8 
Cholinesterase Inhibitor use (%) 90.9% 91.7% 78.8% 93.5% 
Memantine use (%) 20.3% 21.2% 15.2% 21.4% 
Mean Duration of  Follow-up (months) 16.2 (13.5) 16.7 (13.5) 12.9 (9.9) 16.9 (14.0) 
N= 171 544 28 143 
Baseline age (mean + SD) 77.9 + 6.5 77.1 + 7.4 75.8 + 7.3 78.4 + 6.2 
Gender (male, %) 48.8% 50.2% 25% 53.6% 
Median baseline score 
(IQR) 
23 (5) 23 (6) 23 (3) 23 (5) SMMSE 
Median end-point score 
(IQR) 
21 (10) 21 (8) 22.5 (8) 20 (10) 
N= 132 387 26 106 
Baseline age (mean + SD) 78.7 + 6.2 77.4 + 7.4 76.1 + 7.1 79.3 + 5.8 
Gender (male, %) 48.9% 50.5% 23% 55.4% 
Median baseline score 
(IQR) 
39 (17) 39 (19) 39.5 (15) 38 (20) Qmci 
Median end-point score 
(IQR) 
34 (26) 32 (24) 38.5 (23) 33 (25) 
N= 118 352 26 92 
Baseline age (mean + SD) 78.3 + 6.2 76.8 + 7.1 75.5 + 7.9 79.1 + 5.5 
Gender (male, %) 47% 48.9% 31.1% 51.6% 
Median baseline score 
(IQR) 
33.5 (7) 34 (5) 34 (9) 33 (6) ADLs 
Median end-point score 
(IQR) 
31 (7) 31 (7) 33 (7) 31 (7) 
Median baseline score 
(IQR) 
23 (2) 23 (2) 23 (4) 23 (2) Basic ADLs 
(score 5-24) 
Median end-point score 
(IQR) 
23 (4) 23 (4) 23 (4) 23 (4) 
Median baseline score 
(IQR) 
10 (5) 10.5 (5) 11 (4) 10 (6) Instrumental 
ADLs 
(score 4-15) Median end-point score 
(IQR) 
9 (4) 8 (5) 10 (7) 9 (4) 
 
 143 
5.5.4.2 Rate of Decline 
For the total sample, the median change in SMMSE scores was 0.5 points 
per six months interquartile range (IQR of two), between baseline and 
end-point. The median change over six months in Qmci score was 2.25 
points (IQR of seven). The median change in ADLs was one point per six 
months (IQR of three), with median differences for the perindopril, other 
CACE-I, CACE-I and NoCACE-I groups of 0.5, 1.0, 0.95 and 1.4, 
respectively.  
 
The differences were examined using both one tail and two tail tests, the 
results were the same, except for the changes between other CACE-I and 
NoCACE-I groups in Qmci score (the p value of the two tail test is 0.06, but 
the p value of the one tail test is 0.03). Using the two tail test as an example, 
there was a significant reduction in the median rate of decline in total ADL 
scores in the CACE-I group compared to the NoCACE-I group, 0.95 
compared to 1.4 points respectively, p=0.002. The difference in median rates 
of decline in Qmci scores was on borderline significance, p=0.05. There was 
a small but non-significant difference (p=0.19) in the SMMSE median 
six-month rate of decline for CACE-I patients, compared to NoCACE-I, 0.5 
versus 0.6. Significant differences were observed on both the perindopril 
and other CACE-I groups, in rate of decline in ADL scores, compared with 
the NoCACE-I group, 0.5 versus 1.4, p=0.004 and 1.0 versus 1.4, p=0.037, 
respectively. There were no significant differences in SMMSE, Qmci or 
ADL scores, between the perindopril and other CACE-I groups. See Table 
5.7. 
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Table 5. 7 Comparison of Six-Month Cognitive and Functional Rate of 
Decline in CACE-I, NoCACE-I, Perindopril and Other CACE-I Patients 
 Groups 
Mann-Whitney 
U test (two tail) 
Mann-Whitney 
U test (one tail) 
MANOVA 
test 
CACE-I (201)      vs   NoCACE-I (514) 
median*=0.5 median*=0.6 
p = 0.19 p=0.10 
Perindopril (40)   vs  NoCACE-I (514) 
median*=0 median*=0.6 
p = 0.14 p=0.08 
Other CACE-I (161)  vs  NoCACE-I (514) 
median*=0.5 median*=0.6 
p = 0.40 p=0.20 
Perindopril (40)     vs  Other CACE-I (161) 
Changes 
in SMMSE 
median*=0 median*=0.5 
p = 0.32 p=0.16 
P=0.46 
CACE-I (143)      vs   NoCACE-I (376) 
median*=2.0 median*=2.5 
p = 0.046 
#
 p=0.02 
#
 
Perindopril (31)   vs  NoCACE-I (376) 
median*=2.0 median*=2.5 
p = 0.32 p=0.10 
Other CACE-I (112)  vs  NoCACE-I (376) 
median*=2.0 median*=2.5 
p = 0.06 p=0.03 
#
 
Perindopril (31)    vs  Other CACE-I (112) 
Changes 
in Qmci 
median*=2.0 median*=2.0 
p = 0.83 p=0.47 
P=0.28 
CACE-I (128)     vs   NoCACE-I (342) 
median*=0.95 median*=1.4 
p = 0.002 
#
 P<0.001 
#
 
Perindopril (32)   vs  NoCACE-I (342) 
median*=0.5 median*=1.4 
p = 0.004 
#
 p=0.002 
#
 
Other CACE-I (96)  vs  NoCACE-I (342) 
median*=1.0 median*=1.4 
p = 0.037 
#
 p=0.02 
#
 
Perindopril (32)    vs  Other CACE-I (96) 
Changes 
in ADLs 
median*=0.5 median*=1.0 
p = 0.17 p=0.10 
P=0.012 
* Median score is for the change in six months for CACE-I, NoCACE-I and NewCACE-I 
# statistically significant p values 
 
After adjusting the baseline scores (SMMSE, Qmci and ADLs) for patient 
characteristics (age, gender, education, duration of follow-up and BP), 
multivariate regression analysis was used to compare end-point SMMSE, 
Qmci and total ADL scores. This confirmed the significant differences in 
ADL scores between all three groups (perindopril, other CACE-I and 
NoCACE-I), (p=0.012), but no significant differences in cognitive scores 
between them; SMMSE (p=0.46) and Qmci (p=0.28).  
 
 Effect on Basic and Instrumental ADLs 
By examining basic and instrumental ADL scores using both one tail and 
two tail tests, there was no median reduction and no significant difference in 
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BADL scores over six months between the CACE-I and NoCACE-I groups. 
Using two tail test as an example, there was a median 0.83 point decline in 
IADLs in NoCACE-I patients, compared to a median 0.5 point reduction for 
the CACE-I group (p=0.001). For BADL scores, there was a significant 
difference between perindopril and the NoCACE-I (p=0.002) and other 
CACE-I (p=0.006) groups. Subjects taking perindopril had a significant rate 
of decline in IADL scores compared to the NoCACE-I group, median 0.28 
points compared to 0.83, p=0.026. These results were presented in Table 5.8. 
When multivariate regression analysis was used to compare the differences 
in rates of decline in BADLs and IADLs, adjusted for baseline ADLs and 
patient characteristics (age, gender, education, duration of follow-up and 
BP), there were significant differences in IADLs (p=0.017), between the 
three groups (perindopril, other CACE-I and NoCACE-I), but no significant 
differences in BADL scores (p=0.06).  
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Table 5. 8 Comparison of differences in rates of change in basic and 
instrumental activities of daily living (ADL) between CACE-I, 
NoCACE-I, perindopril and Other CACE-I groups 
 Groups 
Mann-Whitney 
U test (two tail) 
Mann-Whitney 
U test (one tail) 
MANOVA 
test 
CACE-I (128)     vs   NoCACE-I (342) 
median*=0 median*=0 
p = 0.19 p = 0.10 
Perindopril (32)    vs  NoCACE-I (342) 
median*=0 median*=0 
p = 0.002
#
 p = 0.001
#
 
Other CACE-I (96)  vs  NoCACE-I (342) 
median*=0.23 median*=0 
p = 0.94 p = 0.46 
Perindopril (32)   vs  Other CACE-I (96) 
Changes  
in Basic ADLs  
median*=0 median*=0.23 
p = 0.006
#
 p = 0.002
#
 
P=0.06 
CACE-I (128)     vs   NoCACE-I (342) 
median*=0.5 median*=0.83 
p = 0.001
#
 p < 0.001
#
 
Perindopril (32)    vs  NoCACE-I (342) 
median*=0.28 median*=0.83 
p = 0.026
#
 p = 0.01
#
 
Other CACE-I (96)  vs  NoCACE-I (342) 
median*=0.5 median*=0.83 
p = 0.005
#
 p = 0.002
#
 
Perindopril (32)   vs  Other CACE-I (96) 
Changes  
in Instrumental 
ADLs  
median*=0.28 median*=0.5 
p = 0.80 p = 0.39 
P=0.017 
*Median score is for the change in six months for CACE-I, NoCACE-I and NewCACE-I 
# statistically significant p values 
 
5.5.5 Conclusion  
Data from secondary analyses were presented in this observational study 
presents for older adults with CI, derived from pooling data from two 
clinical databases. A small (32%, 0.95 versus 1.4 points) reduction were 
found in the rate of decline in ADL scores, measured using a modified 
version of the Lawton-Brody ADL scale, between those currently prescribed 
CACE-Is and patients not currently receiving CACE-Is, over 6 months 
period. These data are consistent with our previous studies, demonstrating a 
slower rate of cognitive and functional decline in persons with dementia 
receiving CACE-Is (Gao et al., 2013a, O'Caoimh et al., 2014). In this study, 
the difference in median rates of decline in ADLs for those in the CACE-I 
compared to the NoCACE-I group, was most apparent for IADLs (0.5 
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versus 0.83 points). This may reflect that the patients with mild to moderate 
dementia (median SMMSE score of 23) had relatively well preserved 
BADLs at baseline. A feature of mild dementia is that there is loss of IADLs 
prior to BADLs (Pérès et al., 2008). Patients with mild dementia, by 
definition are independent in BADL activities, and are likely to score very 
high in this. There was no significant difference in baseline BP readings 
between those in the CACE-I and NoCACE-I groups, after adjusting for age, 
gender and education. This means that the effects observed on cognition and 
ADL were independent of BP lowering. 
 
The results also suggest that use of perindopril was associated with a slower 
rate of decline in total ADL scores, BADL scores, and IADL scores, 
compared to other CACE-Is. The changes between patients taking 
perindopril (CACE-P) with NoCACE-I group, in basic and instrumental 
ADL scores, BADLs and IADLs, over six months, were small but 
statistically significant, p=0.002 and p=0.026, respectively. These results 
suggest that perindopril is superior to other CACE-Is, and associated with a 
statistically significant reduction in the rate of decline in total ADL, BADLs 
and IADLs scores, compared to NoCACE-Is. Perindopril was associated 
with a significant reduction in the rate of decline in BADLs scores, 
compared to other CACE-Is (CACE-O) (p=0.006). Patients taking CACE-Is, 
and its subgroup (CACE-O), compared to NoCACE-I group, had a 
significant reductions in the rate of decline in instrumental ADL scores, 
IADL, p=0.001 and p=0.005, respectively. Perindopril reduces the rate of 
functional decline in both basic and instrumental ADLs (BADLs and 
IADLs), while CACE-O only showed significant effects on IADLs. With 
respect to ADLs, perindopril was also associated with improved exercise 
tolerance in older adults, with normal cognition (Hutcheon et al., 2002, 
Sumukadas et al., 2007). Of note, similar differences in median rates of 
decline were seen between those treated with other CACE-Is, predominantly 
ramipril, suggesting a class effect characteristic of all CACE-Is. 
 
The strengths of this study are that the data came from large numbers and 
included different (AD, vascular and mixed) dementia subtypes, collected 
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from different databases. The study also investigates the effects of CACE-Is 
in an unselected clinic sample of older adults, whose mean age approached 
80 years. The paper has a number of limitations. This study is an analysis of 
observational data of treatments, with anti-hypertensive agents. These 
medications may have caused bias from confounding by indication 
favouring those currently receiving them. Another limitation is that, the 
marker of ADLs used, the standardised Lawton-Brody ADL Scale score, is 
not a gold standard outcome measure. This said, it is a widely used 
instrument that incorporates both instrumental and basic activities of daily 
living (Self-maintenance, 1969, Sheehan, 2012, Sink et al., 2009). Like most 
instruments measuring ADLs, limitations include potential bias arising from 
self or informant reporting rather than a demonstration of ability, and 
insensitivity to small changes in function. 
 
Overall, this study suggests that there is a possible benefit of CACE-Is 
compared to a group not currently treated with CACE-Is, in patients with 
established dementia, across a range of outcome measures, particularly ADLs. 
CACE-Is may have more beneficial effects on IADLs than BADLs. 
Potentially, perindopril may offer even more benefit. As similar effects were 
seen in those receiving other CACE-Is, the effect of ACE-Is may be 
important, and cannot be excluded. The mechanism by which CACE-Is 
exerting these effects is still unclear. While observed differences were small 
and of uncertain clinical significance, if sustained over years, the 
compounding effects could have significant clinical benefits. This paper adds 
to the growing evidence supporting the potential beneficial effects of 
CACE-Is in dementia, and highlights the need for further investigation with 
an adequately powered randomized controlled trial. 
  
5.6 Conclusion 
This chapter presents evidence that centrally acting angiotensin-converting 
enzyme (ACE) inhibitors (CACE-Is), which cross the blood-brain barrier, are 
associated with reduced rate of cognitive and functional decline. The changes 
in cognition and function, over six months, were small but statistical 
 149 
significant. Many statistical methods were applied to analyse the data and 
prove the results. Qmci, SMMSE and Lawton-Brody ADLs were used as the 
outcome measures. The data analyses in these studies of this chapter were 
based on the Knowledge Discovery in Databases (KDD) process.  
 
Three studies were presented in this chapter that showed an association 
between CACE-Is and a reduction in rate of cognitive and ADL decline in 
dementia: 
The first study demonstrated that dementia patients taking CACE inhibitors 
declined slower than those not taking them. This study followed the rates of 
cognitive decline in three groups of patients: dementia patients being treated 
with centrally acting ACE inhibitors (CACE-I), dementia patients being 
treated with non-centrally acting ACE inhibitors (NoCACE-I), and dementia 
patients newly treated with centrally acting ACE inhibitors (newCACE-I). 
After six months, there was a significant reduction in the rate of cognitive 
decline between the CACE-I group and the NoCACE-I group, assessed by 
the Quick Mild Cognitive Impairment (Qmci) score, and a similar but not 
significant reduction in the Standardised Mini-Mental State Examination 
(SMMSE), irrespective of the blood pressure readings or diagnosis of 
hypertension. 
 
A novel finding, however, was that the NewCACE-I patients, started on 
CACE-Is while attending clinic, showed CACE-Is may have cognitive 
enhancing effects, over the first 6 months of treatment, compared to those 
already taking CACE-Is, and those not currently treated with CACE-Is. This 
is the first study to show cognitive scores improved for patients starting, 
rather than those already on maintenance treatment, with CACE-Is, in 
dementia. This may have been related to better medication compliance or 
the effects of improved BP control and cerebrovascular perfusion after 
initial treatment. The findings indicate that ACE inhibitors hold promise as 
an inexpensive way to ease the burden of dementia, which may have very 
important treatment benefit in dementia. 
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The second study reported that centrally acting ACE inhibitors were 
associated with rate of the functional decline of 25%. The benefits were 
statistically significant, over a 12-month period, in patients taking CACE-Is 
compared to those not currently receiving CACE-Is. Although only changes 
in ADL and CSDD scores were statistically significant, the other outcomes 
measures generally demonstrated decreased progression for the CACE-I, 
compared to the NoCACE-I group. In particular, the Qmci screen scores, 
declined 32% less (1.9 points), for the CACE-I group over one year. These 
data are consistent with the first study demonstrating a slower rate of 
cognitive decline in persons with dementia. 
 
The results presented in this study also suggest that perindopril was superior 
to other CACE-Is. Use of perindopril resulted in a slower rate of decline in 
measures of cognition (SADAS-cog and Qmci), global function (CDR-SB) 
and ADLs, compared to CACE-Is. Although no statistically significant 
differences were seen when perindopril was compared directly to other 
CACE-Is, the subgroup taking perindopril had slower rates of decline in these 
outcome measures, many of which approached significance.  
 
The third study polled the data together from two clinical databases from the 
two previous studies. Pooling data increased the number of patients receiving 
CACE-Is available for analysis. This study found a significant reduction in 
the rate of decline in total ADL scores, over six months, in patients taking 
CACE-Is, compared to those who were not. This reflects other studies 
suggesting similar reduced rates of decline in those prescribed beta-blockers 
(Rosenberg et al., 2008b) or CACE-Is (O'Caoimh et al., 2014). In this study, 
total ADLs were divided into basic ADLs (BADLs) and instrumental ADLs 
(IADLs). The difference in median rates of decline in ADLs for those in the 
CACE-I, compared to the NoCACE-I group, was most apparent for IADLs 
(p=0.001). This may reflect the population studied, patients with mild to 
moderate dementia (median SMMSE score of 23) who had relatively 
preserved BADLs at baseline, and as a result were unlikely to show any 
significant change over the period of time. Loss of IADLs characteristically 
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occurs prior to BADLs, and usually in those with mild dementia (Pérès et al., 
2008).  
 
The results of this study also suggest that perindopril may be superior to 
other CACE-Is, with a relatively larger difference in median rates of 
functional decline in six months (64%, 0.5 versus 1.4 points) compared to 
those not currently receiving CACE-Is. This effect was again evident for 
IADLs but not for BADLs. It has been consistently associated with reduced 
cognitive decline (Gao et al., 2013a).  
 
ACE activity is increased in Alzheimer's disease, proportional to the Aβ load. 
Centrally acting ACE-Is (CACE-Is) that cross the blood-brain barrier may 
have a greater impact than those that do not. The effects could be due to these 
drugs reducing swelling in brain tissue or improving blood flow to the brain. 
Anther possibility, is that these drugs reduce inflammation in the brain. 
People who already need treatment for cardiovascular disease such as high 
blood pressure and who are at risk of dementia may benefit if they take a 
centrally-acting ACE inhibitor. 
 
There are a number of other plausible mechanisms by which CACE-Is could 
preferentially impact upon ADLs. Perindopril improves exercise tolerance in 
older adults, with normal cognition, with (Henriksen and Jacob, 2003) and 
without heart failure (Sumukadas et al., 2007). This might be explained by the 
reported ability of ACE-Is to reduce inflammation and to improve endothelial 
function, increasing muscle blood flow and glucose delivery (Onder et al., 
2002), to both skeletal and cardiac muscle, thereby improving exercise 
tolerance and capacity. 
 
In general, the current drugs (donepezil, galantamine and rivastigmine) used 
in the treatment of Alzheimer’s, work for a year and then stop working. 
However, many of these patients were on ACE inhibitors for years. The 
importance of these findings is that these data suggested that they continue 
to extract beneficial effects. While differences were small and of uncertain 
clinical significance, if sustained over years, the compounding effects could 
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have significant clinical benefits. Thus, there is a strong scientific rationale 
for recommending CACE-Is therapy to slow cognitive decline. It is too early 
for doctors to prescribe ACE inhibitors to everyone at risk of dementia. Large 
randomized trials are needed to gain additional insight and to confirm these 
findings. 
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CHAPTER 6 CONCLUSIONS 
 
6.1 Introduction 
This chapter presents the overall conclusions of the research study. It begins 
with the background of cognitive impairment, and reviews the research aims 
and conclusions from the research study. The next two sections briefly 
introduce the databases and outcome measures used in the study. In the 
following section, contributions and potential benefits from the research 
work are presented. The last section finishes with the conclusions, and 
discusses the potential benefits and future direction of research based on 
these findings. 
 
6.2 Research Background: Databases and Outcome 
Measures 
One of the major challenges facing societies in the world today, is 
population ageing. Population ageing will result in an increase in disability 
and a very significant increase in the incidence of age-related health 
problems, especially Alzheimer’s disease (AD) and other dementias. 
Dementia is a collective term that describes a wide range of symptoms 
associated with a decline in memory or other skills, that are severe enough 
to reduce a person's ability to perform everyday activities. The prevalence of 
dementia doubles roughly every five years after the age of 65 years (Prince 
and Jackson, 2009). Alzheimer Disease International (ADI) predicts that 
approximately 115.4 million people worldwide will be affected by dementia 
in 2050 (Dartigues, 2009).  
 
Alzheimer’s Disease and other dementias are one of the most challenging 
illnesses confronting countries with ageing populations. There is as yet no 
treatment to prevent, halt or reverse the progressive decline of brain 
functions (Luengo-Fernandez et al., 2011). It is an expensive condition, with 
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a considerable cost to both public and private finances. In 2009, the total 
worldwide societal cost of dementia was estimated at $422 billion, based on 
34.4 million people with dementia (Wimo et al., 2010). Dementia care costs 
more than cancer and heart disease care combined20. As the prevalence of 
dementia is linked to increasing age, and the number of the ageing people is 
rising, the costs of dementia care will increase considerably in the coming 
decades (Wimo et al., 1997). Currently, for most dementias, including 
Alzheimer's disease (AD), only symptomatic treatment options exist. 
Although there is currently no cure for dementia, multiple drugs can slow 
disease progression and treat symptoms.  
 
Data analysis is a cost effective way to look at the effects of potential drugs. 
There is a need, to discover efficient ways to obtain useful information, to 
improve decision making from large databases containing clinical data 
(Lemke and Mueller, 2003). This interactive and iterative process involves 
various subtasks and decisions and is called Knowledge Discovery in 
Databases (KDD). The engine of KDD, where data is transformed into 
knowledge for decision-making, is data analysis. The aim of this research 
was to investigate the effects of centrally acting ACE inhibitors (CACE-Is) 
on the rate of cognitive and functional decline in dementia, using a three 
phased Knowledge Discovery in Databases (KDD) process. This research 
also validated the Quick mild cognitive impairment (Qmci) test, a new and 
more effective screen tool, as one of the key measures for cognition, against 
the other popular screening and assessment tools. 
 
KDD was used to analyse existing databases, to investigate the effects of 
different drugs, and assess whether certain treatments could slow down the 
rate of cognitive or functional decline in patients with dementia. It was also 
used to compare the abilities of different assessment instruments, e.g. the 
Quick Mild Cognitive Impairment (Qmci) screen, the SMMSE 
(Standardised Mini-Mental State Examination) and ADL (Activities of Daily 
                                                        
20 
http://www.express.co.uk/news/retirement/155986/Dementia-costs-more-than-cancer-and-heart-diseas
e-combined-but-given-less-funding 
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Living) tests, to measure and track changes with treatments over time. The 
principles of KDD were applied throughout the analytical components of 
this research. Three clinical databases, containing information from patients 
with different types and degrees of cognitive impairment, were used in this 
research, and provided a rich data resource. These included the Geriatric 
Assessment Tool (GAT), the Doxycycline and Rifampin for Alzheimer’s 
Disease (DARAD), and the Qmci validation databases. All databases were 
derived from several different geriatric clinics in Canada.  
 
6.2.1 The Databases 
While each of the three databases analysed were similar, each had unique 
properties. In summary, the GAT is a customised software application that 
automates clinicians’ outpatient reviews (Gao et al., 2013a). GAT data were 
collected in outpatient geriatric medicine clinics in two university hospitals 
in Ontario, Canada between 1999 and 2010. The GAT records demographic 
data (age, gender, educational level, medical conditions, diagnoses and 
laboratory findings) and two cognitive screening tests, the Standardised 
Mini-Mental State Examination (SMMSE) and the Qmci. The Qmci was 
administered to each subject by trained raters (clinic nurses), prior to each 
clinic assessment and blind to the eventual diagnosis. The DARAD was a 
multi-centre, blinded, randomised trial conducted between 2006 and 2010, 
comparing the effect of rifampacin and doxycycline to placebo, on the 
progression of AD (Molloy et al., 2012). The DARAD database included 
subjects with mild to moderate AD, recruited from 14 Canadian centers. 
These subjects had detailed cognitive assessments including the SMMSE 
and Qmci, performed every three months, for one year. The Qmci database, 
included subjects recruited from four memory clinics in Ontario Canada 
(O'Caoimh et al., 2012a). It included only subjects aged ≥ 55 years, referred 
for assessment of cognition, and excluded those with LBD, PDD and 
depression. 
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6.2.2 The Outcome Measures 
The outcome measures used in the analyses were an ADL scale, called the 
Lawton-Brody ADL score, SMMSE, and Qmci. The Lawton-Brody scale 
(Self-maintenance, 1969) is an instrument used to assess independence in 
instrumental and basic ADL. It contains 14 subtests, and can be separated 
into basic ADLs (BADLs) and instrumental ADLs (IADLs). The 
Mini-Mental State Examination (MMSE) (Folstein et al., 1975) is an widely 
used screening instrument, developed to assess cognitive function in the 
elderly. It evaluates orientation, memory loss, language problems and 
visuo-constructive abilities. The Standardised Mini-Mental State 
Examination (SMMSE) improved inter-rater reliability by the inclusion of 
explicit administration and scoring guidelines (Molloy et al., 1991a, Molloy 
and Standish, 1997a). The Qmci is a new short assessment test. It has 
potential to replace SMMSE as a screening test for cognition in the clinic 
and in clinical trials. It has improved sensitivity and specificity for 
differentiating MCI from normal cognition, and dementia, compared to the 
SMMSE and the AB Cognitive screen 135 (O'Caoimh et al., 2012a). It 
correlates with the Standardised Alzheimer`s Disease Assessment 
Scale-cognitive section (SADAS-cog), Clinical Dementia Rating (CDR) 
scale and the Lawton-Brody ADL scale (O'Caoimh et al., 2014). It is also 
being validated against the Montreal Cognitive Assessment (MoCA), 
another short cognitive screen with high accuracy in the assessment of early 
cognitive impairment (O'Caoimh et al., 2013c). As an adjunct to this work, 
we used data analysis methods to assess the accuracy of the Qmci and its 
subtests to identify different stages of cognition from normal to MCI, to 
dementia. The Qmci is used as a key cognitive measurement for determining 
the effects of drug therapy on the rate of decline of patients with dementia in 
this research. 
 
6.3 Research Objective and Research Questions 
The aim of this research is to investigate the effects of centrally acting ACE 
inhibitors (CACE-Is) on the rate of cognitive and functional decline in 
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dementia, using a three phased Knowledge Discovery in Databases (KDD) 
process. There are three research questions in Table 6.1 addressed the 
research objective. 
 
 158 
Table 6. 1 Three Research Questions 
Research 
Objective 
To investigate the effects of centrally acting ACE inhibitors (CACE-Is) on the rate of cognitive and 
functional decline in dementia, using a three phased Knowledge Discovery in Databases (KDD) 
process. 
Research 
Questions 
RQ1: key outcome instruments 
for cognition in dementia 
RQ2: effect of CACE-Is on 
cognitive decline in dementia 
RQ3: effect of CACE-Is on functional 
decline in dementia 
Purpose 
To define the key outcome 
instruments for measuring the rate 
of cognitive decline in dementia. 
To prove that centrally acting 
ACE-Is may reduce the rate of 
cognitive decline in dementia. 
To prove that centrally acting ACE-Is 
may reduce the rate of functional decline 
in dementia. 
Motivation 
1. To distinguish the memory loss 
types. 
2. Reliable and more sensitive 
instruments are required. 
3. Short instruments are required. 
1. BP control is associated with rate 
of cognitive decline. 
2. There is little data on the effects 
of CACE-Is on the rate of cognitive 
decline in dementia. 
1. Hypertension may affect the risk of 
decline in ADL score in dementia. 
2. Few studies have investigated whether 
ACE-Is affect ADLs 
Results 
1. Develop a short and simple 
instrument. 
2. Enhance the properties of the test 
to differentiate NC from MCI. 
3. Prove that Qmci strongly 
correlates with SADAS-cog. 
4. Prove that Qmci has superior 
sensitivity and specificity for 
differentiating MCI from NC and 
dementia compared to the SMMSE, 
the ABCS 135, and MoCA. 
1. Prove that the use of CACE-Is is 
associated with a reduced rate of 
cognitive decline in dementia. 
2. Prove that cognitive scores may 
improve in the first six months after 
CACE-I treatment. 
1. Prove that CACE-Is are associated with 
a reduced rate of functional decline in 
dementia. 
2. Prove that CACE-Is may have more 
beneficial effects on instrumental ADLs. 
3. Prove that patients taking perindopril 
had a significant reduction in rate of 
functional decline. 
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RQ1 (Research Question 1) proves that Qmci, a new screening test for 
cognitive impairment, has better sensitivity and specificity for 
differentiating MCI from normal cognition and dementia compared to the 
SMMSE, the ABCS 135, and MoCA. It also correlates with the SADAS-cog, 
CDR scale and the Lawton-Brody ADL scale. RQ2 finds that, there is a 
statistically significance difference, in the median, six-month, rate of decline 
in cognitive scores between CACE-I and NoCACE-I patients. The findings 
in RQ3 show that, there is a significant reduction in the rate of decline in 
total ADL scores in patients taking CACE-Is, compared to those who were 
not (NoCACE-I group). 
 
6.4 Contributions and Results 
This research makes a number of contributions as follows. The primary 
contributions of the study are to explain: (1) the effect of the centrally acting 
ACE inhibitors on the rate of cognitive and functional decline in dementia; 
and (2) the validation of a new and quick cognitive screening tool, Qmci, 
which can potentially replace the cognitive screening tools currently in use 
today. The secondary contribution of the study is its development of a 
prototype of a clinical data process that can be used by clinicians and 
researchers in designing data analysis systems for their studies. The 
objective of this section is, to briefly re-examine this study to ascertain the 
contributions it makes in the following areas: cognitive screening test, and 
the effect of CACE-Is in dementia. Table 6.2 demonstrates the relationships 
between research questions, studies and contributions in this research. 
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Table 6. 2 The Map on Research Questions, Studies and Primary Contributions 
Research 
Objective 
To investigate the effects of centrally acting ACE inhibitors (CACE-Is) on the rate of cognitive and 
functional decline in dementia, using a three phased Knowledge Discovery in Databases (KDD) process. 
Research 
Questions 
RQ1: key outcome instruments for 
cognition in dementia 
RQ2: effect of CACE-Is on 
cognitive decline in dementia 
RQ3: effect of CACE-Is on functional 
decline in dementia 
Studies  
(chapter number) 
(Chapter 4) Study One (Chapter 5) Study Two & Three (Chapter 5) 
Research 
Contributions 
Contribution Two: 
 Cut-off scores were developed 
for the Qmci in patients 
presenting with memory loss. 
 Qmci can differentiate MCI from 
NC, and dementia, and suggests 
superior sensitivity and 
specificity over other short 
cognitive screening tools. 
 Qmci incorporates several 
important cognitive domains 
making it useful across the 
spectrum of CI. LM is the best 
performing subtest for 
differentiating MCI from NC. 
Contribution One: 
 Patients currently taking CACE-Is, declined slower than those not 
currently treated with them in dementia. 
 The NewCACE-I group improved slightly over the first six 
months of treatment, compared to CACE-I and NoCACE-I groups. 
 CACE-Is are associated with a reduced rate of functional decline 
in dementia. 
 Perindopril may be superior to other CACE-Is in ADLs. 
 CACE-Is are associated with a significant reduction in the rate of 
decline in instrumental ADLs in dementia. 
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The following sections provide the details of the two research contributions. 
 
6.4.1 Research Contribution One 
 This research presents the evidence that centrally acting 
angiotensin-converting enzyme (ACE) inhibitors (CACE-Is), are 
associated with a reduced rate of cognitive and functional decline in 
dementia. 
 
Three studies were used in this research to investigate an association 
between anti-hypertensive drugs, which lower high blood pressure or 
hypertension, called centrally acting ACE inhibitors (CACE-Is) and the 
reduction in the rates of decline in dementia. As there is little evidence that 
anti-hypertensive medications affect other dementia subtypes (Hardy, 2009, 
Kehoe et al., 1999, Lehmann et al., 2005), only patients with AD, vascular, 
or mixed AD-vascular dementia, were included in this research. 
 
6.4.1.1 Study One: CACE Study in GAT Database 
The first study found that patients with dementia, currently taking CACE-Is, 
declined slower than those not currently treated with them. This study 
investigated rates of cognitive decline in three groups of patients: dementia 
patients being treated with centrally acting ACE inhibitors (the CACE-I 
group), dementia patients being treated with non-centrally acting ACE 
inhibitors (NoCACE-I), and dementia patients who started and were newly 
treated with centrally acting ACE inhibitors (NewCACE-I). After six 
months, there was a significantly greater reduction in the rate of cognitive 
decline between the CACE-I group and the NoCACE-I group, assessed by 
the Qmci score. There was a similar, but not significant reduction, in 
the SMMSE, irrespective of the blood pressure readings or diagnosis of 
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hypertension. 
 
A novel finding, however, was that the NewCACE-I group, started on 
CACE-Is while attending clinic, declined at a significantly slower rate, 
improving slightly over the first six months of treatment, compared to those 
already taking CACE-Is and those not currently treated with CACE-Is. This 
suggests that CACE-Is may have cognitive enhancing effects, particularly 
when patients are initially started on treatment. This is the first study to 
show improvement in cognitive scores in patients starting, rather than those 
already on maintenance treatment, with CACE-Is, in dementia. Although 
this may have been related to better medication compliance, or the effects of 
improved BP control, and cerebrovascular perfusion after initial treatment, it 
is an important and potentially interesting finding. Overall, the results of this 
first study suggest that ACE inhibitors hold promise as an inexpensive way 
to modify the rate of progression of dementia and indicated that further 
study is required. 
 
6.4.1.2 Study Two: CACE Study in DARAD Database 
The second study found that centrally acting ACE inhibitors also affected 
clinically meaningful patient outcomes such as ADLs and mood, as well as 
supporting the findings of the first study (investigating the effects on 
cognition). In this second study CACE-Is slowed functional decline (decline 
in ADLs) by 25%. This reduction in the rate of decline in ADLs, was 
statistically significant over a 12-month period, between patients taking 
CACE-Is to those not currently receiving CACE-Is. Although only changes 
in ADLs and certain depression scores (CSDD) were statistically significant, 
the other outcomes measures generally demonstrated decreased progression 
for the CACE-I, compared to the NoCACE-I group. In particular, the Qmci 
screen scores declined 32% less (1.9 points), in the CACE-I group, over one 
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year. These data were consistent with the first study demonstrating a slower 
rate of cognitive decline in persons with dementia. 
 
The results presented in this study also suggest that perindopril may be 
superior to other CACE-Is. Perindopril was associated with a slower rate of 
decline in measures of cognition (SADAS-cog and Qmci), global function 
(CDR-SB) and ADLs, compared to other CACE-Is. Although no statistically 
significant differences were seen in the subgroup taking perindopril, they 
had slower rates of decline in these outcome measures, many of which 
approached significance. The subgroup taking perindopril was small and not 
robust enough to show statistical differences.  
 
6.4.1.3 Study Three: CACE Study in GAT and DARAD Databases 
Combined 
The third study pooled the data from the two clinical databases together 
from the two previous studies. Data were pooled to increase the power of 
the analyses by increasing the number of patients currently receiving 
CACE-Is, available for analysis. This study found a significant reduction in 
the rate of decline in total ADL scores, over six months, in patients taking 
CACE-Is, compared to those who were not. Another question addressed in 
this analysis was whether the apparent effects on ADLs were attributable to 
changes in basic ADLs (BADLs) and/or instrumental ADLs (IADLs). In this 
study, total ADLs were divided into BADLs and IADLs. The difference in 
median rates of decline in ADLs, for those in the CACE-I compared to the 
NoCACE-I group, was greater than IADLs (p=0.001). We hypothesise that 
this may reflect the population studied. Patients with mild to moderate 
dementia (median SMMSE score of 23), have relatively impaired IADL and 
well preserved BADL scores. So given that BADL scores were very high, it 
was not possible to show differences in these scores between groups. So this 
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population had improvement in IADL scores and BADL scores for the most 
part remained constant. 
 
The results of this study again suggested that perindopril may be superior to 
other CACE-Is, with a relatively larger reduction in median rates of 
functional decline over six months (64%, 0.5 versus 1.4 points), compared 
to those not currently receiving CACE-Is. This effect was again evident for 
IADLs but not for BADLs. The study also confirmed a consistent 
association between use of CACE-Is and reduced rates of cognitive decline 
(Gao et al., 2013a). 
 
In summary, the findings from the three studies may help to provide further 
research in the area to improve the treatment of dementia patients. The 
observed effects (differences) were small and of uncertain clinical 
significance for the treatment periods explored. Yet the compounding effects 
of these benefits, if sustained over years, could have significant clinical 
benefits. In the MCI and early stage dementia patients, it could effectively 
prevent or delay progress from MCI to dementia. CACE-Is improve ADLs, 
and help dementia patients maintain independence. Potentially, perindopril 
may offer even more benefit than the other CACE-Is. 
 
6.4.2 Research Contribution Two 
 This research validated that the Quick Mild Cognitive Impairment 
(Qmci) test is an efficient, quick, and accurate screening tool for 
screening patients with cognitive impairment.   
 
Adults with memory loss present a challenge to clinicians, who must 
determine if the memory changes represent normal aging, mild cognitive 
impairment or early dementia. Screening for the presence of cognitive 
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impairment (CI) is important to facilitate early diagnosis, plan for the future, 
identify reversible causes and initiate treatment (Boise et al., 1999). While 
screening programmes for detecting CI are advocated (Boustani et al., 2003) 
(Cordell et al., 2013), there is limited evidence supporting routine screening 
in clinical practice (Boustani et al., 2005), primarily because there are no 
sensitive and specific cognitive screening tests that can differentiate normal 
cognition (NC) and MCI from dementia (Winblad et al., 2004, Boustani et 
al., 2005), but particularly because of the effects of age and education 
compound interpretation of these tests, and must be taken into account. Few 
tests have sufficient sensitivity and specific in people with low education 
(Cordell et al., 2013). 
 
A number of cognitive screening instruments have been used in an attempt 
to differentiate normal cognition (NC), and MCI from dementia (Molloy et 
al., 2005, Lonie et al., 2009). To standardise assessments and allow 
comparison between settings, there is a need for short instruments that are 
reliable, valid, and responsive to change, across a wide range of cognitive 
function. They need multiple standardised scoring formats that measure 
changes early (high ceiling) and continue to measure changes effectively 
into the late stages of dementia (low floor). Table 6.3 lists the key characters 
of several existing well-known cognitive screening instruments, comparing 
with Qmci. 
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Table 6. 3 Key Characteristics for Cognitive Screening Instruments 
        Test 
Name 
Characters 
SMMSE SADAS-cog MoCA ABCS 135 Qmci 
Examining Time 10 minutes 
45 minutes, and 
requires training 
At least 10 minutes 3 - 5 minutes 4 minutes 
Total scores 30 points 70 points 30 points 135 points 100 points 
Has total cut off 
scores for NC, MCI 
and dementia? 
Yes. Yes. Yes, but with poor 
specificity. 
No. Yes. Age and 
education specific 
cut-offs are 
available as well. 
Differentiation of 
MCI from NC and 
dementia 
Only 1 - 2 points 
range for MCI. 
It is comprehensive 
and useful at 
different stages of 
dementia. 
Highly sensitive 
and specific at 
differentiating MCI 
from NC and 
dementia. 
Some subtests, 
such as orientation, 
registration and 
clock drawing did 
not enhance the 
discriminatory 
properties of the 
test in 
differentiating NC 
from MCI. 
It has 10 points 
range for MCI. 
It has superior 
accuracy for 
detecting MCI 
compared to the 
SMMSE and 
similar accuracy 
as MoCA. 
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However, no single existing cognitive screening instrument is ideal, and to 
date, none are established as the standard (Gifford and Cummings, 1999). 
They are limited by their inability to detect significant variations between 
patients with respect to age and/or educational status (Crum et al., 1993). 
Hence, new instruments are required that have a higher ceiling and are not 
as dependent on education. The Quick Mild Cognitive Impairment screen 
(Qmci) was developed to address this problem. It is the improved version of 
ABCS 135, and developed to enhance the sensitivity of the ABCS 135. 
 
The Qmci is a short screening test for CI, that was developed as a rapid, 
valid and reliable tool for the early detection and differential diagnosis of 
MCI and dementia (O'Caoimh et al., 2012a). It is scored out of 100 points 
and has a median administration time of 4 minutes (O'Caoimh et al., 2013a). 
Throughout the analysis, Qmci has better sensitivity and specificity for 
differentiating MCI from normal cognition and dementia, compared to the 
SMMSE and the ABCS 135 (O'Caoimh et al., 2012a). It correlates with the 
standardised Alzheimer`s Disease Assessment Scale-cognitive section 
(SADAS-cog), Clinical Dementia Rating (CDR) scale and the 
Lawton-Brody activities of daily living scale (O'Caoimh et al., 2014). It was 
also being validated against MoCA, with more accuracy, and a shorter 
administration time.  
 
This research provides usable cut-off scores for the Qmci based upon large 
numbers of patients presenting with memory loss across both clinical and 
research settings. It shows that the Qmci can differentiate MCI from NC, 
and dementia, and suggests superior sensitivity and specificity over other 
short cognitive screens such as the SMMSE (Molloy et al., 1991a) and 
MoCA (Nasreddine et al., 2005). This analysis also provided cut-off scores, 
adjusted for age and education, which not used directly in subsequent 
analysis, provide an important part of the development of any short 
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cognitive screening test. Based upon this analysis, a cut-off score of <60 for 
CI (either MCI or dementia), a range of 59 to 51 for MCI, and <50 points 
for dementia is suggested. Thus, the Qmci is a useful tool in the clinic, to 
screen for CI, and to differentiate between normal cognition, MCI and 
dementia. 
 
6.4.3 Research Contribution Three  
 This is a secondary contribution. By using the KDD process in these 
studies, this research introduced a new data process prototype, CDAF 
(Clinical Data Analysis Framework), for data analysis especially in 
clinical research.    
 
Healthcare systems around the world are struggling to keep up with patient 
needs, and improve quality of care, while reducing costs at the same time. 
Meanwhile, more and more data is being captured around healthcare 
processes. As data get collected, they are not only required to store in an 
electronic format but also to use them in meaningful ways. As we know 
KDD is a generic term for processing data, and there is a need to standardise 
the data processing procedure in clinical research. To formalize the KDD 
process in clinical research, we introduce the concept of the Clinical Data 
Analysis Framework (CDAF). It helps clinicians and researchers to better 
understand the data analysis procedure in clinical research, and provide a 
roadmap to follow while planning and executing the analysis in the project. 
The results can provide support to healthcare providers on issues such as 
preventive care, diagnosis, treatment, monitoring and follow ups, using 
artificial intelligence reasoning to synthesize clinical information, as a 
precursor to a Randomized Control Trial. The CDAF is not developed to 
replace a clinicians’ assessment but, instead, to facilitate correct assessment 
and reasoning. The processes of CDAF are shown as Figure 6.1. 
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Figure 6. 1. Data Process Steps in CDAF 
 
In the CDAF, the Data Pre-processing phase includes a number of steps to 
prepare data: learning target, data collection, data warehousing into database, 
structuring target data, data cleaning, and data transforming. And then data 
analysis methods are applied to build patterns/extract findings in the Data 
Analysis phase. Finally, in the Data Post-processing phase, discovered 
information is evaluated, visualised and applied to support clinical decision 
or enhance the understanding of diseases. These phases can be summarised 
as follows:  
1. Data Pre-processing. This is the phase for preparing the clinical data. At 
the beginning, researchers need to determinate medical and data analysis 
goals, learn the terminology and relevant prior knowledge. Then understand 
the mechanisms of data collection, initial data exploration and verification. 
Selection of row data samples on which the discovery process is to be 
performed. Decisions on algorithm inputs (features) and structuring and 
cleaning the database need to be considered. This includes decisions on 
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strategies for handling missing data fields or evidently inadmissible 
instances. The processed data will then be transformed into an appropriate 
format for the analysis tools. 
2. Data Analysis. This phase includes the decisions on algorithms, training 
and testing procedures; generation of diagnostic rules in a particular 
representational form or set of such representations. It is concerned with 
applying computational techniques to the actual extraction of the 
information from the data. 
3. Data Post-processing. This phase describes and discusses the results, 
including interpreting the discovered patterns as well as a possible 
visualization of the extracted patterns. The discovered information may be 
incorporated into an up-and-running system, taking an action based on the 
knowledge or simply documenting it for management or later use. 
 
The CDAF phases provide a platform for traceability, allowing for ‘stepping 
back’ in the data analysis process. Therefore, the CDAF can save time 
during clinical data analysis. Potentially, a computerized intelligent CDAF 
system could reduce healthcare costs through avoiding delays in treatment, 
redundant tests or referrals due to misdiagnosis. Furthermore, the efficiency 
and ease of extracting the data from the CDAF system and use them for 
reporting are very important for clinicians. Depending on the nature of data, 
denormalised data structure is better suited for some data sets such as Vital 
Signs, where as normalised data structure is better suited for some data sets 
such as labs. Thus, there are benefits of a CDAF for the clinician, 
researchers and those in charge of financial budgets. 
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6.5  Research Limitations 
This research had a number of limitations including: 
 The GAT was not a randomized control trial study. 
 Neither the GAT nor the DARAD were designed to examine the effects 
of CACE-Is. Both were secondary analyses of existing databases and 
thus were observational studies, limiting the strength of conclusions 
which could be drawn. 
 Another limiting factor is the potential for confounding by indication for 
drugs (CACE-Is), such that other reasons for using CACE-Is could have 
created bias. 
 Pooling patients from different sources may also create bias. The GAT 
data sampled outpatients (unselected patients referred to a geriatric 
medicine memory clinic), while the DARAD included a highly selected 
sample of patients, selected to meet the inclusion criteria for a 
multi-centre randomized control trial. That said, common inclusion and 
exclusion criteria were used in this pooled analysis, and patients were 
assessed and managing by the same supervising consultant geriatrician. 
 The patients included in these studies all had established dementia and 
therefore may have been taking CACE-Is for many years. It was not 
possible to identify duration of treatment, or previous history of 
anti-hypertensive treatment, retrospectively, from the databases. The 
duration of hypertension or the presence of end organ damage related to 
hypertension was likewise not taken into account. Furthermore, although 
it was possible to adjust findings for some commonly prescribed 
treatments for dementia, such as the use of Cholinesterase Inhibitors and 
Memantine, it was not possible to comment on other treatments.   
 The NoCACE-I group is a large heterogeneous group of patients, 
including those treated for hypertension, those without hypertension, 
and those with hypertension, but not on treatment. For example, a large 
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percentage of patients in the NoCACE-I group (i.e. in DARAD, 41%) 
were not receiving any anti-hypertensive treatments. This limits the 
conclusions that can be drawn about comparisons of the rates of decline 
between the CACE-I and NoCACE-I groups.  
 Several of the outcome measures used in this study, while widely used in 
clinical practice, are not recognized standards. The marker of ADLs used, 
the Lawton-Brody ADL Scale score, is not a gold standard outcome 
measure, but it is a widely used instrument that incorporates both 
instrumental and basic activities of daily living. Likewise the Qmci is 
not a gold standard and is not widely used in clinical practice. This 
necessitated the need to validate the instrument, work that was done in 
the department as a side issue to this thesis. In this work, we showed that 
the Qmci compares to gold standards including the Standardised 
ADAS-cog and the CDR. 
 Finally, the data included in these databases were collected in a single 
country, Canada. This may reduce the generalizability of the findings. 
However, Canada is a large multi-cultural country, and the data were 
collected over many years across the whole country with 14 clinical 
research centers contributing data. 
 
6.6 Summaries, Suggestions and Future Work 
In summary, these three studies suggest that CACE-Is are associated with a 
reduced rate of cognitive and functional decline, as assessed with Qmci, 
SMMSE and ADLs, in patients with AD, vascular or mixed AD-vascular 
dementias. Potentially, of all the CACE-Is, perindopril may offer the most 
benefit. This supports the growing body of evidence for the use of ACE-Is 
and other anti-hypertensive agents in the management of dementia (Poon, 
2008). The finding of a reduced rate of progression in cognition and 
function was small. However, if such differences were sustained over years, 
 173 
the compounding effects may well have significant clinical benefits. Future 
study with an appropriately powered randomised trial is needed to confirm 
these findings and determine if, and for how long, these effects are sustained 
(Todd et al., 2010). In a randomised trial of sufficient length, if these data 
can be reproduced, incorporating appropriate outcome measures, such as an 
amyloid positron emission tomography, then these agents are likely to have 
significant benefits in delaying or even preventing dementia (Gao et al., 
2013a). This study is important and these findings showed lead to new 
research to investigate if commonly used anti-hypertensive medications can 
modify AD and other dementing illnesses. 
 
Although much of the early work looking at anti-hypertensives in dementia 
focused on ACE-Is, more recently other anti-hypertensives have been 
implicated. These include drugs that also act on the renin-angiotensin 
aldosterone system, such as ARBs and direct renin inhibitors and other 
classes of anti-hypertenives, including beta-blockers and calcium channel 
blockers (CCB).  
  
ARBs, including valsartan (Wang et al., 2007) and telmisartan (Mogi et al., 
2008), can reduce Aβ levels in animal studies. Some observational studies 
show that Angiotensin receptor blockers are associated with a significant 
reduction in the incidence and progression of dementia (Li et al., 2010). 
Those currently treated with ARBs have lower incident rates of dementia, 
compared to those taking some CACE-Is, or other cardiovascular 
comparator drugs (Li et al., 2010). 
 
Direct renin inhibitor (DRI) aliskiren, acting as an active inhibitor of renin 
(Brown, 2008), can reduce the formation of angiotensin I from 
angiotensinogen. It also may provide neuronal protection in subcortical 
vascular dementia (Dong et al., 2011b). Aliskiren reduces brain damage and 
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working memory deficits related to acute cerebral ischaemia, possibly 
through a reduction in oxidative stress in mouse models (Dong et al., 2011b). 
The effects of DRIs on Aβ and ischaemia may be an important factor that 
induces neuronal damage in mixed dementia (Brunnström et al., 2009).  
 
A recent study suggests beta blockers might reduce the risk of dementia 
(White et al., 2013). By lowering the heart rate, beta blockers may reduce 
wear and tear on small blood vessels throughout the body, including those 
that carry oxygen and fuel to every corner of the brain. Fed by healthier 
vessels, the aging brain would be less likely to suffer microinfarcts. Further 
prospective randomized studies comparing different antihypertensive classes 
are needed to provide more evidence regarding the effects of 
antihypertensive drugs on dementia risk and to determine whether certain 
antihypertensive classes provide greater benefits than others. 
 
Furthermore, the findings in this research were based on the data-driven 
analytical methods, following with Clinical Data Analysis Framework 
(CDAF) based on Knowledge Discovery Databases (KDD) process, 
including three phases of data processing (data pre-processing, data analysis, 
and data post-processing). CDAF provides scientific ways to structure and 
select useful data, extract implicit and useful information from raw data, and 
visualise the outcomes. Data analysis is the core phase in CDAF, which 
consists of applying different methods (i.e. statistics or data mining) that, 
under acceptable computational efficiency limitations, produce a particular 
enumeration of patterns (or models) over the data. This research 
successfully applied a number of statistical methods to find useful 
information from a verity of clinical databases. 
 
The use of appropriate data analytical processes and methods could 
effectively lead to finding new and useful knowledge in the medical area. 
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By using CDAF, the data process steps are traceable, and the results are 
more believable. On the other hand, unlike the traditional knowledge 
discovery process in clinical trials, CDAF can be very advantageous, as it 
allows quicker and less expensive approaches to store, prepare, demonstrate 
and analyse data. It focuses on the implementation of discovery results in 
databases, and novel techniques can be used to find unknown patterns or 
relationships in clinical data. This approach in clinical databases can be used 
into future work, to examine different diseases from different data sources. 
We could choose the best drug candidates, to see which are the most 
effective in modifying various diseases. Similar methodology can be applied 
in different clinical trials and databases, as it is very low-cost and quick. In 
this way, researchers can build the case to examine the data from clinical 
trials and studies for the future. 
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ABSTRACT
Objectives: There is growing evidence that
antihypertensive agents, particularly centrally acting ACE
inhibitors (CACE-Is), which cross the blood–brain barrier,
are associated with a reduced rate of cognitive decline.
Given this, we compared the rates of cognitive decline in
clinic patients with dementia receiving CACE-Is (CACE-I)
with those not currently treated with CACE-Is (NoCACE-I),
and with those who started CACE-Is, during their first
6 months of treatment (NewCACE-I).
Design: Observational case–control study.
Setting: 2 university hospital memory clinics.
Participants: 817 patients diagnosed with Alzheimer’s
disease, vascular or mixed dementia. Of these, 361 with
valid cognitive scores were included for analysis, 85
CACE-I and 276 NoCACE-I.
Measurements: Patients were included if the baseline
and end-point (standardised at 6 months apart)
Standardised Mini-Mental State Examination (SMMSE) or
Quick Mild Cognitive Impairment (Qmci) scores were
available. Patients with comorbid depression or other
dementia subtypes were excluded. The average 6-month
rates of change in scores were compared between CACE-
I, NoCACE-I and NewCACE-I patients.
Results:When the rate of decline was compared
between groups, there was a significant difference in the
median, 6-month rate of decline in Qmci scores between
CACE-I (1.8 points) and NoCACE-I (2.1 points) patients
(p=0.049), with similar, non-significant changes in
SMMSE. Median SMMSE scores improved by 1.2 points
in the first 6 months of CACE treatment (NewCACE-I),
compared to a 0.8 point decline for the CACE-I (p=0.003)
group and a 1 point decline for the NoCACE-I (p=0.001)
group over the same period. Multivariate analysis,
controlling for baseline characteristics, showed
significant differences in the rates of decline, in SMMSE,
between the three groups, p=0.002.
Conclusions: Cognitive scores may improve in the first
6 months after CACE-I treatment and use of CACE-Is is
associated with a reduced rate of cognitive decline in
patients with dementia.
INTRODUCTION
As populations age worldwide, the incidence
of dementia will increase. By 2040,
approximately 81 million people worldwide
will be affected.1 Until now, no agents have
been identiﬁed that prevent, modify or
reverse dementia, and available treatments
for dementia are predominantly symptom-
atic.2 There is growing recognition of the
role of cardiovascular risk factors, especially
in midlife, in the conversion and progres-
sion of mild cognitive impairment (MCI)
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and dementia.3–5 Blood pressure (BP) control, in par-
ticular, is associated with both a reduced incidence of
cognitive impairment (CI) and rate of cognitive
decline.6–9 Several antihypertensive agents are asso-
ciated with a lower risk of developing dementia, includ-
ing calcium channel blockers (CCBs),10 11 diuretics,8
angiotensin receptor blockers (ARBs)12–14 and ACE
inhibitors (ACE-Is).15 16 ACE-Is and ARBs affect the
renin angiotensin system and may lower dementia risk,
independent of their BP lowering properties.17 Results
of clinical trials investigating the potential role of anti-
hypertensives are limited and conﬂicting.18 The
Perindopril Protection against Recurrent Stroke Study
(PROGRESS) demonstrated that a combination of peri-
ndopril (ACE-I) and indapamide (diuretic) was asso-
ciated with a signiﬁcant reduction in the incidence of
stroke and in cognitive decline, compared to placebo.8
The Systolic Hypertension in Europe (Syst-Eur) study
found that the combination of enalapril (ACE-I),
nitrendipine (CCB) and/or hydrochlorothiazide (diur-
etic) reduced the incidence of dementia by 55%, com-
pared to placebo.19 20 Monotherapy with the ARB,
candesartan, in the Study on Cognition and Prognosis
in the Elderly (SCOPE) also showed modest effects.14
Not all studies have shown cognitive beneﬁts with anti-
hypertensive agents; some implicate them in the wor-
sening of cognition.21 The ONTARGET and
TRANSCEND trials, two parallel studies involving more
than 25 000 patients, found that ACE-Is did not have
any measurable effects on cognition.22 Although the
evidence is limited, treatment with antihypertensives
has been associated with reduced rates of cognitive23 24
and functional decline25 in those with established
Alzheimer’s disease (AD).
ACE-Is were one of the ﬁrst antihypertensives to be
studied, particularly in AD, the most prevalent form of
dementia.26 Patients with AD have abnormal cleavage of
amyloid precursor protein resulting in a pathological
accumulation of amyloid β (Aβ).27 The relationship
between ACE and the accumulation of Aβ is complex
and different polymorphisms have been postulated to
either increase,28 or decrease,29 the risk of developing
AD. ACE activity is increased in AD, proportional to the
Aβ load.30 Centrally acting ACE-Is (CACE-Is) that cross
the blood–brain barrier may have a greater impact than
those that do not. The CACE-I perindopril, administered
to mouse models, showed a signiﬁcant protective
effect31 and reversed CI more than did the non-centrally
acting imidapril and enalapril.32 Patients receiving
CACE-Is have a reduced rate of cognitive decline com-
pared to both non-centrally acting ACE-Is and CCBs.15
The Cardiovascular Health Study demonstrated no
reduced risk in the incidence of dementia in those
taking CACE-Is compared to other classes of antihyper-
tensives.33 Those prescribed CACE-Is had a reduced rate
of cognitive decline and less impairment in instrumental
activities of daily living compared to those taking non-
centrally acting agents.34 Prescription of ARBs and
ACE-Is is also associated with reduced incidence of both
vascular dementia and mixed dementia subtypes.35 36
Outside of clinical trials, there are few data on the
effects of CACE-Is on the rate of cognitive decline in
patients with dementia. Given this, and the growing evi-
dence for antihypertensive agents, particularly CACE-Is,
in reducing the incidence and rate of cognitive decline,
we compared the rates of decline in patients taking
CACE-Is (called CACE-I) with those not currently pre-
scribed CACE-Is (called NoCACE-I), in those with estab-
lished dementia, attending a memory clinic. We also
examined whether patients started on CACE-Is while
attending clinic (called NewCACE-I), behaved differently
during their ﬁrst 6 months of treatment, compared to
the NoCACE-I group and those already established on
CACE-Is.
METHODS
Data collection
Data were analysed from the Geriatric Assessment Tool
(GAT) database, a customised software application that
automates physicians’ clinic assessments. Data were col-
lected in memory clinics in two university hospitals in
Ontario, Canada. The database contains over 8000 indi-
vidual assessments from 1749 people aged 41–104 years.
GAT data, collected between 1999 and 2010, includes
age, gender, education, medical diagnosis, BP, laboratory
ﬁndings, medications, etc and the scores of two cogni-
tive screening tests, the Standardised Mini-Mental State
Examination (SMMSE)37 38 and the Quick Mild
Cognitive Impairment (Qmci) screen,39 40 a new cogni-
tive screen, more sensitive and speciﬁc for differencing
MCI from normal cognition and dementia than the
SMMSE.39 Both tests were administered to patients by
trained raters (clinic nurses) blind to the diagnosis,
prior to each assessment, to monitor progression.
The Qmci has six subtests covering ﬁve cognitive
domains: orientation, working memory, semantic
memory (verbal ﬂuency for animals), visual spatial
(clock drawing) and two tests of episodic memory
(delayed recall and immediate recall logical memory). It
is scored out of 100 points.
Subjects
Patients with dementia were diagnosed by a consultant
geriatrician using NINCDS41 and the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) criteria.42 Only patients with AD, vascular or
mixed dementias (Alzheimer’s/vascular) were included
in this analysis. As there is little evidence that antihyper-
tensive medications affect other dementia subtypes,
patients with Parkinson’s disease dementia,43 44 fronto-
temporal dementia,45 Lewy body dementia,46 alcohol-
related dementia, post-trauma and post-anaesthetic
dementia were excluded. Patients with MCI, n=235,
deﬁned as those with subjective and corroborated
memory loss, without obvious loss of function,47 were
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excluded. Patients with MCI were excluded because few,
n=12, had baseline and end-point Qmci scores available.
Although the SMMSE was available, it is insensitive to
MCI,39 and rates of cognitive decline vary, depending on
the cognitive measures used.48 Patients with normal cog-
nition, n=181 and depression, n=397 were also excluded.
Participants were screened for depression using the
15-point Geriatric Depression Scale.49 As there is limited
evidence that ACE-Is affect comorbid depression,50 while
depression negatively affects the results of cognitive
testing,51 397 participants with depression were
excluded: 260 with CI and comorbid depression and 137
with normal cognition and depression. Patients with
depression were predominantly (63%) women and were
signiﬁcantly younger than patients without depression,
mean age 72.7 (SD 10.7), p<0.001. Patients were also
excluded if they did not have the results of either the
Qmci or SMMSE available at both the baseline and end
point. Changes between the baseline and end-point (last
visit) scores were standardised at 6 months to facilitate
comparison between all groups. In total, 56% (n=456)
of patients with dementia did not have the same cogni-
tive test recorded at two visits and were therefore
excluded. Regression analysis, adjusting for baseline
characteristics (age, gender, education and BP) between
participants without follow-up and those included,
showed no signiﬁcant difference in baseline SMMSE
(p=0.06) or Qmci scores (p=0.51). Patient selection is
presented graphically in ﬁgure 1. The CACE-I group
included patients currently prescribed the following
CACE-Is: perindopril, ramipril, trandolapril, captopril,
fosinopril, lisinopril, prinivil and monopril.34 52
Figure 1 Flow chart demonstrating the breakdown of the patients included in the Geriatric Assessment Tool (GAT) database.
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NoCACE-I included patients who were not currently
receiving CACE-Is, irrespective of the BP readings, diag-
nosis of hypertension or whether they were receiving
other antihypertensive medications.
Analysis
Our goal was to determine whether there were differ-
ences in rates of change, from the baseline to the end
point (the time point when cognitive scores were last
available), in Qmci and SMMSE scores between patients
in the NoCACE-I, NoCACE-I and NewCACE-I groups
while attending clinic. Given that regulatory authorities
like the US Food and Drug Administration require evi-
dence of change in cognitive tests over 6 months41 53 to
conﬁrm beneﬁt from new medications, we used change
scores from the baseline, on a six-monthly basis, accord-
ing to the formula:
Rate of decline ¼ (Baseline score end - point score)
 6=duration in months
We also used multivariate regression to compare end-
point cognitive scores (SMMSE and Qmci), adjusted for
the baseline cognitive scores and characteristics (age,
years of education, duration of follow-up and BP),
between the three groups (CACE-I, NoCACE-I and
NewCACE-I). Data were analysed using SPSS V.18.0. The
Kolmogorov-Smirnov and Shapiro-Wilk tests were used
to test for normality. Non-normally distributed data were
compared with the Mann-Whitney U test. Categorical
data were analysed with χ2 tests.
RESULTS
Baseline characteristics
In total, there were 817 patients with dementia. Of
these, 361 with SMMSE and Qmci scores recorded at
two or more visits were included for analysis, 85 receiv-
ing CACE-Is and 276 receiving NoCACE-Is. The mean
age of those included was 77.9 years with an SD of
8.1 years. Half (50.3%) were men and the mean time
spent in education was 11.2 years. The mean age of
patients taking CACE-Is was 77.2 years compared to
77 years for the NoCACE-Is group. Men represented
51.8% of the CACE-I group compared to 49.6% of the
NoCACE-I group. Within the NoCACE-I group, 30 parti-
cipants had been started on ACE-Is while attending
clinic (NewCACE-I). Table 1 shows the baseline charac-
teristics, including demographics and medication use,
for the CACE-I, NoCACE-I or NewCACE-I groups.
Both SMMSE and Qmci scores were available for 147
participants at the baseline and end point, while 206
participants had SMMSE scores only and 8 had Qmci
scores alone. For the participants included, the mean
SMMSE scores at the baseline and end point were 21.6
(SD±5.6) and 18.1 (SD±8.0), respectively. Mean Qmci
scores were 36.8 (SD±13.6) and 31.3 (SD±18.3), respect-
ively. Table 2 presents the baseline and end-point Qmci
and SMMSE scores for the CACE-I, NoCACE-I or
NewCACE-I groups. After adjusting for the baseline char-
acteristics (age, education, duration of follow-up and
BP), there were no signiﬁcant differences in the baseline
cognitive scores (SMMSE and Qmci) between the three
groups (CACE-I, NoCACE-I and NewCACE-I).
In relation to medications, 88.2% of the CACE-I group,
82.6% of the NoCACE-I group and 80% of those in the
NewCACE-I group were receiving cholinesterase inhibi-
tors (CholEIs). A smaller percentage was currently pre-
scribed memantine. There was no difference in the
distribution of CholEIs (p=0.40) or memantine (p=0.98)
between the CACE-I, NoCACE-I and NewCACE-I groups.
Rate of decline
The median change in SMMSE scores between the base-
line and end point for those included was 0.69 points
per 6 months (IQR of 2). The median SMMSE score dif-
ferences for the CACE-I, NoCACE-I and NewCACE-I
groups were 0.8, 1.0 and −1.2, respectively, per
6 months. For the Qmci, the median change was 2
points per 6 months, with median Qmci score differ-
ences for the CACE-I and NoCACE-I groups of 1.8 and
2.1, respectively, per 6 months.
There was a small but non-signiﬁcant difference in the
SMMSE median rate of decline over 6 months for
patients taking CACE-Is, compared to NoCACE-I
patients, p=0.77. The difference in the median rates of
Table 1 Baseline characteristics of CACE-I, NoCACE-I or NewCACE-I patients
Groups CACE-I NoCACE-I NewCACE-I
Number 85 276 30
Age (mean±SD) 77.2±6.4 77.0±7.6 77.3±8.2
Male (%) 44 (51.8) 137 (49.6) 15 (50)
Education (mean±SD) 10.6±3.8 11.4±4.0 12.1±3.9
Systolic BP in mm Hg (mean±SD) 133.4±21.2 135.5±16.9 141.1±16.2
Diastolic BP in mm Hg (mean±SD) 70.1±12.6 72.5±11.5 78.1±17.0
Cholinesterase inhibitor use (%) 75 (88.2) 228 (82.6) 24 (80)
Memantine use (%) 23 (27.1) 72 (26.1) 8 (26.7)
BP, blood pressure; CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is;
NoCACE-I, patients who are not currently prescribed CACE-Is.
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decline in Qmci scores reached borderline signiﬁcance,
p=0.049. The median decline in scores (rate per
6 months) for the NewCACE-I group, on the SMMSE,
was −1.2 points for the NewCACE-I group, signiﬁcantly
less than for the CACE-I group (median 0.8); p=0.003
and NoCACE-I group (median 1.0), p=0.001. The Qmci
could not be compared for the NewCACE-I group, as
the numbers were too small. These results are presented
in table 3. Multivariate regression analysis was used to
compare the end-point cognitive scores (SMMSE and
Qmci), adjusting for baseline cognitive scores (SMMSE
and Qmci) and patient characteristics (age, education,
duration of follow-up and BP). There were signiﬁcant
differences in end-point scores for the SMMSE
(p=0.002) between all three groups (CACE-I, NoCACE-I
and NewCACE-I). No signiﬁcant difference was seen, for
the Qmci, comparing the CACE-I and NoCACE-I
groups, (p=0.172).
CONCLUSION
This study demonstrates a small reduction in the rate
of cognitive decline, measured with the SMMSE and
Qmci, in patients taking CACE-Is compared to the
NoCACE-I group. The changes in Qmci scores over
6 months were small but statistically signiﬁcant. The
SMMSE scores, while non-signiﬁcant, suggested a
possible slower progression among those currently
receiving CACE-Is. NewCACE-I patients, started on
CACE-Is while attending clinic, showed a median
improvement rather than a decline in SMMSE scores,
over the ﬁrst 6 months of treatment, compared to those
already taking CACE-Is and those not currently treated
with CACE-Is. These results conﬁrm an association
between the use of CACE-Is, particularly during the
ﬁrst 6 months of treatment, and a reduced rate of cog-
nitive decline. This is the ﬁrst study to demonstrate that
cognitive scores improve in patients starting on
CACE-Is, compared to those already established on
maintenance treatment. This may have been related to
better medication compliance, the effects of improved
BP control or increased cerebrovascular perfusion after
initial treatment.54 55
The strength of the study lies in its large numbers and
inclusion of different (AD, vascular and mixed) demen-
tia subtypes. The study also investigates the effects of
CACE-Is in an unselected clinic sample of older adults,
whose mean age approached 80 years. It has a number
of limitations. This study is an analysis of observational
data collected in a ‘real world’ setting, where treatments,
including antihypertensive agents, were administered on
the basis of clinical judgement. Observational studies
like this are subject to bias in that those who receive
treatment may be systematically different from those
Table 3 Comparison of differences in Qmci and SMMSE scores between baseline and end point
Groups
Mann-Whitney
U test (p Values)
Changes in Qmci CACE-I (53) vs NoCACE-I (102) 0.049
median = 1.8* vs median = 2.1*
Changes in SMMSE CACE-I (113) vs NoCACE-I (240) 0.77
median = 0.8* vs median = 1.0*
NewCACE-I (30) vs NoCACE-I (240) 0.001
median =−1.2* vs median = 1.0*
NewCACE-I (30) vs CACE-I† (83) 0.003
median =−1.2* vs median = 0.8*
*Median score shows the change in six months for CACE-I, NoCACE-I and NewCACE-I
†CACE-I group excluding NewCACE-I patients.
CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is; NoCACE-I, patients who are
not currently prescribed CACE-Is; Qmci, Quick Mild Cognitive Impairment; SMMSE, Standardised Mini-Mental State Examination.
Table 2 Baseline and end-point (last visit) SMMSE and Qmci scores
N
Baseline age,
mean (±SD)
Gender
(male, %)
Duration of follow-up
in months, median
(Q3–Q1)
Baseline score,
median (Q3−Q1)
End-point score,
median (Q3–Q1)
SMMSE CACE-I 83 77.3 (±6.6) 53 17 (34–7) 22 (25–19) 20 (25–14)
NoCACE-I 270 77.1 (±7.6) 49.3 18 (31–9) 23 (26–19) 20 (25–13)
NewCACE-I 30 77.3 (±8.2) 50 6 (7–4) 23 (27–18) 24 (27–19)
Qmci CACE-I 41 78.9 (±6.1) 56.1 16 (31–7) 36 (44–23) 29 (49–15)
NoCACE-I 114 78.0 (±7.6) 49.1 11 (24–6) 38 (47–27) 32 (45–17)
CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is; NoCACE-I, patients who are
not currently prescribed CACE-Is; Qmci, Quick Mild Cognitive Impairment; SMMSE, Standardised Mini-Mental State Examination.
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who do not. That said, the baseline demographic charac-
teristics of the groups were similar and few participants,
in the NewCACE-I group, received other medications
that could have accounted for the differences observed.
Compliance with antihypertensive treatment, which has
been shown to reduce with time,56 57 could also have
been a confounding factor and may have accounted for
the improvement in the NewCACE-I group. Similarly,
duration of treatment with antihypertensive medications,
prior to attending clinic, could not be established for
the CACE-I and NoCACE-I groups in this retrospective
analysis.
Although most patients in the database had a Qmci or
SMMSE recorded, large numbers lacked results at the
baseline or end point, limiting the numbers that could be
included in the analysis. It is possible that the results
would have differed with more complete data on all
patients. However, the baseline cognitive scores were
similar between those included and excluded because of
missing data. In the comparison of the subgroup scores,
change over the ﬁrst 6 months of treatment was analysed
as this is the accepted time scale to show evidence of
beneﬁt in clinical drug trials.53 Although a small percent-
age (9%) had a shorter interval between the baseline
and end-point scores, the duration of follow-up was stan-
dardised at 6 months to facilitate comparison. The
accepted standard for measuring cognitive change is the
ADAS-cog.58 As this was an observational study in a clinic
setting, only the Qmci and the commonly used SMMSE
were available. The ADAS-cog is not an ideal test59 and
the Qmci has been shown to be as sensitive to change as
its standardised version, the SADAS-cog.60 Signiﬁcant dif-
ferences, between NewCACE-I and the other groups’
scores, using the SMMSE, could not be replicated with
the Qmci, as the numbers were too small to analyse.
In summary, this study demonstrates an association
between the use of CACE-Is and reduced rates of cogni-
tive decline, in an unselected sample of clinic patients
with dementia, particularly in the ﬁrst 6 months of treat-
ment. This supports the growing body of evidence for
the use of ACE-Is and other antihypertensive agents in
the management of dementia.18 Although the differ-
ences were small and of uncertain clinical signiﬁcance,
if sustained over years, the compounding effects may
well have signiﬁcant clinical beneﬁts. However, this may
be tempered by recent evidence suggesting that ACE-Is,
by interfering with degradation of Aβ, could contribute
to increased amyloid burden,61–63 potentially accelerat-
ing dementia severity and rates of cognitive decline.34
Indeed, ACE-Is may even increase mortality in patients
with CI, suggesting that if ACE-Is are proven to be bene-
ﬁcial in dementia, not all patients will beneﬁt.64 Further
study with an appropriately powered randomised trial is
needed to conﬁrm these ﬁndings and determine if and
for how long these effects are sustained.65 If these data
can be reproduced in a randomised trial of sufﬁcient
length incorporating appropriate outcome measures,
such as an amyloid positron emission tomography, then
these agents are likely to have signiﬁcant beneﬁts in
delaying or even preventing dementia.
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Abstract.
Background:Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are associated with reduced rates of cognitive
decline in patients with dementia. CACE-Is may also improve exercise tolerance in functionally impaired older adults with normal
cognition, suggesting that CACE-Is may positively influence activities of daily living (ADL) in dementia.
Objective: To compare rates of decline in patients with mild to moderate Alzheimer’s disease (AD) receiving CACE-Is to those
not currently treated with CACE-Is (NoCACE-I), included in the Doxycycline and Rifampicin for Alzheimer’s Disease study
(n = 406).
Methods:Patients were included if baseline and end-point (twelve months apart) scores were available for measures including the
Standardized Alzheimer’s Disease Assessment Scale – Cognitive Subscale; Quick Mild Cognitive Impairment screen; Clinical
Dementia Rating Scale (CDR-SB), and Lawton-Brody ADL Scale.
Results: There was a significant, 25% difference (median one-point) in the 12-month rate of decline in ADL scores in patients
taking CACE-Is (n = 91), compared to the NoCACE-I group (n = 274), p = 0.024. This remained significant after adjusting for
age, gender, education, and blood pressure, p = 0.034. When individual CACE-Is were compared to the NoCACE-I group, a
significant reduction in the rate of decline in ADLs (median one versus four points), were only observed for perindopril, p = 0.01.
The CDR-SB was also reduced (median one-point) for the perindopril compared to the NoCACE-I group, p = 0.04.
Conclusion: This observational study suggests that CACE-Is, and potentially perindopril in particular, are associated with a
reduced rate of functional decline in patients with AD, without an association with mood or behavior. This suggests that CACE-Is
may slow disease progression in AD.
Keywords: ACE inhibitors, Alzheimer’s disease, cognitive, dementia, function, psychological decline
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INTRODUCTION
Although higher midlife blood pressure (BP) is asso-
ciated with increased risk of dementia [1], it is not a
simple association [2]. Authors have suggested that
a variety of anti-hypertensives improve cognition in
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This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.
596 R. O’Caoimh et al. / Centrally Acting ACE Inhibitors in Alzheimer’s Disease
older adults with elevated BP [3, 4] and have poten-
tial as therapeutic agents in dementia [5–11]. Results
are however, inconsistent [12–14] with some observa-
tional studies even suggesting harm [15, 16].
Dementia and angiotensin converting enzyme
Angiotensin converting enzyme inhibitors (ACE-Is)
and angiotensin receptor blockers (ARBs) may lower
dementia risk or slow progression independent of their
BP lowering properties [9, 10, 17, 18]. Centrally act-
ing ACE-Is (CACE-Is), which cross the blood-brain
barrier, are associated in observational studies with a
reduced incidence of mild cognitive impairment (MCI)
[19, 20] and dementia [14], and slower rates of cog-
nitive decline in Alzheimer’s disease (AD), relative to
non-centrally acting ACE-Is [21, 22]. In patients with
AD, CACE-Is may modulate the pathological accu-
mulation of amyloid- (A), a key neuropathological
hallmark of AD [23]. ACE gene polymorphisms are
associated with increased risk of AD [24, 25]: alle-
les putatively associated with AD are also associated
with low levels of plasma ACE [26, 27]. Pre-clinical
studies suggest that ACE degrades A [28–30], and
marked increases in ACE activity have been reported
in the frontal cortex of patients with AD [31–33]. More
recently, lack of evidence from large scale genetic stud-
ies [5, 16] has diminished interest in ACE [24] while
interest in Angiotensin II, the potent vasoconstrictor
formed by ACE action in AD pathology, has increased
[35, 36].
Centrally-acting ACE–Is and cognition
The strongest pre-clinical evidence to date for the
utility of ACE-Is in affecting cognitive decline is
for the CACE-I perindopril. Perindopril reversed A-
induced cognitive impairment [37], inhibited brain
ACE activity, elevating extracellular acetylcholine lev-
els in mice [38], while two non-centrally acting ACE-Is
did not. Perindopril, but not other ACE-Is, significantly
inhibited hippocampal ACE and prevented cognitive
impairment in mouse models of AD [39, 40, 41].
Clinically, the Cardiovascular Health Study reported
observational data that perindopril, rather than non-
centrally acting ACE-Is or calcium channel blockers,
decreased the rate of decline in patients with mild to
moderate AD [14]. Results, however, are inconsistent.
Secondary analysis of randomized trials have failed
to detect an effect of ACE-Is [42] or ARBs on cogni-
tion [12, 43]. Furthermore, a small placebo controlled
clinical trial in non-demented offspring of AD patients
showed no effect on cognition [44].
Effects of CACE-Is on ADLs and the behavioral
and psychological symptoms of dementia (BPSD)
Observational studies suggest that beta-blockers are
associated with reduced rates of functional decline in
patients with established AD [45]. Although, there is
no association for ACE-Is [14, 45], they are associ-
ated with increased exercise tolerance, muscle strength
[46], and lower falls risk [46, 47], suggesting effects
independent of their BP lowering properties. Further-
more, the discontinuation of ACE-Is in those with
AD is associated with increased rates of functional
decline [48]. Studies investigating ACE genotypes in
functional decline suggest both increased [49] and
decreased disability [50]. There is also evidence that
ACE-Is modulate mood, including anxiety [51] and
depression in hypertensive patients with normal cog-
nition [52]. Again, evidence is inconsistent [53, 54].
Objective
The aim of this paper was to compare rates of cog-
nitive, functional, and neuropsychological decline in
patients with AD receiving CACE-Is (called CACE-Is)
to those not currently treated with CACE-Is (NoCACE-
I) by conducting a secondary analysis of data from a
randomized control trial.
METHODS
Data collection
We performed a secondary analysis of data from the
Doxycycline and Rifampin for Alzheimer’s Disease
(DARAD) trial [55], a multi-center, blinded, random-
ized 2 × 2 factorial controlled trial, conducted between
2006 and 2010, comparing two antibiotics (doxycy-
cline and rifampicin) to placebo, to investigate if these
can delay progression of AD [55]. The co-primary
outcomes were the Standardized Alzheimer’s Disease
Assessment Scale–Cognitive Subscale (SADAS-cog)
[56] and the Clinical Dementia Rating scale-Sum of the
Boxes (CDR-SB) [57]. Secondary outcomes included
the Standardized Mini-Mental State Examination
(SMMSE) [58, 59], Quick Mild Cognitive Impairment
screen (Qmci) [60–62], the Geriatric Depression Scale
(GDS) [63], Cornell Scale for Depression in Dementia
(CSDD) [64], Lawton-Brody ADL Scale [65], and the
Dysfunctional Behaviour Rating Instrument (DBRI),
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frequency (DBRIF) and reaction (DBRIR), subscales
[66, 67]. The SADAS-cog, CDR-SB, Qmci, Lawton-
Brody ADL Scale, and DBRI were available at one,
three, six, nine, and twelve months (end-point). The
SMMSE was recorded at screening and end-point, the
GDS at baseline and end-point and the CSDD at base-
line, six-months and end-point only.
The SADAS-cog is a standardized version of the
ADAS-cog [68], the existing, accepted standard for
measuring cognitive function in clinical trials [69].
Consisting of 11 domains (including word recall,
object naming, command following, construction,
orientation, word recognition, language, speech com-
prehension, word finding and recall), the SADAS-cog
improved inter-rater reliability using explicit admin-
istration and scoring guidelines. Scored from 0–70,
scores ≥13 indicate increasing cognitive impairment
[56]. The CDR-SB, a measure of global function, is
scored from 0–18 with a score of 0 indicating no
impairment, 0.5–4.0 possible impairment, and 4.5–9.0,
9.5–15.5, and 16.0–18.0 suggesting mild, moderate,
and severe impairment, respectively [57]. The Qmci
screen is a short (3–5 min), cognitive screening instru-
ment composed of six subtests, covering five domains:
orientation, registration, clock drawing, delayed recall,
verbal fluency (naming animals) and logical memory
(immediate verbal recall of a short story), scored out of
100 points. It has superior accuracy for detecting MCI
compared to the SMMSE [60] and similar accuracy as
the Montreal Cognitive Assessment (O’Caoimh 2013
unpublished work). The Lawton-Brody ADL Scale,
combining both basic (Physical Self-Maintenance
Scale) and instrumental ADLs, covering 14 categories,
is scored out of 64 points, with higher scores suggest-
ing greater independence [65]. The GDS short-form is
scored from 0–15 with a score ≥5 suggesting depres-
sion [63, 70]. The CSDD is a 19-item scale, range of
0–39: normal <6, probable depression 10–17, definite
depression ≥18. The DBRI, completed by caregivers,
scores the frequency of (from ‘never’ to ‘greater than
five times per day’) and reaction to (impact from ‘no
problem’ to ‘great deal of a problem’) 25 behaviors
[66].
Participants
In total, 406 patients with mild to moderate AD
(SMMSE scores between 14 and 26) were included
from 14 geriatric outpatient clinics in Canada [55].
All patients were aged 50 years or more and met
the National Institute of Neurological Disorders and
Stroke (NINCDS) criteria for AD [71]. In this study,
patients were subdivided into a CACE-I group, includ-
ing patients currently prescribed centrally acting
ACE-Is: ramipril (n = 57), perindopril (n = 21), lisino-
pril (n = 9), trandolapril (n = 3), and fosinopril (n = 1)
[14, 19], and a NoCACE-I group not currently receiv-
ing CACE-Is, irrespective of BP readings, diagnosis of
hypertension, or receipt of other anti-hypertensives.
Analysis
The average 12-month rate of change in outcomes,
measured as the difference between baseline and
12-month scores, were compared between patients
receiving CACE-Is and the NoCACE-I group. For the
Qmci, CSDD, GDS, and Lawton-Brody ADL Scale,
change was calculated as the baseline minus the 12-
month score. The SADAS-cog, CDR-SB, DBRIF, and
DBRIR scales were calculated as the score at month
12 minus the baseline. In this way, irrespective of the
scoring instructions, positive change denoted improve-
ment. The SMMSE, used as an inclusion criterion, was
not used in the analysis. Data were analyzed using
SPSS 20.0. Non-normally distributed numerical data
were compared using the independent samples median
test, while chi-square tests were used for categori-
cal data. Multivariate regression analysis was used to
compare baseline measurement scores, adjusted for
baseline characteristics; age, years of education, and
BP (systolic and diastolic), between the CACE-I and
NoCACE-I groups and CACE-I subgroups: perindo-
pril and other CACE-Is. Multivariate regression was
also used to compare the rate of decline, in each mea-
sure, between the subgroups.
RESULTS
Baseline demographics
Co-primary outcome measures were available for
365 patients at 12 months; for most, secondary out-
comes were also available. The remaining 41 patients
were lost to follow-up because of death (n = 13), refusal
(n = 14), adverse events (n = 6), withdrawal from the
trial (n = 5), and other reasons (moved, caregiver death,
n = 3). Table 1 presents patients’ baseline character-
istics. Of the 365 patients included, 91 were taking
CACE-Is during the course of the trial: 21 receiving
perindopril and 70 other CACE-Is (Figure 1). Although
no difference in baseline outcome measure scores were
present between the CACE-I and NoCACE-I groups,
when the CACE-I subgroups (perindopril and other
CACE-Is) were compared to the NoCACE-I group,
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Table 1
Differences in baseline demographic characteristics and outcome measures of patients receiving centrally acting ACE inhibitors (CACE-I) to
those not currently treated with CACE-Is (NoCACE-I)
CACE NoCACE Perindopril Other CACE-Is p-value1 p-value2
(n = 91) (n = 274) (n = 21) (n = 70)
Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age 79 (8) 78 (10) 78 (9) 79 (10) 0.90 0.72
Gender (male %) 45.1% 51.1% 23.8% 51.4% 0.46 0.05
Education (years) 12 (4) 12 (5) 12 (5) 12 (3.5) 0.06 0.15
Blood pressure systolic 138 (19) 134 (22.5) 140 (19) 135.5 (17.25) 0.41 0.45
Blood pressure diastolic 70 (14) 72 (14) 70 (11) 70 (12.5) 0.41 0.66
Cholinesterase inhibitor use (%) 89.0% 92.3% 76.2% 92.9% 0.32 0.03
Memantine use (%) 15.4% 15.3% 14.2% 15.7% 0.64 0.99
SMMSE 23 (4.5) 22.5 (5) 24 (2) 23 (5) 0.14 0.22
Qmci 39.5 (18) 39 (19) 40 (12) 39 (20) 0.74 0.90
SADAS-cog 18 (12) 21 (11) 16 (9) 19 (12) 0.05 0.04
Lawton-Brody ADL 51 (10) 52 (10) 52 (9) 51 (11) 0.34 0.57
CDR-SB 5 (4) 5 (4) 4.5 (4) 6 (4) 0.74 0.23
CSDD 3 (5) 3 (4) 4 (8) 3 (5) 0.09 0.23
GDS 1 (2) 1 (3) 2 (2) 1 (2) 0.74 0.82
DBRIF 4 (13) 5 (10) 3 (11) 4 (13) 0.61 0.88
DBRIR 11 (12) 13 (11) 12 (16) 11 (12) 0.45 0.75
1p-values are provided for independent samples median test (numerical data) or Chi-square test (categorical data) for comparison between CACE-
I and NoCACE-I groups; 2p-values are provided for independent samples median test (numerical data) or Chi-square test (categorical data) for
comparison between perindopril, other CACE-Is and NoCACE-I groups; ADL, activities of daily living; CDR-SB, Clinical Dementia Rating
scale-Sum of the Boxes; CSDD, Cornell Scale for Depression in Dementia; DBRIF, Dysfunctional Behaviour Rating Instrument-frequency;
DBRIR, Dysfunctional Behaviour Rating Instrument-reaction; GDS, Geriatric Depression Scale; IQR, interquartile range; Qmci, Quick Mild
Cognitive Impairment screen; SADAS-cog, Standardized Alzheimer’s Disease Assessment Scale–Cognitive Subscale; SMMSE, Standardized
Mini-Mental State Examination.
Fig. 1. Flow diagram demonstrating the breakdown of the patients
included from the Doxycycline and Rifampin for Alzheimer’s
Disease (DARAD) trial database receiving centrally acting ACE
inhibitors (CACE-Is: perindopril and others) and those not currently
treated with CACE-Is (NoCACE-I).
there was a marginal statistically significant differ-
ence in baseline characteristics for gender (p = 0.05),
cholinesterase inhibitor use (p = 0.03), and SADAS-
cog scores (p = 0.04) (Table 2).
Table 2
Comparison of the rate of decline, from baseline to one year, between
patients receiving centrally acting ACE inhibitors (CACE-I) and
those not currently treated with CACE-Is (NoCACE-I)
Variable CACE-I NoCACE-I p-value1 p-value2
Median Median
(IQR) (IQR)
Blood pressure systolic 0 (30) 1.5 (24) 0.38 0.69*
Blood pressure diastolic 0 (20) 0 (18) 0.69 0.71*
SADAS-cog 2 (9) 4 (8) 0.41 0.86
CDR-SB 2 (4) 1.5 (3.5) 0.83 0.84
Qmci 4 (12) 5 (13) 0.15 0.49
Lawton-Brody (ADL) 3 (6) 4 (7) 0.024 0.034
CSDD 0 (3) 1 (4) 0.13 0.001
GDS 0 (2) 0 (2) 0.95 0.94
DBRIF 0 (9) 0 (8) 0.50 0.24
DBRIR 4 (13) 2 (11) 0.50 0.44
1p-values are provided for unadjusted comparisons between CACE-I
and NoCACE-I groups; 2p-values are provided for multivari-
ate regression (adjusted for age, gender, education, and blood
pressure) for comparison between the CACE-I and NoCACE-I
groups; *Adjusted for age, gender, and education; ADL, activi-
ties of daily living; CDR-SB, Clinical Dementia Rating scale-Sum
of the Boxes; CSDD, Cornell Scale for Depression in Demen-
tia; DBRIF, Dysfunctional Behaviour Rating Instrument-frequency;
DBRIR, Dysfunctional Behaviour Rating Instrument-reaction;
GDS, Geriatric Depression Scale; IQR, interquartile range;
Qmci, Quick Mild Cognitive Impairment screen; SADAS-cog,
Standardized Alzheimer’s Disease Assessment Scale–Cognitive
Subscale.
R. O’Caoimh et al. / Centrally Acting ACE Inhibitors in Alzheimer’s Disease 599
Rate of decline
Patients receiving CACE-Is had a median decline
of three points (IQR six) in ADL scores between
baseline and 12 months, in comparison to a decline
of four points (IQR seven) in the NoCACE-I group
(p = 0.024). No statistically significant differences in
decline were evident for the other outcome mea-
sures in the unadjusted analysis. However, patients
taking CACE-Is demonstrated a median decline in
Qmci screen scores of four (IQR 12) versus five
(IQR 13) points in the NoCACE-I group (p = 0.15).
The deterioration in CDR-SB and CSDD scores was
also less marked in the CACE-I group relative to the
NoCACE-I group, although again differences were
not statistically significant (Table 2). Adjusting for
age, education, gender, and BP confirmed a signifi-
cant difference in ADL scores (p = 0.034). The adjusted
analysis also showed a significant one point difference
in the rate of decline between groups in the CSDD
scores (p = 0.001, Table 2): 57% (n = 52) of CACE-
I improved or remained the same, compared to 47%
(n = 128) in the NoCACE-I group.
When individual CACE-Is were compared to the
NoCACE-I group, a significant median reduction in the
rate of decline in ADLs, one point compared to four
points, was observed for those receiving perindopril
(p = 0.01). The CDR-SB was also reduced by a median
of one point (p = 0.04) for the perindopril compared
to the NoCACE-I group. Median decline in CDR-SB
scores was 0.5 (IQR 3) in patients receiving perindopril
versus 2.5 (IQR 4) in those receiving other CACE-Is
(p = 0.05). Patients receiving other CACE-Is showed
a median decline in ADL scores of three points (IQR
seven), compared to one point (IQR six) for perindo-
pril (p = 0.09). Patients reported few adverse events that
could possibly be related to ACE-I treatment. Of those
taking CACE-Is, six noted a fall, while none reported
cough or orthostatic symptoms.
DISCUSSION
This study found a small (25%, three versus four
points) reduction in the rate of decline in ADL
scores, measured with the Lawton-Brody ADL Scale,
over a 12-month period, in patients taking CACE-Is
compared to those not currently receiving CACE-Is.
Other outcomes measures were also associated with
a decreased progression for the CACE-I compared
to the NoCACE-I group, although only changes in
ADL and CSSD scores were statistically significant. In
particular, the Qmci screen scores declined 20% less
(four versus five points respectively), for the CACE-I
group over one year, not inconsistent with other studies
demonstrating a slower rate of cognitive decline in per-
sons with dementia receiving CACE-Is [21, 22, 72].
Investigators have not previously reported a reduced
rate of decline in ADLs in patients with established
dementia receiving CACE-Is, although the effect has
been shown with beta-blockers [45]. Since we found
no significant changes in BP over the 12-month follow-
up period, these benefits are likely to be independent
of an anti-hypertensive effect. There are a number of
possible mechanisms by which CACE-Is could impact
upon ADLs. Perindopril improves exercise tolerance
in older adults with normal cognition, with [73] and
without heart failure [46]. This might be explained by
the reported ability of ACE-Is to reduce inflammation
and to improve endothelial function, increasing muscle
blood flow and glucose delivery [74] to both skeletal
and cardiac muscle, thereby improving exercise toler-
ance and capacity. Previous trials have demonstrated
benefits, equivalent to six months of training, with
four weeks exposure to ACE-Is [46]. These effects
appear to be unique to ACE-Is, when compared to
other classes of anti-hypertensives [75], further sup-
porting that the benefits are independent of the drugs
BP lowering properties. In addition, individuals with
polymorphisms, resulting in low ACE activity, have
an enhanced response to training [76] although this
contrasts with the observations of increased ADL
disability for the same gene variants in older popu-
lations [49]. The association between treatment with
either ACE-Is and/or ARBs, with a lower incidence of
falls also supports the theory that these medications
may produce global effects on physical function [47].
Therefore, one year of ACE-I treatment could, the-
oretically, result in improvements in muscle strength
and function, sufficient to alter the rate of decline in
ADLs.
Other studies, however, contradict these findings.
Results from the Cardiovascular Health Study, investi-
gating incidence of dementia, suggest that exposure to
ACE-Is and non-CACE-Is in particular, are associated
with an increased dependency in ADLs [14]. Although
these reductions may have been relative to smaller
disimprovements with other anti-hypertensives, such
as calcium channel blockers, which are also asso-
ciated with reduced incidence of dementia [77, 78]
and possibly reduced progression that is currently
being tested in clinical trials [Nilvad registered trial
EudraCT Number: 2012-002764-27]. The TRAIN
study demonstrated no benefit in muscle strength or
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exercise performance for fosinopril over placebo in
patients with high cardiovascular risk but normal cog-
nition [79].
In this study, the use of perindopril was associ-
ated with a slower rate of decline in measures of
cognition (SADAS-cog and Qmci), global function
(CDR-SB), and ADLs compared to other CACE-Is,
although only the CDR-SB reached statistical signifi-
cance. The potential benefits of perindopril on exercise
tolerance over other ACE-Is has been commented upon
previously [79], with most studies reporting positive
findings using perindopril [46, 73, 79] and negative
findings using other agents such as fosinopril [79] or
quinapril [81].
The results presented here also suggest that depres-
sive symptoms (measured using the CSDD) were
more likely to improve or remain unchanged in
patients receiving CACE-Is. Although reductions in
the adjusted one-year rate of decline were statistically
significant for the CSDD, between the CACE-I and
NoCACE-I groups, the effects were small (both had a
median three-point change over the year, see Table 2).
The frequency of the BPSD, as measured by the DBRIF
and DBRIR, reduced for both CACE-I and NoCACE-I
groups, although this did not achieve statistical sig-
nificance. Thus, minimal or no effects of CACE-Is on
mood or the BPSD were demonstrated in this study.
Both the CACE-I and NoCACE-I groups appeared
to demonstrate little difference in rates of decline in
their GDS, CSDD, and DBRI scores over the year
of follow-up. Although more patients in the CACE-
I group compared to the NoCACE-I group showed a
significant improvement in CSDD scores (57% versus
47%) over one year, CSDD scores were significantly
higher in the CACE-I group at baseline. These data
support the current evidence that ACE-Is, in general,
have little effect on mood and depression [53, 54].
Strengths of our study include that the data were
collected as part of a clinical trial, with rigorous inter-
viewer training and quality checks. Furthermore, the
DARAD trial had a relatively low loss to follow-up
and good compliance with measurements throughout
[55]. Other strengths include the large numbers, regu-
lar assessment, and measurement of a wide variety of
outcomes over one year [55]. Limitations to this study
included the fact that patients had established demen-
tia, median SMMSE of 23, and may have been taking
CACE-Is for many years. Another limitation is that
as this was an observational study, derived from the
secondary analyses of data from a randomized control
trial; it was not possible to identify duration or previous
history of anti-hypertensive treatment. Furthermore,
compliance with anti-hypertensive medications, which
has been shown to reduce with time, may also have
been a confounder [82, 83]. A percentage of patients
in the NoCACE-I group (41%) were not receiving any
anti-hypertensive treatment. By lowering BP, which is
associated with progression of cognitive and functional
impairment [45], these medications may have caused
bias from confounding by indication favoring those
currently receiving them. However, baseline character-
istics including BP were similar between the CACE-I
and NoCACE-I groups and were not associated with
rates of decline. Likewise, most anti-hypertensive
drugs have been linked with reduced rates of cogni-
tive and or functional decline [9, 10, 14, 17, 18, 45].
There were marginal differences of borderline signifi-
cance between the three groups (CACE-I, NoCACE-I,
and perindopril) in gender, cholinesterase inhibitor use,
and SADAS-cog scores. However, the difference in
deterioration in ADLs remained after adjustment for
these variables. The marker of ADLs used, the Lawton-
Brody ADL Scale score, is not a gold standard outcome
measure, but it is still a widely used instrument that
incorporates both instrumental and basic activities of
daily living [14, 65, 84]. Indeed, like most instruments
measuring ADLs, it is subject to potential bias arising
from self or informant reporting rather than a demon-
stration of ability, and insensitivity to small changes in
function. Another limitation and perhaps most impor-
tant, is that inferences regarding treatment effects are
limited by the small effects, the borderline significance
of the findings, and the multiple comparisons increas-
ing the likelihood of chance findings. Small effects may
however also reflect that this analysis was conducted in
patients with more advanced disease. Therefore greater
effects may be gained from longer treatment periods
in patients with less advanced pathology or people
with early stages of cognitive impairment (e.g., MCI),
where cognitive benefits have previously been reported
[19, 20].
Overall, this study suggests the possibility of ben-
efit for patients with established AD taking CACE-Is
compared to a group not currently treated with CACE-
Is, across a range of outcome measures, particularly
ADLs. The finding of a reduced rate of progression
in ADL disability is small and if real of uncertain
significance and with an unclear mechanism. Never-
theless, if such an effect were sustained over years,
patient-important benefit may result. Our data pro-
vide modest support for the hypothesis that CACE-Is,
and perhaps perindopril in particular, may slow dis-
ease progression in patients with dementia. At present
no anti-hypertensive agents have been licensed for the
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treatment of AD. These data support the need for fur-
ther study.
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Abstract
Introduction: differentiating mild cognitive impairment (MCI) from normal cognition (NC) is difﬁcult. The AB Cognitive
Screen (ABCS) 135, sensitive in differentiating MCI from dementia, was modiﬁed to improve sensitivity and speciﬁcity,
producing the quick mild cognitive impairment (Qmci) screen.
Objective: this study compared the sensitivity and speciﬁcity of the Qmci with the Standardised MMSE and ABCS 135, to
differentiate NC, MCI and dementia.
Methods: weightings and subtests of the ABCS 135 were changed and a new section ‘logical memory’ added, creating the
Qmci. From four memory clinics in Ontario, Canada, 335 subjects (154 with MCI, 181 with dementia) were recruited and
underwent comprehensive assessment. Caregivers, attending with the subjects, without cognitive symptoms, were recruited
as controls (n= 630).
Results: the Qmci was more sensitive than the SMMSE and ABCS 135, in differentiating MCI from NC, with an area
under the curve (AUC) of 0.86 compared with 0.67 and 0.83, respectively, and in differentiating MCI from mild dementia,
AUC of 0.92 versus 0.91 and 0.91. The ability of the Qmci to identify MCI was better for those over 75 years.
Conclusion: the Qmci is more sensitive than the SMMSE in differentiating MCI and NC, making it a useful test, for MCI
in clinical practice, especially for older adults.
Keywords: quick mild cognitive impairment screen, mild cognitive impairment, standardised mini-mental state examination,
AB cognitive screen 135, sensitivity
Introduction
Mild cognitive impairment (MCI) represents a heteroge-
neous group of disorders of memory impairment [1].
Individuals with MCI have variable, subtle, cognitive
changes. Although many go on to develop dementia, the
rate of progression varies considerably. The annual conver-
sion rate from MCI to dementia is estimated at between 5
and 10% [2]. The reason for this is partly due to variability
in the deﬁnitions used [3] and in the diagnostic methods
employed. When people present with memory loss, it is
important to differentiate between MCI and dementia, as
treatment choices differ. In particular, patients with demen-
tia beneﬁt from cholinesterase inhibitors, while those with
MCI do not have a sustained response [4]. Clinical and
functional assessments are used to differentiate between
these two groups. While those with MCI generally do not
have functional impairment, evidence suggests that subtle
functional changes are present in 31% [5].
Several cognitive screening tools have been used in an
attempt to differentiate normal cognition (NC), and MCI
from dementia [6, 7]. Not all are able to distinguish
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between dementia and MCI, and it has been suggested
that no single screening tool will ﬁt all situations [8]. One
of the most widely employed tools is the Folstein
Mini-Mental State Examination (MMSE) [9]. The
Standardised Mini-Mental State Examination (SMMSE)
improved inter-rater reliability by the inclusion of explicit
administration and scoring guidelines [10, 11]. The
MMSE and SMMSE have a limited role in identifying
MCI [12], lacking sufﬁcient sensitivity to differentiate
between NC and MCI, in particular, where individuals
have higher levels of academic achievement [13]. The AB
Cognitive Screen 135 (ABCS 135) was developed to
address this problem [6].
Description of the ABCS 135
The ABCS 135, a short screening test, administered in 3–5
min, is more sensitive in differentiating NC from dementia,
and more importantly, MCI from dementia than the
SMMSE. The ABCS 135 evaluates ﬁve domains, orienta-
tion, registration, clock drawing, delayed recall (DR) and
verbal ﬂuency (VF) [6] (Table 1). Although, the ABCS 135
is sensitive and quick to employ, it could be argued, that
much of the test is redundant. All the domains differentiate
NC and MCI from dementia, but orientation, registration
and clock drawing did not enhance the discriminatory
properties of the test in differentiating NC from MCI. For
this reason, the Quick Mild Cognitive Impairment (Qmci)
screen was developed to enhance the sensitivity of the
ABCS 135.
Development of the Qmci
The Qmci, is a modiﬁed version of the ABCS 135,
scored out of 100 points, placing greater emphasis on
verbal memory and ﬂuency, along with DR,
(Supplementary data are available in Age and Ageing
online, Appendix 1). As analysis of the ABCS 135 subt-
ests found that DR and VF, were more sensitive at dif-
ferentiating MCI from NC than orientation, registration
and clock drawing [14], these three subtests had their
weightings reduced by a factor of 2.5, 5 and 2, respect-
ively (Table 1). Logical memory (LM), which is highly
sensitive and speciﬁc in differentiating NC from MCI
[15] was added and given the largest weighting, necessitat-
ing the reduction of weightings for all the other subtests.
LM is a linguistic memory test (for stories) [16] and is
unaffected by age or education [17]. VF and DR are
highly sensitive tests for distinguishing MCI from NC
[14], and although their weighting were cut, by a factor
of 0.66 and 0.8 respectively, to allow for the introduction
of LM, their relative weighting, compared to the other
subtests, increased.
The Qmci, has six domains; ﬁve orientation items
(country, year month, day and date), ﬁve registration items
and a clock drawing test, each scored within 1 min. It also
has a recall section (timed at 20 s), a test of VF (60 s) and a
LM test with 30 s for administration and 30 s for response.
It can be administered and scored in 5 min.
The primary objective of this study was to compare the
sensitivity and speciﬁcity of the new Qmci with the ABCS
135 and SMMSE to distinguish individuals with NC from
those with MCI and dementia.
Methods
Subjects
Subjects attending four memory clinics across Ontario,
Canada (Hamilton, Paris, Niagara Falls and Grand Bend) re-
ferred for the investigation of cognitive loss were recruited
between 2004 and 2010. Normal controls were selected by
convenience sampling. All caregivers, or those attending
with the subjects, were asked if they themselves had
memory problems. Those without memory problems were
invited to participate as normal controls. A diagnosis of de-
mentia was based on NINCDS [18] and DSM-IV criteria
[19]. Dementia severity was correlated with the Reisberg
FAST scale [20]. A diagnosis of MCI was made by a consult-
ant geriatrician if patients had recent, subjective but corro-
borated memory loss without obvious loss of social or
occupational function. Subjects were excluded if they were
under 55 years of age, unable to communicate verbally in
English, if they had depression (as deﬁned by a Geriatric
Depression Scale greater than seven [21]), or if a reliable
collateral was not available. Subjects with Parkinson’s disease
and Lewy body dementia were excluded as these typically
present with exaggerated functional deﬁcits and a different
MCI syndrome [22]. Ethics approval was obtained and sub-
jects provided verbal consent. Assent was obtained from
individuals with cognitive impairment.
Data collection
Each subject had demographic data collected which
included age, gender and number of years of education.
Each had a physical examination and work-up for causes of
cognitive impairment including a brain CT (computerised
tomogram) scan, an electrocardiogram and blood tests.
Each subject had the SMMSE and the Qmci administered
sequentially but randomly by the same trained rater, who
was blind to the eventual diagnosis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Comparison of ABCS version 135 and Qmci
ABCS 135 Score Qmci Score
Orientation 25 Orientation 10
Registration 25 Registration 5
Clock drawing 30 Clock drawing 15
Delayed recall 25 Delayed recall 20
Verbal fluency 30 Verbal fluency 20
Logical memory 30
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Statistical analysis
Data were entered into SPSS version 16.0 [23]. Subjects
were subdivided according to age, > or <75 years and edu-
cational level achieved, > or <12 years (approximating high
school/secondary school level). ABCS 135 data, based on
the Qmci, were reconstituted from data collected from the
Qmci. The Shapiro–Wilk test was used to test normality
and found that the majority of data were non-parametric.
This was analysed using the Mann–Whitney U test,
whereas Student’s t-tests compared scores for parametric
data. Data were also analysed using Receiver operating char-
acteristics (ROC) curves.
Results
A total of 965 participants, 551 females (57%) and 414
males (43%), were included in the study. Overall, 630 sub-
jects had NC (65%), 154 had MCI (16%) and 181 (19%)
had dementia. The median age of the total population was
70.5 years; those with NC had a mean age 67 years
compared with 75.5 for the MCI group and 79 for the
dementia group. The dementia group was older than the
NC (P < 0.001) and MCI (P < 0.001) groups. They also had
spent less time in education, 10 years compared with the
normal control (13 years, P < 0.001) and MCI (12 years,
P < 0.005) populations. Dementia was divided into mild
(n= 141), moderate (n= 33) and severe cognitive impairment
(n = 7). The normal population had a median SMMSE
score of 29 and a median Qmci score of 76, the MCI group
scored 28 and 62 and the dementia group scored 22 and
36 on the SMMSE and Qmci, respectively. These results
and demographics are summarised with inter-quartile range
(IQR) in Table 2. All three cognitive tests (SMMSE, ABCS
135 and the Qmci) were sensitive in differentiating MCI
from NC. The Qmci was best able to do this in a clinically
useful way. The median difference in scores between sub-
jects with either MCI or NC was one for the SMMSE
compared with 14 for the Qmci. This represents a differ-
ence of 3.33% of the total score of 30 with the SMMSE
and a 14% difference for the Qmci (scored out of 100).
All three tests distinguished dementia from MCI.
Patients with MCI, scored a median 26 points more on the
Qmci than those with dementia (P < 0.001), whereas there
was a 40 point difference in the Qmci between those with
NC and dementia (P< 0.001). Figure 1 shows two ROC
curves demonstrating the sensitivities and speciﬁcities of
the Qmci, ABCS 135 and SMMSE in differentiating MCI
from NC and MCI from dementia. Although the Qmci,
ABCS 135 and the SMMSE were able to distinguish MCI
from NC, the Qmci was more sensitive with an area under
the curve (AUC) of 0.86 (95% CI: 0.83–0.89) compared
with 0.83 (95% CI: 0.79–0.86) for the ABCS 135 and 0.67
(95% CI: 0.62–0.72) for the SMMSE. The Qmci was also
more sensitive at differentiating MCI from dementia, AUC
of 0.92 (95% CI: 0.89–0.95) versus 0.91 (95% CI: 0.88–
0.94) for the ABCS 135 and 0.91 (95% CI: 0.88–0.94) for
the SMMSE. When moderate and severe dementia cases
were removed from analysis, the AUC of the Qmci and
SMMSE for differentiating MCI from mild dementia cases
alone was unchanged at 0.92 (95% CI: 0.89–0.95) and 0.90
(95% CI: 0.85–0.93), respectively.
Subanalysis for age (> or < 75 years of age) and educa-
tion (> or <12 years) showed that the Qmci was more sen-
sitive, with a larger AUC, than the SMMSE. The Qmci was
best for distinguishing MCI from NC in an older age
group, (over 75 years), with more time, (>12 years), in edu-
cation, with an AUC of 0.86 (95% CI: 0. 79–0.92)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Characteristics of the normal, MCI and dementia groups, including median Qmci, SMMSE and ABCS 135 scores
and inter-quartile range (IQR), (Q1–Q3 = IQR; Q1 = 1st Quartile, Q3 = 3rd Quartile)
Group Normal MCI Dementia
Number of subjects 630 154 181
Age
Mean 67.4 73.6 78.1
Median 67 75.5 79
Range 44–92 50–88 49–93
Proportion female (57.0%) n= 551
Mean age 67.0 73.3 78.7
Median age 66.5 75 80
Range 50–92 50–87 49–93
Proportion male (43.0%) n= 414
Mean age 68.0 73.9 77.6
Median age 68 76 79
range 44–85 51–88 53–92
Education (years in education)
Mean 13.8 12.2 11.0
Median 13 12 10
Range 5–29 5–26 3–20
Qmci (median with IQR) 76 (83–69 = 14) 62 (68–53 = 15) 36 (45–23 = 22)
SMMSE (median with IQR) 29 (30–28 = 2) 28 (29–27 = 2) 22 (25–18 = 7)
ABCS 135 (median with IQR) 115.5 (121–109 = 12) 102 (111–94 = 17) 70 (83.5–45.5 = 38)
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compared with 0.55 (95% CI: 0.44–0.66) for the SMMSE.
The only subjects where the difference in sensitivity
between the Qmci and SMMSE was less obvious was for
younger individuals, (<75 years) with less than 12 years in
education, AUC of 0.72 (95% CI: 0.62–0.82) for the Qmci
versus 0.65 (95% CI: 0.54–0.76) for the SMMSE. The
SMMSE, ABCS 135 and Qmci were all able to differentiate
MCI from dementia, irrespective of age or educational
status (P < 0.001).
Conclusion
This study compares the reﬁned ABCS tool, the newly
developed Qmci, to the established SMMSE and the original
ABCS 135 in their ability to discriminate NC and MCI from
dementia. The results presented here show that the Qmci is
more sensitive than the SMMSE and the ABCS 135 in dif-
ferentiating MCI from NC, whereas all three are able to dis-
tinguish NC from dementia. Although, the SMMSE was
useful in differentiating MCI and NC groups, from demen-
tia subjects, it was not able to separate MCI from NC. The
small percentage difference (3.33%) of the total score for
the SMMSE between those with NC and MCI shows that
the SMMSE is not clinically useful in distinguishing MCI
from normals. The Qmci had a wider and more clinically sig-
niﬁcant percentage difference in median scores to help dis-
criminate MCI from dementia. Similarly, the median
SMMSE score for MCI cases and controls, even taking the
IQR into account, at 28 out of 30 (IQR: 29–27 = 2) lies
within the accepted cut-off interval for NC, at greater than
25 out of 30 [11, 24]. This again suggests that the SMMSE
is not adequately sensitive in detecting MCI. The Qmci was
also more sensitive than the SMMSE in differentiating MCI
from NC among older adults, over 75 years, especially those
with more than 12 years in education.
Of note, age and educational level did not affect the
ability of the Qmci or SMMSE to discriminate between
MCI and dementia. The dementia group in this study was
signiﬁcantly older and had spent less time in formal educa-
tion than either the MCI group or the NC group. The de-
mentia group was weighted towards the mild spectrum of
dementia. This is important, as differentiating MCI from
mild dementia is more challenging than differentiating it
from severe dementia. Removing moderate and severe de-
mentia cases from analysis, showed that the Qmci retains
and even improves its increased sensitivity, for differentiat-
ing MCI from mild dementia, conﬁrming that this tool is
useful across the whole range of the cognitive impairment
spectrum.
Our paper has several limitations. First, we cannot
be certain that all patients were classiﬁed appropriately
as having normal or impaired cognition. This is difﬁcult
to do, especially where controls are drawn from a
sample of convenience. Controls in this study did not
have any complaints of memory loss. We acknowledge
that one of the major clinical challenges is to separate
symptomatic patients with NC from those with MCI,
especially as approximating 50%, attending some
memory clinics with subjective memory problems, have
NC [25]. However, within the conﬁnes of a sample of
convenience, the subjects chosen as normal controls
were tested rigorously, screened for cognitive impairment
and depression and underwent the same detailed assess-
ment as cases with MCI and dementia. Future validation
of the Qmci, will target controls with NC, referred to
the memory clinic.
Second, we used NINCDS and DSM IV criteria to
make a diagnosis of dementia. While there is no deﬁned
gold standard, these criteria are broadly accepted and
have been validated internationally [26]. Third, the diag-
nosis of dementia was based on a single assessment
Figure 1. ROC curve demonstrating sensitivities and speciﬁcities of the Qmci, ABCS 135 and SMMSE in differentiating (a). MCI
from normal cognition, (b). MCI and dementia.
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which may have reduced accuracy and one rater scored
both cognitive tests which may have led to ‘practice’
effects. However, the raters were blind to the eventual
diagnosis made at the clinical assessment. Finally, we
compared the Qmci to the SMMSE and ABCS 135
which are not gold standards for differentiating MCI
from NC or dementia. This said, the SMMSE is the
most widely used screen for dementia and no gold
standard yet exists for the diagnosis of MCI.
The strengths of this study are the large sample size,
comprehensive assessment and bigger number of controls
than the original ABCS 135 validation paper. The diagnosis
of MCI and diagnosis and grading of dementia are based on
both functional and cognitive assessments. This study was
performed at multiple sites. Future research will focus on
comparing the Qmci to other short cognitive tests such as
the Montreal Cognitive Assessment [27] and further reﬁne-
ment of the different domains in the test.
The study conﬁrms that the Qmci, a short cognitive
screen, is more sensitive in differentiating NC from MCI,
than the widely used SMMSE. Compared with the ABCS
135, the Qmci is more sensitive in differentiating MCI, takes
the same time to complete and is conveniently scored out
of 100, making it easy to interpret in clinical practice.
Key points
• The Qmci is more sensitive than the SMMSE in differen-
tiating MCI from NC.
• The Qmci is more sensitive than the SMMSE in differen-
tiating MCI from dementia.
• The Qmci is more sensitive at differentiating MCI from
NC in older adults, over 75.
• The Qmci needs to be compared with other short-
cognitive screening tools.
Supplementary data
Supplementary data mentioned in the text is available to
subscribers in Age and Ageing online.
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Preventing delirium in an acute hospital
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Abstract
Background: delirium is a clinical syndrome associated with multiple short and long-term complications and therefore
prevention is an essential part of its management. This study was designed to assess the efﬁcacy of multicomponent
intervention in delirium prevention.
Methods: a total of 287 hospitalised patients at intermediate or high risk of developing delirium were randomised to receive
a non-pharmacological intervention delivered by family members (144 patients) or standard management (143 patients). The
primary efﬁcacy outcome was the occurrence of delirium at any time during the course of hospitalisation. Three validated
observers performed the event adjudication by using the confusion assessment method screening instrument.
Results: there were no signiﬁcant differences in the baseline characteristics between the two groups. The primary outcome
occurred in 5.6% of the patients in the intervention group and in 13.3% of the patients in the control group (relative risk:
0.41; conﬁdence interval: 0.19–0.92; P = 0.027).
Conclusion: the results of this study show that there is a beneﬁt in the non-pharmacological prevention of delirium using
family members, when compared with standard management of patients at risk of developing this condition.
Keywords: delirium, primary prevention, elderly
Introduction
Delirium is a clinical syndrome characterised by an
altered level of consciousness and cognitive disorders that
develop over a short period of time (usually over hours
or days) and tend to ﬂuctuate during the course of the
day [1]. The etiology of this syndrome is often
multifactorial.
What makes delirium important is not only its high oc-
currence rate among hospitalied patients but also its conse-
quences. The occurrence rate ranges from 6 to 56% [2, 3]
in hospitalised patients. Its consequences include the contri-
bution to increased morbidity and mortality, being cause of
distress to patients and their families and increased costs
[3]. An example of this is that the presence of delirium in
hospitalisation is an independent factor for mortality 1 year
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Which part of the Quick mild cognitive
impairment screen (Qmci) discriminates
between normal cognition, mild cognitive
impairment and dementia?
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Abstract
Introduction: the Qmci is a sensitive and speciﬁc test to differentiate between normal cognition (NC), mild cognitive im-
pairment (MCI) and dementia. We compared the sensitivity and speciﬁcity of the subtests of the Qmci to determine which
best discriminated NC, MCI and dementia.
Objective: the objective was to determine the contribution each subtest of the Qmci makes, to its sensitivity and speciﬁcity
in differentiating MCI from NC and dementia, to reﬁne and shorten the instrument.
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Methods: existing data from our previous study of 965 subjects, testing the Qmci, was analysed to compare the sensitivity
and speciﬁcity of the Qmci subtests.
Results: all the subtests of the Qmci differentiated MCI from NC. Logical memory (LM) performed the best (area under
the receiver operating curve of 0.80), registration the worst, (0.56). LM and verbal ﬂuency had the largest median differences
(expressed as percentage of total score) between MCI and NC, 20 and 25%, respectively. Other subtests did not have clinic-
ally useful differences. LM was best at differentiating MCI from NC, irrespective of age or educational status.
Conclusion: the Qmci incorporates several important cognitive domains making it useful across the spectrum of cognitive
impairment. LM is the best performing subtest for differentiating MCI from NC.
Keywords: Quick mild cognitive impairment screen, mild cognitive impairment, standardised Mini-Mental State Examination,
sensitivity and specificity, cognitive domains
Introduction
As time is limited in clinical practice, short cognitive screens
help to improve diagnostic efﬁciency and are useful in detect-
ing and quantifying cognitive impairment. One of the major
challenges in cognitive testing has been the development of
rapid screening tests to differentiate mild cognitive impair-
ment (MCI) from normal cognition (NC). Tools, such as the
Folstein MMSE [1] and standardised Mini-Mental State
Examination (SMMSE) [2, 3], are useful in distinguishing NC
and MCI from dementia, but take time to complete, and are
less able to distinguish MCI from NC [4, 5]. Identifying MCI
is important as it can be a prodrome to dementia [6] and
allows earlier recognition of individuals at risk [7]. Although
treatment options are limited, a diagnosis of MCI should
prompt the search for reversible causes of cognitive impair-
ment. The International Working Group on MCI suggested
that population screening cannot be recommended at
present, as there is insufﬁcient evidence for sensitive and spe-
ciﬁc tools, including cognitive tests [7]. Few tools used for
detecting MCI are speciﬁc for the condition, because they
were developed as dementia screening tests [8]. Some, such
as the Montreal Cognitive Assessment (MoCA) [9], the
Alzheimer’s Disease Assessment Scale-Cognitive section
(ADAS-cog) [10] and the AB Cognitive Screen 135 (ABCS
135) [5], have shown improved sensitivity for detecting MCI
when compared with the SMMSE.
The MoCA is widely used and valid in different clinical
settings including Parkinson’s disease, cerebrovascular
disease [11] and Huntington’s disease [12], but takes at least
10 min to perform. The ADAS-cog [10] also screens for
MCI [13], but takes up to 45 min, requires trainings [14]
and has ceiling effects, possibly limiting its usefulness
[15, 16]. The addition of executive function and functional
ability subtests has recently improved its sensitivity [16].
The ABCS 135 is more sensitive and shorter than the
SMMSE at differentiating MCI from NC and dementia [5].
It is composed of ﬁve subtests, orientation, registration,
clock drawing, delayed recall for words (DR) and verbal
ﬂuency (VF) for animals. The Qmci, the Quick mild cogni-
tive impairment screening test, was developed to improve
upon the ABCS 135 and is more sensitive and speciﬁc in
differentiating MCI from NC [4].
Development of the Qmci
The Qmci was created from the ABCS 135, by reweighting
the original subtests and adding a logical memory (LM)
section. Previous analysis of the ABCS 135 subtests found
that DR and VF were more sensitive than orientation,
registration and clock drawing, in distinguishing MCI from
NC [17]. LM, a verbal memory test, using immediate recall,
was added because it is highly sensitive and speciﬁc in dif-
ferentiating MCI from NC [18]. The original subtests had
their absolute scores reduced, to allow for the introduction
of LM, with the weightings of DR and VF increasing rela-
tive to the others. Orientation scores 10 points, registration
5, clock drawing 15, DR and VF 20 each and LM 30. The
Qmci total score of 100 points is easier to use than a total
score of 135, in the original ABCS 135.
The Qmci, therefore, has six subtests covering the follow-
ing cognitive domains: orientation, working memory (regis-
tration), visuospatial/executive function (clock drawing),
semantic memory (VF) and two episodic memory domains
(DR and LM). The Qmci can be completed in 3–5 min,
median time 4.24, and is more sensitive than the SMMSE
and ABCS 135 in discriminating MCI from NC and demen-
tia [4]. It is more clinically useful than these other tests, as it
has greater median percentage differences between subjects
with MCI and NC [4].
The primary objective of this study was to compare the
sensitivity and speciﬁcity of different subtests of the Qmci
in differentiating between NC, MCI and dementia. The sec-
ondary objective was to assess the effect of age and educa-
tional attainment on the sensitivity and speciﬁcity of
individual Qmci subtests.
Methods
Subjects
Subjects were recruited between 2004 and 2010 from
patients attending four memory clinics in Ontario, Canada.
A total of 1,006 subjects were assessed, 53 were excluded,
965 individuals were included; 16% (n = 154) had MCI,
19% (n = 181) dementia and 65% (n = 630) NC. Normal
controls, selected by convenience sampling, comprised ex-
clusively of caregivers attending with the subjects, without
325
Examining the subtests of the Quick Mild Cognitive Impairment screen
symptoms of memory loss. Subjects were excluded if they
were unable to communicate verbally in English (n= 12),
if they had depression (n= 33), including 21 controls with
subjective memory loss but NC, or if a reliable collateral
history was unavailable (n= 8). Parkinson’s disease and
Lewy body dementia cases were excluded as they typically
present with marked functional impairment and a different
MCI syndrome [19].
Dementia was diagnosed based on NINCDS [20] and
DSM-IV criteria [21] and was correlated with the Reisberg
FAST scale [22]. The majority (78%) of dementia cases
were mild (n= 141). Removing moderate and severe cases
did not affect sensitivity [4]. As no consensus on diagnostic
criteria exists [23], MCI was diagnosed clinically, by a con-
sultant geriatrician following a comprehensive assessment
of patients with recent, subjective and or corroborated
memory loss without obvious loss of function. Assessment
included comprehensive history, physical examination,
laboratory screening, functional assessment, behavioural
scores and depression screening (Geriatric Depression
Scale, GDS, greater than seven [24]). No objective cognitive
test was used in the classiﬁcation of MCI. This in keeping
with criteria previously proposed by the MCI Working
Group of the European Consortium on Alzheimer’s
Disease (EADC) [25], but differs from others such as the
International Working group on MCI [7] which suggests
the use of objective cognitive testing. Cognitive tests were
performed in random order, by trained raters, blind to the
diagnosis and prior to the assessment.
The functional level was measured using the Quick
Activity of Daily Living (Qadl) score, unpublished work,
measuring basic and instrumental ADLs. Unless there was
co-existing physical disability, all subjects with MCI had
normal Qadl scores. Subjects with dementia varied, depend-
ing upon stage and physical disability. Behaviours were
recorded using the Quick Behaviour score, unpublished
work, which condenses 12 items from the Dysfunctional
Behaviour Rating Instrument [26]. The most frequent behav-
iour reported was repetition, 81.9% for dementia, 82.1% for
MCI, P= 0.36. Statistically signiﬁcant differences were seen
for social withdrawal, 47.5% for dementia versus 22.4% for
MCI, P= 0.003, sleep disturbance (61.4 versus 46%,
P= 0.05) and aggression (10.5 versus 1.5%, P= 0.038).
Ethical approval was obtained and subjects provided consent.
Data analysis
Data were analysed using SPSS 16.0. Subgroup analysis was
performed for age (greater and less than 75 years, to
provide balance in sample size between groups) and for
years of formal education (greater or less than 12 years,
based upon UNESCO data [27]). Normality was tested
using the Shapiro–Wilk test. The majority of the data were
not normally distributed and were analysed using a Mann–
Whitney U test. Normally distributed data were analysed
using Student’s t-tests. Pearson Chi-squared tests were used
to establish the difference between the distributions when it
was not possible to analyse differences in medians. Receiver
operating characteristics (ROC) curves were constructed
based upon the sensitivity and speciﬁcity of the Qmci subt-
ests. Area under the curve (AUC) was calculated for each
subtest and analysed for age and years of education. Nine
subjects, without complete data, were excluded from this
analysis. Test–retest reliability was demonstrated by measur-
ing the Qmci on two separate occasions, 1 week apart, for a
small sample of subjects, chosen by simple randomisation,
n= 20. Pearson’s correlation coefﬁcient showed good test–
retest correlation, 0.86.
Results
Figure 1 shows box plot distributions for each Qmci
subtest, with median and inter-quartile range (IQR) scores
for subjects with dementia, MCI and NC. The VF and LM
subtests of the Qmci clearly distinguish between dementia,
MCI and NC. Orientation and registration did not show a
median difference between MCI and NC. All individual
subtests had statistically signiﬁcant differences, P < 0.001,
in distributions between NC, MCI and dementia.
Table 1 shows the median scores and IQR’s for the Qmci
subtests along with the P-value of the median difference
between the scores of subjects with either MCI and NC or
MCI and dementia. The overall median scores and differ-
ences are also shown for the Qmci as a whole. Although there
were statistically signiﬁcant differences between Qmci subtests
scores, they were not all able to differentiate MCI and NC in
a clinically useful way. The median difference in scores
between MCI and NC was clinically useful for DR (four
point difference), VF (four points) and LM (7.5 points).
These differences, expressed as a percentage of the total score
for each subtest, are 20% (four point difference out of a total
score of 20), for DR, 20% for VF and 25% for LM. There
was a median one point difference for clock drawing (6.66%),
and no difference (0%), for orientation and registration,
between MCI and NCs, suggesting that these three subtests
are clinically less useful.
ROC curves in Figure 2a illustrate the sensitivity and
speciﬁcity of the Qmci in differentiating NC from MCI,
compared with the ABCS 135 and the SMMSE. The Qmci
performs better in distinguishing NC from MCI with an
AUC of 0.86, compared with the ABCS 135 (0.82), and the
SMMSE (0.67). Taken in isolation, the LM component of
the Qmci, scored higher than the ABCS 135 and SMMSE
(AUC of 0.80 and 0.67, respectively). We also examined the
individual subtests of the Qmci to assess their accuracy. The
ROC curves in Figure 2b compare the ability of the subt-
ests to discriminate between MCI and NC. The most accur-
ate subtest is LM (AUC of 0.80), followed by VF (0.77),
and DR (0.73). Registration (0.56), orientation (0.57) and
clock drawing (0.66) were the least accurate subtests. The
best performing SMMSE subtest was short-term memory
(0.66), the worst registration (0.51).
The Qmci (total), ABCS 135, SMMSE and LM subtest
had similar performance in differentiating MCI from
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dementia. LM, alone, performed particularly well with an
AUC of 0.82. The AUC for the Qmci total score was 0.92
(95% CI: 0.89–95), suggesting it has similar accuracy,
in differentiating MCI from dementia, to the ABCS 135
(AUC 0.91; 95% CI: 0.88–0.94) and the SMMSE (0.91;
95% CI: 0.86–0.94). Each of the subtests of the Qmci
Figure 1. Box plots distributions for each subtest of the Qmci showing the median and inter-quartile range scores for dementia
(D), mild cognitive impairment (MCI) and normal cognition (NC).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Qmci subtests: median scores and IQR (Q1 = 1st Quartile, Q3 = 3rd Quartile) by diagnosis, and P-value of the
median difference between MCI and NC, dementia and MCI, along with AUC scores for SMMSE and the best performing
Qmci subtest, LM, by age and education, for differentiating NC from MCI
Item NC median
(Q3-Q1 = IQR)
(n= 630)
MCI median
(Q3-Q1 = IQR)
(n= 154)
Dementia median
(Q3-Q1 = IQR)
(n= 181)
P-value of the
median diff
between MCI-NC
P-value of the
median diff between
MCI-Dementia
Qmci total 76 (83–69 = 14) 62 (68–53 = 15) 36 (45–23 = 22) P< 0.001 P< 0.001
Qmci subtests (score out of)
Orientation (10) 10 (10–10 = 0) 10 (10–9 = 1) 7 (9–5 = 4) P< 0.001 P< 0.001
Registration (5) 5 (5–5 = 0) 5 (5–4 = 1) 5 (5–3 = 2) P< 0.001 P= 0.002
Clock drawing (15) 15 (15–15 = 0) 14 (15–13 = 2) 11 (14–2 = 12) P< 0.001 P< 0.001
Delayed recall (20) 16 (20–12 = 8) 12 (16–8 = 8) 0 (8–0 = 8) P< 0.001 P< 0.001
Verbal fluency (20) 11 (13–9 = 4) 7 (9–6 = 3) 4 (6–2 = 4) P< 0.001 P< 0.001
Logical memory (30) 20 (24–16 = 8) 12.5 (16–10 = 6) 8 (10–2 = 8) P< 0.001 P< 0.001
Group (MCI and NC, n=X) Test variables Area under curve
(95% CI)
Median diff MCI and NC
(P-value)
Age ≤75 with education <12 years n= 127 SMMSE 0.65 (0.54–0.76) 29 (P = 0.011)
LM 0.72 (0.62–0.82) 15.49a (mean) (P < 0.001)
Age ≤75 with education ≥12 years n= 449 SMMSE 0.66 (0.57–0.75) 29 (P < 0.001)
LM 0.79 (0.73–0.86) 20 (P < 0.001)
Age >75 with education <12 years n= 71 SMMSE 0.64 (0.51–0.77) 28 (P = 0.034)
LM 0.74 (0.62–0.85) 14.35a (mean) (P < 0.001)
Age >75 with education ≥12 years n= 127 SMMSE 0.55 (0.44–0.66) 29 (P = 0.350)
LM 0.79 (0.71–0.88) 16.91a (mean) (P < 0.001)
Overall SMMSE 0.67 (0.62–0.72) 29 (P < 0.001)
LM 0.80 (0.76–0.84) 18 (P < 0.001)
aNormally distributed data.
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accurately distinguished MCI from dementia, (see
Figure 2c). The best tests were orientation (AUC of 0.88)
and DR (0.84). Registration was again the worst perform-
ing test (AUC of 0.64). The best performing SMMSE
subtest was orientation (0.82) and the worst was registra-
tion (0.54).
Table 1 also shows AUC values for the SMMSE com-
pared with the best performing subtest, LM. The AUC
for the LM was superior to the SMMSE, in differentiating
MCI from NC, irrespective of the educational level, or
age (over or under 75 years) of subjects. The improved
performance of LM over the SMMSE was more evident
for the older age group (age over 75) who had over 12
years of formal education, AUC of 0.79 (95% CI: 0.71–
0.88) versus 0.55 (95% CI: 0.44–0.66). There was a sig-
niﬁcant difference between the median scores for LM, for
the MCI and NC groups, irrespective of age or educa-
tional status. This difference was not signiﬁcant for the
SMMSE for older people, >75 years with >12 years in
education (P = 0.350).
Conclusion
The importance of MCI is only matched by difﬁculties in
its diagnosis, particularly in its differentiation from NC.
The Qmci can differentiate MCI from NC and is more sen-
sitive and speciﬁc than the SMMSE and ABCS 135 in dis-
tinguishing MCI from NC and dementia [4]. The Qmci
includes a battery of subtests, but not all differentiate MCI
from NC in a clinically useful way. This study found that
subtests with the greatest median differences between MCI
from NC, expressed as a percentage of their total scores,
were DR, VF and LM. LM, added to the original ABCS
135, improved the sensitivity of the test in differentiating
MCI from NC and is the most useful subtest of the Qmci.
Orientation, registration and clock drawing, as individual
subtests, do not enhance the discriminating power of the
tool to the same extent. These subtests have lower ceilings
and are insensitive to early cognitive changes [17]. When
age and education were taken into account, the best per-
forming subtest, LM, was more accurate than the SMMSE
Figure 2. ROC curves illustrating the sensitivities and speciﬁcities of (a) Qmci, logical memory component (LM) of the Qmci,
ABCS 135 and SMMSE in differentiating MCI from NC (b) Qmci subtests in differentiating MCI from NC and (c) Qmci subtests,
in differentiating dementia from MCI. *Area under the curve (AUC).
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in differentiating MCI from NC, suggesting that alone, it
may be better at distinguishing MCI in the oldest and most
educated subjects. All subtests could differentiate dementia
from MCI and NC. None of the SMMSE subtests per-
formed better than the complete SMMSE or LM.
From the results, we conclude that tests targeting epi-
sodic memory (DR and LM) best discriminate MCI from
NC, whereas orientation is best for assessing dementia,
allowing the Qmci accurately monitor disease progression.
The remaining subtests, further enhance sensitivity, struc-
ture the test and may enhance its ability to identify MCI
syndromes that convert to different dementia subtypes.
The strength of this study is that it included large
numbers of patients with MCI and dementia, and that the
tool was validated in a clinical sample in a busy memory
clinic, increasing the generalisability of these results. A
weakness is that it compares the Qmci to the SMMSE and
ABCS 135, which are not gold standards for diagnosing
MCI or dementia. No objective cognitive testing was used
in the diagnosis of MCI which may also have led to bias al-
though the diagnosis and criteria remain ill-deﬁned [23].
The GDS, used to support a diagnosis of depression, is
limited in advanced dementia [28], although the majority of
subjects in this study were at an early stage. Subjects were
only classiﬁed with MCI if there was no evidence of func-
tional impairment. This may have created bias given that
evidence suggests that up to 30% of subjects with MCI
may have subtle impairment in instrumental ADLs [29].
Another limitation is that the reweighting of the subtests in
favour of DR, VF and LM, may have overestimated their
contribution to the sensitivity of the Qmci, minimising the
role of the other subtests. However, the overall improved
sensitivity of the Qmci over the ABCS 135, in differentiating
MCI from NC, suggests that the reweighting and addition
of LM, have enhanced the test as a whole. Including only
caregivers, attending with subjects, as normal controls,
could also have led to bias, as the challenge in diagnosing
MCI lies in differentiating MCI from persons with subject-
ive memory problems who have NC. This population
accounts for up to 50% of referrals in memory clinics [30],
but accounted for <10% of our clinic population.
In summary, this study conﬁrms that reweighting the
Qmci subtests and adding LM, improved the ability of the
original ABCS 135, to differentiate subjects with MCI and
NC. This paper further highlights and describes some attri-
butes of an ideal short cognitive screening test for MCI
that can be used in everyday clinical practice. The Qmci
incorporates several important cognitive domains, across
the spectrum of cognition and its subtests allow discrimin-
ation of MCI from both NC and dementia, allowing moni-
toring of progression. The Qmci also has the advantage of
being quick to administer, easily translatable (linguistically
and culturally), and of having alternative forms. Other
tools, such as the SMMSE and the ABCS 135, are less sen-
sitive and because of their scoring range, are less practical
for use clinically. Comparison with other rapid screening
tools, such as the MoCA, is now required.
Key points
• All subtests of the Qmci differentiated MCI from NC and
dementia.
• LM is the best performing test, registration the worst.
• LM is the best subtest at distinguishing mild cognitive im-
pairment in the oldest and most educated people.
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Abstract
Objectives: The Alzheimer’s Disease Assessment Scaleecognitive section and its standardized version (SADAS-cog) are the current
standard for assessing cognitive outcomes in clinical trials of dementia. This study compares a shorter cognitive instrument, the Quick Mild
Cognitive Impairment (Qmci) screen, with the SADAS-cog as outcome measures in clinical trials.
Study Design and Setting: The SADAS-cog, Qmci, Clinical Dementia Rating (CDR) scale, and the LawtoneBrady activities of daily
living (ADL) scale were assessed at multiple time points, over 1 year in a multicenter randomized clinical trial of 406 patients with mild to
moderate Alzheimer’s dementia. Correlations were estimated using regression at each time point, all time points, and mean values across
time. Responsiveness was assessed using the standardized response mean (SRM).
Results: Regression for pooled time points showed strong and significant correlation between the SADAS-cog and Qmci (r 5 0.75,
P! 0.001). Correlations remained strong for mean values across time and at each time point. The SADAS-cog and Qmci also correlated
with CDR and ADL scores. There was no difference in SRMs between the SADAS-cog and Qmci [t(357) 5 0.32, P 5 0.75].
Conclusion: The Qmci correlated strongly with the SADAS-cog and both were equally responsive to deterioration. We suggest that
clinicians and investigators can substitute the shorter Qmci for the SADAS-cog.  2014 The Authors. Published by Elsevier Inc. All rights
reserved.
Keywords: Quick Mild Cognitive Impairment (Qmci) screen; Standardized Alzheimer’s Disease Assessment Scaleecognitive section (SADAS-cog); Clinical
Dementia Rating (CDR) scale; Short cognitive screen; Correlation; Clinical trials
1. Introduction
A number of cognitive screening instruments are used
in clinical care and research. To standardize assessments
and allow comparison between settings, there is a need
for valid and reliable cognitive assessment tools. No single
cognitive screening instrument is ideal, and to date, none
are established as the standard [1]. Several are limited by
their inability to detect significant variations between pa-
tients with respect to age and/or educational status [2]. Re-
searchers and clinicians require short instruments that are
reliable, valid, and responsive to change across a wide range
of cognitive function. They needmultiple standardized scor-
ing formats that measure changes early (high ceiling) and in
the later stages of dementia (low floor).
The existing accepted standard for measuring cognitive
function in clinical trials in dementia is the Alzheimer’s Dis-
ease Assessment Scaleecognitive section (ADAS-cog)
[3e5]. TheADAS-cog has 11 domains, includingword recall,
object naming, command following, construction and idea-
tional praxis, orientation, word recognition, language, speech
comprehension, word finding and recall, and takes
30e40 minutes to complete [3]. Total scores range from 0 to
70; higher scores (18) indicate greater cognitive impairment.
The minimal important change has been determined to be
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What is new?
Key findings
 The Quick Mild Cognitive Impairment (Qmci)
screen correlates strongly and significantly to
the Standardized Alzheimer’s Disease Assessment
Scaleecognitive section (SADAS-cog) over time.
 The Qmci had moderate correlation with the Clin-
ical Dementia Rating scale and activities of daily
living.
What this adds to what was known?
 This study confirms that short screening tools can
be used instead of longer cognitive assessments
in clinical trials.
 The Qmci, specifically designed to identify mild
cognitive impairment, can be used to identify and
measure cognitive impairment in clinical trials, po-
tentially improving the ability to detect early cog-
nitive changes in clinical trials.
What is the implication and what should change
now?
 This study suggests that investigators could sub-
stitute the shorter Qmci for the SADAS-cog as a
cognitive outcome measure in clinical trials, partic-
ularly where differentiating mild cognitive im-
pairment from normal cognition and dementia is
important.
approximately four points and many regulatory authorities,
including the US Food and Drug Administration, require
evidence of such change at 6 months to confirm the benefit
of any new medication [6e8].
The ADAS-cog, although comprehensive and useful at
different stages of dementia, has limitations. The ADAS-
cog is long, requires training, and there is concern about
the instruments’ interrater reliability [9]. It also has a ceiling
effect, limiting usefulness in the initial stages of dementia
[10]. To overcome these limitations, the Standardized Alz-
heimer’s Disease Assessment Scaleecognitive section
(SADAS-cog) was developed, to improve interrater reliabil-
ity using explicit administration and scoring guidelines
[11]. The SADAS-cog is equally lengthy, taking up to
45 minutes.
1.1. The Quick Mild Cognitive Impairment screen
The Quick Mild Cognitive Impairment (Qmci) screen
was developed to screen for mild cognitive impairment
(MCI). The Qmci was refined from the AB Cognitive
Screen (ABCS 135) [12], by reweighting the original
subtests and adding a logical memory section. It measures
cognition across a full range of cognition from normal cog-
nition (NC) to MCI and severe dementia. The Qmci has six
domains: orientation, registration, clock drawing, delayed
recall, verbal fluency, and logical memory scored as fol-
lows: orientation (10), registration (5), clock drawing
(15), registration (20), verbal fluency (20), and logical
memory (30). It takes 3e5 minutes to complete. The Qmci
is more sensitive and specific than the Standardized Mini-
Mental State Examination (SMMSE) [13,14] at differenti-
ating MCI from NC and dementia [12]. The Qmci is scored
out of 100, and depending on age and educational levels, 50
is the cutoff for dementia. The Qmci can be completed in
3e5 minutes, median time of 4.24 minutes [15].
1.2. The DARAD trial
The doxycycline and rifampicin for Alzheimer’s Disease
(DARAD) was a multicenter, blinded, randomized con-
trolled trial comparing two antibiotics, rifampicin and
doxycycline, with placebo to confirm if preliminary evi-
dence, suggesting that these antibiotics can delay the pro-
gression of Alzheimer’s disease [16], was correct [17].
Outcome measures included functional, mood, behavioral,
and two cognitive assessments, the SADAS-cog and Qmci.
We used data from the DARAD trial to compare the
Qmci and SADAS-cog to determine if the Qmci is an alter-
native to the SADAS-cog as an outcome in clinical trials.
We also investigated the extent to which the two tests were
correlated and compared their validity and responsiveness
(sensitivity to change).
2. Methods
2.1. Study sample
The DARAD trial investigated the use of two antibiotics,
doxycycline and rifampicin, in 406 patients with mild to
moderate Alzheimer’s dementia. Subjects were randomized
into four arms: doxycycline 100 mg twice daily with rifam-
picin 300 mg daily, doxycycline 100 mg twice daily with
placebo rifampicin daily, rifampicin 300 mg daily with pla-
cebo doxycycline twice daily, or placebo doxycycline twice
daily with placebo rifampicin daily [17]. Patients were re-
cruited from 14 Canadian geriatric clinics between 2006
and 2010. The DARAD database contains data for a range
of variables at 1, 3, 6, 9, and 12 months. Patients aged
50 years or more, meeting the National Institute of Neuro-
logical Disorders and Stroke (NINCDS) criteria for Alz-
heimer’s disease [6], and with SMMSE scores between
14 and 26 were included. Patients were excluded if they
were unable to communicate verbally in English.
2.2. Measures
The coprimary outcomes in the DARAD trial were the
SADAS-cog and the Clinical Dementia Rating scale (CDR)
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using the sum of the boxes technique [18,19]. Secondary out-
comes included the Qmci and the LawtoneBrody activities
of daily living (ADL) scale [20]. The LawtoneBrody scale
measures both basic (Physical Self-Maintenance Scale) and
instrumental (Lawton IADL scale) ADLs and has excellent
interrater reliability [21]. The SADAS-cog, Qmci, and
CDR were administered by a trained rater, in a random se-
quence, blinded to each study arm.
2.3. Data analysis
Data from the DARAD database were analyzed using
SPSS, version 18 (SPSS, Chicago, IL, USA) [22]. The
ShapiroeWilk test was used to test normality and found
that most data were approximately symmetrical, having
a small deviation from normality. The median and inter-
quartile range (IQR) were reported for skewed continuous
data (age and SMMSE). This analysis included only those
patients who had complete data. The correlations between
the Qmci and the SADAS-cog were calculated using the
data collected at 1, 3, 6, 9, and 12 months. The original
values were standardized to remove within-subject varia-
tions, and simple regression analyses were run to estimate
correlation coefficients. To address the validity of the two
instruments, the relationship between both the SADAS-
cog and the Qmci and two other variables (ADL and
CDR) were analyzed using different analytical ap-
proaches. Correlations were analyzed at each time point,
then for all time points together, and finally for mean
values across time. Fisher’s Z test was used to determine
differences in correlations between tests.
To compare the responsiveness of the two instruments,
at each time point, the standardized response mean
(SRM), the mean score change divided by the standard de-
viation (SD) of the score change using baseline as the ini-
tial score, were calculated for the SADAS-cog and Qmci.
Paired-samples t tests were performed to detect if a statisti-
cally significant difference existed in the SRM between the
SADAS-cog and Qmci.
3. Results
Overall, 365 of the 406 patients who entered the DARAD
study completed 1 year [17]. Median age of the total popula-
tion was 79 years, IQR 10.Median SMMSE score at baseline
was 23, IQR 5. More than 90% were taking a cholinesterase
inhibitor and 13%, theN-Methyl-D-aspartate receptor antag-
onist, memantine. Three hundred sixty patients had complete
data for the Qmci and 363 for the SADAS-cog, 364 for the
ADL screen, and 360 for the CDR. Three hundred fifty-
eight patients had complete data for the Qmci and SADAS-
cog, at each time point, over the year.
Correlation coefficients between the outcome measures
along with their confidence intervals (CIs), at each time
point, at all time points, and using mean values across time Ta
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are reported in Table 1. The correlation coefficients demon-
strated significant strong correlation between the Qmci and
the SADAS-cog, at each time point (r 5 0.69; 95% CI:
0.62, 0.78; P  0.001 for the first month and 0.76;
95% CI: 0.70; 0.83; P  0.001 for the last month).
The data most closely correlated at 9 months (r 5 0.78;
P  0.001). Each patient was included five times (corre-
sponding to each time point) in the calculation, which
would be expected to inflate the value of the correlation co-
efficient. However, estimating correlations between mea-
sures overall, at all time points, pooled together, showed
that the correlations between the SADAS-cog and Qmci re-
mained strong and significant (r 5 0.75; 95% CI: 0.72,
0.78; P  0.001). Correlations increased to 0.8 using
mean values across time.
The relationship between the SADAS-cog and Qmci and
the other measures, ADL and CDR, at each of the five time
points, showed modest to strong significant correlations.
Correlations between the CDR and SADAS-cog (range
from 0.41 to 0.59) were stronger than those between the
ADL and SADAS-cog (range from 0.31 to 0.49).
Fig. 1 provides the correlations between the SADAS-cog
and Qmci and between the Qmci and SADAS-cog and the
other variables, ADL and CDR, at each time point. CIs
for correlations between the outcome measures at different
time points overlap, indicating no difference between them.
Fisher’s Z test confirmed that there was no statistically sig-
nificant difference in correlations between the SADAS-cog
and Qmci with either ADL (z 5 1.67; P 5 0.09) or CDR
scores (z 5 0.28; P 5 0.78). The correlation between
the SADAS-cog and itself (Table 2A), across time points,
varied from 0.79 to 0.91, higher than the correlations
between the SADAS-cog and the Qmci, which ranged
between 0.73 and 0.83 (Table 2B).
Responsiveness of the SADAS-cog and Qmci, deter-
mined using the SRM, demonstrated that the mean change
in SADAS-cog scores, between months 1 and 12, calcu-
lated for each patient, was 5 points, with an SD of 7.56.
The estimated mean difference in scores, repeated for the
Qmci, was 5.41 points, SD of 10.02. Paired-samples t test
showed that there was no statistically significant difference
in the SRMs for SADAS-cog and Qmci [t(357) 5 0.32,
P 5 0.75]. This means that the changes in Qmci scores
are very similar to changes in SADAS-cog scores, between
months 1 to 12.
There was a statistically significant increase in SADAS-
cog scores from a mean of 21.56, SD of 7.89 at month 1, to
a mean of 26.56, SD of 12.01 at month 12 [t(362) 5 12.60,
P ! 0.001]. There was also a statistically significant de-
crease in Qmci scores from month 1 (mean 5 38.58,
SD 5 12.83) to month 12 (mean 5 32.76, SD 5 15.593;
t(359) 5 10.23, P ! 0.001).
4. Discussion
This study compared the SADAS-cog with the Qmci,
ADL, and CDR, by comparing observations at multiple
time points, from data collected in the DARAD trial, over
1 year. The SADAS-cog correlated closely with the Qmci,
irrespective of the method of analysis. Although individual
values of the Qmci corresponded to a relatively wide range
of values on the SADAS-cog, high correlation between the
two tests (0.69e0.76) demonstrates that the information
Fig. 1. Scatter plot depicting correlations between (A) SADAS-cog and Qmci, (B) SADAS-cog and LawtoneBrody activities of daily living (ADL)
scale, and (C) SADAS-cog and CDR, at each time point (1, 3, 6, 9, and 12 months). SADAS-cog, Standardized Alzheimer’s Disease Assessment
Scaleecognitive section; Qmci, Quick Mild Cognitive Impairment; CDR, Clinical Dementia Rating.
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obtained is sufficiently similar to justify substitution of the
Qmci. Although the ratio of the mean change in Qmci
scores between the first and final visits (5.41) to the SD
of the change (10.02dratio 0.54) is smaller than that for
the SADAS-cog (5.0 and 7.56dratio 0.68), both differ-
ences were significant at values of !0.001, and the appar-
ent differences in SRMs are easily explained by chance
(P 5 0.75), suggesting that the Qmci and the SADAS-
cog are equally sensitive to change and have similar
responsiveness.
The SADAS-cog and Qmci also correlated with the ADL
and CDR. The CI for correlation coefficient estimates for
the Qmci and SADAS-cog and CI for correlations between
the SADAS-cog and ADL or CDR did not overlap, indicat-
ing a significantly stronger relationship between the Qmci
and SADAS-cog than between the ADL or CDR and
SADAS-cog and Qmci scores. In other words, the Qmci
and SADAS-cog are better predictors of each other than
of the other two measures (ADL and CDR). This is ex-
pected given that the SADAS-cog and Qmci are discrete
measures of cognitive function, which are distinct from
ADLs [23]. Therefore, the magnitude of change in func-
tional measures cannot be inferred from tests of cognitive
function and requires direct measurement. This suggests
that in addition to the use of cognitive testing, clinical trials
in dementia should incorporate measures of ADLs.
The strength of this article lies in its methodology. Cor-
relation between the SADAS-cog and each of the measures
was demonstrated using different statistical methods. Each
consistently confirmed strong correlation between the
SADAS-cog and Qmci and moderate-to-strong correlation
between the SADAS-cog and Qmci, ADL and CDR. The
correlations demonstrated at each of the five time points
were similar to the pooled correlation coefficients. Another
strength, is that these data, a post hoc analysis of the DAR-
AD trial database, represent the ‘‘real life’’ performance of
the Qmci, compared with the accepted standard, in a previ-
ously conducted, multicenter, blinded, randomized
controlled trial. Given that a four-point change, at 6 months,
in the ADAS or SADAS-cog is widely recognized as a clin-
ically significant difference [7,8], the similar responsive-
ness of the Qmci and SADAS-cog suggests that
a comparable change in the Qmci is equivalent to a signifi-
cant change in the SADAS-cog. Given that the Qmci is
shorter and easier to score, these data support the use of
the Qmci as an alternative to the SADAS-cog in clinical
trials.
This article has several limitations. Although a four-
point change in the SADAS-cog is traditionally accepted
as significant, it is not an ideal test. Comparing the Qmci
with the SADAS-cog only suggests that the Qmci has sim-
ilar sensitivity and responsiveness, not that it is a ‘‘gold
standard.’’ Although useful, the Qmci is less comprehensive
than the SADAS-cog and not all neuropsychological do-
mains are accounted for. That said, in contrast to the
SADAS-cog, the Qmci is shorter and easier to apply, cover-
ing many relevant cognitive domains including orientation,
working memory, visuospatial, executive function, se-
mantic memory, and episodic memory. In contrast, the
SADAS-cog is overly long and heavily weighted toward
language. The SADAS-cog, because of ceiling effects, is
less responsive to detecting MCI [24], possibly limiting
its usefulness. The Qmci, in contrast, is accurate at differen-
tiating MCI from NC and dementia [12], suggesting that
where this is the outcome measure of interest, the Qmci
could be used in preference. Although the SADAS-cog
requires substantial training [9], the Qmci, particularly the
clock drawing subtest, also requires training. Explicit
scoring and administration guidelines, including a clock-
scoring template, are available to improve reliability. That
said, clock drawing is a widely used screen for cognitive
impairment [25], different scoring methods are consistent
[26], and there is similar interrater reliability between
trained and untrained raters [27]. It is also regarded as be-
ing the easiest and quickest stand-alone cognitive screen
[25]. The ADL measure used in this study, the Lawtone
Brody scale, has limitations. Although it has excellent
interrater reliability [21] and measures both basic and
instrumental ADLs, like most ADL measures it is self-
reported, potentially over or underestimating functional im-
pairment and is not a gold standard for measuring ADLs.
In summary, the ADAS-cog and its standardized form,
the SADAS-cog, are valid, reliable, and widely used cogni-
tive measures in clinical trials [17,20,28,29]. They have
been validated internationally from Iceland [30] to Turkey
[31] and Hong Kong [32] and despite flaws, remain the
standard. These data demonstrate that the Qmci correlates
strongly, significantly, and correspondingly over time to
the SADAS-cog and that both are equally sensitive with
similar responsiveness to deterioration over time. Although
the correlation with each other was stronger, the SADAS-
cog and Qmci had moderate to strong correlations with both
functional (LawtoneBrody scale) and global assessments
(CDR), confirming their utility in clinical practice and drug
Table 2. Correlation of (A) the SADAS-cog to itself and (B) the Qmci to
itself, over each time point (1, 3, 6, 9, and 12 months)
A (1) (2) (3) (4)
(1) SADAS-cog at 1 mo d
(2) SADAS-cog at 3 mo 0.86a d
(3) SADAS-cog at 6 mo 0.86a 0.89a d
(4) SADAS-cog at 9 mo 0.83a 0.88a 0.90a d
(5) SADAS-cog at 12 mo 0.79a 0.84a 0.87a 0.91a
B (1) (2) (3) (4)
(1) Qmci at 1 mo d
(2) Qmci at 3 mo 0.80a d
(3) Qmci at 6 mo 0.79a 0.83a d
(4) Qmci at 9 mo 0.77a 0.81a 0.83a d
(5) Qmci at 12 mo 0.73a 0.76a 0.78a 0.82a
Abbreviations: SADAS-cog, Standardized Alzheimer’s Disease As-
sessment Scaleecognitive section; Qmci, Quick Mild Cognitive Im-
pairment screen.
a Correlation is significant at the 0.001 level.
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trials. Although further validation will be required, this
study provides a rationale for using the shorter Qmci, as
a cognitive outcome measure in clinical drug trials, partic-
ularly where differentiating MCI from NC and dementia is
important.
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D. Key Instruments for this Research 
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Quick Mild Cognitive Impairment screen (Qmci)
Name:                              DOB:                      Years in Education:                   Date:   
1. Orientation (one minute)
(Give 2 points for correct answer, 1 if attempted and incorrect, 0 if no attempt) 
What country is this? __________ 
What year is this?  __________ 
What month is this? __________ 
What is today’s date?  __________ 
What day of the week is this? __________ 
Score __________ / 10
2. Word Registration (30 seconds)
To begin say… 
“I am going to say 5 words.  After I have said these 5 words, repeat them back to me.  
Are you ready?” (Give 1 point per word repeated, in any order, no hints)
Dog  rain butter love door 
     
Score __________ / 5
Alternate word groups include… 
cat dark pepper fear bed
rat heat bread round chair
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© O’Caoimh R, Molloy D. W 2011. 
3. Clock Drawing (one minute) 
“Use the circle provided to draw a clock face, set the time to ‘ten past eleven’.” 
(Give 1 mark for each number, 1 for each hand & 1 for the pivot correctly placed.  
Loose 1 mark for each number duplicated or greater than 12, e.g, 15 or 45). 
Score:  Numbers  Correct + ______/ 12 
  Errors - ______ 
 Hands  + ______/ 2 
 Pivot  + ______/ 1 
   Total    + ______/ 15 
4. Delayed Recall (30 seconds)
To begin say…  
“A few minutes ago I named five words.  Name as many of those words as you can 
remember.” (Recall in any order, within 30 seconds, giving 4 points per word, no hints)
dog  rain butter love door 
     
Score __________ / 20
5. Verbal Fluency (one minute)
 “Name as many animals as you can in one minute.  Ready? Go.” 
(Give half a point per animal named; to a maximum of 40. Accept all ‘creatures’ including birds, 
fish, insects etc. Do NOT count suffixes twice, e.g. mouse/mice but allow points for similar 
names e.g. calf, cow, and bull. Alternative forms include fruit & veg or towns & cities).
Score __________ / 20
List here, in ‘shorthand’ if required: 
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6. Logical Memory (30 seconds) 
 “I am going to read you a short story. After I have finished reading I want you to 
tell me as much of the story as you can.  OK?”  [patient signifies agreement, then 
begin reading the paragraph at about 1 second for each word unit]  “The red… fox… 
ran across........… the bushes.”  
(Give 2 points per highlighted word, recalled exactly, immediately within 30 seconds, in any 
order, no hints.Two alternative stories are provided). 
6. Logical Memory       
The red The brown The white 2 / 0 
fox dog hen 2 / 0
ran across ran across walked across 2 / 0
the ploughed the metal the concrete  2 / 0 
field. bridge. road. 2 / 0 
It was chased by It was hunting It was followed by 2 / 0
a brown a white a black 2 / 0
dog. rabbit. cat. 2 / 0 
It was a hot It was a cold It was a warm 2 / 0 
May October September 2 / 0
morning. day. afternoon. 2 / 0
Fragrant  Ripe Dry 2 / 0 
blossoms apples leaves 2 / 0 
were forming on were hanging on were blowing in  2 / 0
the bushes. the trees. the wind. 2 / 0
Score __________ / 30
Qmci Total Score ____________ / 100 
                                               
                                              Scored by _____________________________Date    /    / 
*adjust for age and education 
*Normal > 60 
MCI=50-60 
Dementia <50 
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Quick Mild Cognitive Impairment screen (Qmci)
Administration and Scoring Guidelines 
1.   Orientation  
    Scoring
2 points for the correct answer, 1 point for wrong answers, and 0 points for no answer or 
a conceptually unrelated answer (see details below). 
 Timing
Maximum of 10 seconds for each answer.  
Instructions and Scoring Guide 
Year If the person gives the correct year score 2 points, the incorrect year score 1 
point, and 0 points if no year is given.
Country Score 2 points for correct country, 1 point for incorrect country, and 0 if no 
country is named.
Month Score 2 points for the correct month or for the previous or following month if 
within two days of the change of the month (for example, if the date is 
September 30th, score the full 2 points if person answers October. Similarly, 
if the date is October 2nd, score 2 points if person says September). Score 1 
point if the month is incorrect and 0 if no month is named.
Date Score 2 points for exact date or ± one day, 1 point for any other date, 0 if no 
date is named.
Day of 
week 
2 points for correct day, 1 point for incorrect day, 0 if no day named.
To begin say...  
“I’d like to ask you some questions and give you some problems to solve.  Would that be 
OK?”
What country is this? __________ 
What year is this?  __________ 
What month is this? __________ 
What is today’s date?  __________ 
What day of the week is this? __________ 
Score __________ / 10
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2. Word Registration  
Instructions and Scoring Guide 
    Scoring
Score 1 point for each word recalled after the first reading. If subject recalls all five, 
repeat the five items once and then go on to clock drawing.  If subject does not repeat all 
5, repeat the 5 items and ask the subject to repeat them.  Do this until the subject 
correctly recalls all 5 items or for a maximum of 3 trials. Do not score for trials 2 and 3.  
These trials are to help the person learn in preparation for the delayed recall task.   
 Timing
Say the words very deliberately, one per second.  Allow 10 seconds for the recall. 
To begin say… 
“I am going to say 5 words.  After I have said these 5 words, repeat them back to me.  Are 
you ready?”
Dog  rain butter love door 
Score __________ / 5
When finished, say…  “Remember these words because I’ll ask you to recall them later.”
Alternate word groups include… 
cat dark pepper fear bed
rat heat bread round chair
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3. Clock Drawing  
Instructions and Scoring Guide 
    Scoring
Place the circle of the transparent scoring template over the circle of the patient’s 
completed clock.  Rotate the template circle so that the “12” s align.  Score 1 point each if 
the 1, 2, 4, 5, 7, 8, 10, and 11 are in the correct quadrants.  Score 1 point each if the 12, 
3, 6, and 9 touch their quadrant lines.  Subtract one point for each number repeated or for 
numbers above 12.  (Should the patient not have drawn a “12” align the template with the 
3, 6, or 9.) 
Score the placement of hands according to the tips and pivot.  Give 1 point for each hand 
between the dashed lines.  Score 1 point for hands connecting at the pivot. 
 Timing
One minute.  
To begin… 
Give the sheet of paper with the pre-drawn circle and a pencil to the patient. Say “Now put in the
numbers like the face of a clock.”  Then say “Set the hands to show ten past eleven.”  
Place the numbers and hands as carefully as you can.”
You may prompt at each stage…”put in the numbers…. put the time as ten past eleven”.  
Score:  Numbers  Correct + ______/ 12 
  Errors - ______ 
 Hands  + ______/ 2 
 Pivot  + ______/ 1 
   Total    + ______/ 15 
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4. Delayed Recall 
Instructions and Scoring Guide 
    Scoring
 Score 4 points for each word recalled. Subjects may recall words in any order.   
 Timing
10 seconds. 
To begin say…  
A few minutes ago I named five words.  Name as many of those words as you can 
remember.
dog  rain butter love door 
Score __________ / 20
Alternate word groups include… 
cat dark pepper fear bed
rat heat bread round chair
5. Verbal Fluency 
Instructions and Scoring Guide 
    Scoring.  
Give ½ point for each correct word recalled to a maximum of 40 words.  Round up the 
final score.  Do not count words with different suffixes twice (e.g. fish / fishes, mouse / 
mice, etc.).  Accept alternate species (e.g. blue jay, robin, sparrow, duck, etc.). Alternate 
forms include fruits and vegetables, cities and towns.   
 Timing. 
60 seconds. Write down each word the patient says.  (You may need to develop some 
kind of “shorthand” for the speedier patients, such as writing the first 3 letters of each 
word and then completing them later.) 
To begin say…  
“Name as many animals as you can in one minute.  Ready? Go.”
Score __________ / 20
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6. Logical Memory 
Instructions and Scoring Guide 
    Scoring.  
Give 2 points for each correct word item recalled verbatim.   All bolded words within each 
section must be recalled for score 2 points.  Otherwise score 0.  Recall may be in any 
order.   
 Timing. 
30 seconds. Check off each word unit recalled.   
To begin say…  
“I am going to read you a short story. After I have finished reading I want you to tell me as 
much of the story as you can.  OK?”  [patient signifies agreement, then begin reading the 
paragraph at about 1 second for each word unit]  “The red… fox… ran across........… the 
bushes.”  
6. Logical Memory       
The red The brown The white 2 / 0 
fox dog hen 2 / 0
ran across ran across walked across 2 / 0
the ploughed the metal the concrete  2 / 0 
field. bridge. road. 2 / 0 
It was chased by It was hunting It was followed by 2 / 0
a brown a white a black 2 / 0
dog. rabbit. cat. 2 / 0 
It was a hot It was a cold It was a warm 2 / 0 
May October September 2 / 0
morning. day. afternoon. 2 / 0
Fragrant  Ripe Dry 2 / 0 
blossoms apples leaves 2 / 0 
were forming on were hanging on were blowing in  2 / 0
the bushes. the trees. the wind. 2 / 0
Score __________ / 30
Qmci Total Score ____________ / 100 
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The Clock Transparency Scoring Template 
Scoring 
Place this scoring template over the completed clock with the template’s “12 o’clock” line placed 
over the subject’s 12.  Adjust the template to maximize the score for the numbers and hands. The 
total score is 15. Record scores on the score sheet as follows: 
Numbers 
x For the numbers 12, 3, 6, and 9 score one (1) point if they touch their respective lines, 
zero (0) point if missed, and zero (0) if the number is omitted.  
x For the numbers 1, 2, 4, 5, 7, 8, 10, and 11 score one (1) point for each number in the 
correct quadrant, zero (0) point if the number is outside the quadrant, and zero (0) if the 
number is omitted. 
x Subtract one point for each number repeated or more than 12. 
Hands
x Score the placement of the entire hand. If the hands are drawn within range, score one (1) 
point for each hand; if the hands are drawn outside the hatched line or are omitted score 
zero (0); Give one (1) point if the hands join at the pivot. 
10
12
6
1
2
11
8
7 5
4
9  3 
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ProvidedbytheAlzheimer’sDrugTherapyInitiativeforphysicianuse.
STANDARDIZED MINI-MENTAL STATE EXAMINATION (SMMSE) 

 QUESTION TIMEALLOWED SCORE
1 a. Whatyearisthis? 10seconds /1
 b. Whichseasonisthis? 10seconds /1
 c. Whatmonthisthis? 10seconds /1
 d. Whatistoday’sdate? 10seconds /1
 e. Whatdayoftheweekisthis? 10seconds /1
2 a. Whatcountryarewein? 10seconds /1
 b. Whatprovincearewein? 10seconds /1
 c. Whatcity/townarewein? 10seconds /1
 d. INHOME–Whatisthestreetaddressofthishouse?
 INFACILITY–Whatisthenameofthisbuilding?
10seconds /1
 e. INHOME–Whatroomarewein?INFACILITY–Whatfloorareweon? 10seconds /1
3 SAY:Iamgoingtonamethreeobjects.WhenIamfinished,Iwantyoutorepeat
them.RememberwhattheyarebecauseIamgoingtoaskyoutonamethemagainin
afewminutes.Saythefollowingwordsslowlyat1ǦsecondintervalsǦball/car/man
20seconds /3
4 SpellthewordWORLD.Nowspellitbackwards. 30seconds /5
5 NowwhatwerethethreeobjectsIaskedyoutoremember? 10seconds /3
6 SHOWwristwatch.ASK:Whatisthiscalled? 10seconds /1
7 SHOWpencil.ASK:Whatisthiscalled? 10seconds /1
8 SAY:Iwouldlikeyoutorepeatthisphraseafterme:Noifs,andsorbuts. 10seconds /1
9 SAY:Readthewordsonthepageandthendowhatitsays.Thenhandtheperson
thesheetwithCLOSEYOUREYESonit.Ifthesubjectreadsanddoesnotclosetheir
eyes,repeatuptothreetimes.Scoreonlyifsubjectcloseseyes
10seconds /1
10 HANDthepersonapencilandpaper.SAY:Writeanycompletesentenceonthat
pieceofpaper.(Note:Thesentencemustmakesense.Ignorespellingerrors)
30seconds /1
11 PLACEdesign,eraserandpencilinfrontoftheperson.SAY:Copythisdesignplease.

Allowmultipletries.Waituntilpersonisfinishedandhandsitback.Scoreonlyfor
correctlycopieddiagramwitha4Ǧsidedfigurebetweentwo5Ǧsidedfigures.
1minute /1
12 ASKthepersonifheisrightorleftǦhanded.Takeapieceofpaperandholditupin
frontoftheperson.SAY:Takethispaperinyourright/lefthand(whicheverisnonǦ
dominant),foldthepaperinhalfoncewithbothhandsandputthepaperdownon
thefloor.Score1pointforeachinstructionexecutedcorrectly.
Takespapercorrectlyinhand
Foldsitinhalf
Putsitonthefloor
30seconds 



/1
/1
/1
 TOTALTESTSCORE  /30
Note:  This tool is provided for use in British Columbia with permission by Dr. William Molloy.  This questionnaire should not be 
further modified or reproduced without the written consent of Dr. D. William Molloy. 
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Quick Activities of Daily Living (Qadl) Score -- for caregiver 
Tell us how the patient manages his / her “activities of daily living”.  How does he / she 
function every day?  Circle the number that best applies in the past week.  If the person does 
not do this activity, e.g. another person does shopping, circle “N/A” for not applicable.
Type of activity 
What is the level of care 
required?
How much of a 
problem is this? 
In the past week how well was he/she able to… 
na Not applicable-never did this  
0 Performs spontaneously and 
 independently 
1 Needs prompting (verbal) 
2 Needs set-up (physical)  
3 Needs supervision (stand by) 
4 Needs assistance (physical) 
5 Complete care required  
0 None  
1 Little 
2 Moderate 
3 Great 
4   Extreme 
manage their own medications na 0 1 2 3 4 5 0 1 2 3 4 
handle money (pay bills, shop, etc.) na 0 1 2 3 4 5 0 1 2 3 4 
use the telephone na 0 1 2 3 4 5 0 1 2 3 4 
prepare food na 0 1 2 3 4 5 0 1 2 3 4 
groom (hair, shaving, nails, etc.) na 0 1 2 3 4 5 0 1 2 3 4 
bath (bath, shower) na 0 1 2 3 4 5 0 1 2 3 4 
walk na 0 1 2 3 4 5 0 1 2 3 4 
toilet (urine / feces) na 0 1 2 3 4 5 0 1 2 3 4 
251
transfer (e.g. bed to chair) na 0 1 2 3 4 5 0 1 2 3 4 
feed themselves (eat and drink) na 0 1 2 3 4 5 0 1 2 3 4 
Is this person mainly limited or impaired by physical problems?   
Check off if any of the following reduced the person’s ability to care for him / her self. 
 Blindness  Hearing    Weakness    Arthritis   
Memory and thinking 
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Citation: Morris, J.C. The Clinical Dementia Rating (CDR): Current vision and scoring rules 
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This is a semi-structured interview. Please ask all of these questions.  Ask any additional 
questions necessary to determine the subject’s CDR. Please note information from 
additional questions. 
 
 
Memory Questions for Informant: 
 
1. Does he/she have a problem with his/her memory or thinking?  Yes  No 
1a. If yes, is this a consistent problem (as opposed to inconsistent)?   Yes  No 
2. Can he/she recall recent events?       Yes  No 
3.  Can he/she remember a short list of items (shopping)?    Yes  No 
4.  Has there been some decline in memory during the past year?   Yes  No 
5. Is his/her memory impaired to such a degree that it would have interfered  
 with his/her activities of daily life a few years ago (or pre-retirement  
 activities)? (collateral source’s opinion)      Yes  No 
6.  Does he/she completely forget a major event (e.g. a trip, a party,  
 a family wedding) within a few weeks of the event?     Yes  No 
7. Does he/she forget pertinent details about the major event?    Yes  No 
8. Does he/she completely forget important information of the distant past  
 (e.g. date of birth, wedding date, place of employment)?    Yes  No 
9. Tell me about some recent event in his/her life she should remember.   
 (For later testing, obtain details such as location of the event, time of day,  
 participants, how long the event was, when it ended and how the patient  
 or other participants got there)       
 Within 1 week:   
   
   
 Within 1 month:   
   
   
10.  When was he/she born?   
11.  Where was he/she born?   
12.  What was the last school he/she attended?   
 Name   
 Place   
 Grade   
13.  What was his/her main occupation/job (or spouse’s job if patient was not employed)?   
   
14.  What was his/her major job (or spouse’s job if patient was not employed)?   
   
15. When did he/she (or spouse) retire and why?   
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Orientation Questions for Informant: 
 
How often does he/she know the exact: 
 
1. Date of the Month? 
 
 Usually  Sometimes   Rarely  Don’t Know 
 
2. Month? 
 
 Usually  Sometimes   Rarely  Don’t Know 
 
3. Year? 
 
 Usually  Sometimes   Rarely  Don’t Know 
 
4. Day of the Week? 
 
 Usually  Sometimes   Rarely  Don’t Know 
 
5. Does he/she have difficulty with time relationships (when events happened in relation to 
each other)? 
 
 Usually  Sometimes   Rarely  Don’t Know 
 
6. Can he/she find his/her way around familiar streets? 
 
 Usually  Sometimes   Rarely  Don’t Know 
 
7. How often does he/she know how to get from one place to another outside his/her 
neighbourhood? 
 
 Usually  Sometimes   Rarely  Don’t Know 
 
8. How often can he/she find his/her way around indoors? 
 
 Usually  Sometimes   Rarely  Don’t Know 
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
Judgement and Problem Solving Questions for Informant: 

1. In general, if you had to rate his/her abilities to solve problems at the present time, would 
you consider them: 
 
 As good as they have ever been  
 Good, but not as good as before 
 Fair 
 Poor 
 No ability at all 
 
2. Rate his/her ability to cope with small sums of money (e.g. calculate change, leave a small 
tip): 
 
 No loss  
 Some loss 
 Severe loss 
 
3. Rate his/her ability to handle complicated financial or business transactions (e.g. balance 
cheque book, pay bills): 
 
 No loss 
 Some loss 
 Severe loss 
 
4. Can he/she handle a household emergency (e.g. plumbing leak, small fire)? 
 
 As well as before 
 Worse than before because of trouble thinking 
 Worse than before, another reason (why)   
   
 
5. Can he/she understand situations or explanations? 
 
 Usually  Sometimes  Rarely  Don’t Know 
 
6. Does he/she behave* appropriately (i.e. in his/her usual (premorbid) manner) in social 
situations and interactions with other people? 
 
 Usually  Sometimes  Rarely  Don’t Know 
 
 
 
 
 
 
 
 
 
__________________________ 
* This item rates behaviour, not appearance
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Community Affairs Questions for Informant 
 
Occupational         Yes    No   N/A 
 
1.  Is the patient still working? 
 If not applicable, proceed to item 4 
 If yes, proceed to item 3 
 If no, proceed to item 2  
 
2. Did memory or thinking problems contribute to the patient’s  Yes    No   D/K 
 decision to retire? (Question 4 is next) 
 
3.  Does the patient have significant difficulty in his/her job because of problems with  
 memory or thinking? 
 
  Rarely or Never     Sometimes    Usually   Don’t Know 
 
4.  Did he/she ever drive a car?       Yes    No 
 Does the patient drive a car now?       Yes    No 
 If no, is this because of memory or thinking problems?    Yes    No 
 
5. If he/she is still driving, are there problems or risks     Yes    No 
 because of poor thinking? 
 
6. *Is he/she able to independently shop for needs? 
  
  Rarely or Never     Sometimes     Usually  Don’t Know 
 (Needs to be accompanied (Shops for limited number 
 on any shopping trip)  of items: buys duplicate  
     items or forgets needed items) 
 
7. Is he/she able to carry out activities independently outside the home? 
  Rarely or Never     Sometimes     Usually  Don’t Know 
 (Generally unable to perform (Limited and/or routine  (Meaningful 
 Activities without help)  e.g. superficial participation participation in 
     In church or meetings; trips to activities e.g. voting) 
     beauty salons) 
 
8. Is he/she taken to social functions outside the family home?   Yes    No 
If no, why not   
 
9. Would a casual observer of the patient’s behaviour think the patient was ill?  Yes  No 
 
10. If in a nursing home, does he/she participate well in social functions (thinking)?  Yes  No 
 
IMPORTANT: 
Is there enough information available to rate the subject’s level of impairment in community 
affairs? 
If not, please probe further. 
 
Community Affairs: Such as going to church, visiting friends or family, political activities, professional 
organisations such as bar association, other professional groups, social clubs, service organisations, 
educational programs. 
 
*Please add notes if needed to clarify patient’s level of functioning in this area 
Home and Hobbies Questions for Informant: 
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1a. What changes have occurred in his/her abilities to perform household tasks?   
 
   
 
1b. What can he/she still do well?   
 
   
 
2a. What changes have occurred in his/her abilities to perform hobbies?   
 
  
 
2b. What can he/she still do well?   
 
  
 
3. If in a nursing home, what can he/she no longer do well (Home and Hobbies)?   
 
   
 
Everyday Activities (The Dementia Scale of Blessed): 
 
       No Loss   Severe Loss 
4.  Ability to perform household tasks        0  0.5          1 
 
Please describe   
 
   
 
   
 
5. Is he/she able to perform household tasks at the level of: 
(Pick one. The informant does not need to be asked directly) 
 
  No meaningful function 
 (Performs simple activities, such as making a bed, only with much supervision) 
 
 Functions in limited activities only 
 (With some supervision, washed dishes with acceptable cleanliness; sets table) 
 
  Functions independently in some activities 
 (Operates appliances, such as a vacuum cleaner; prepares simple meals) 
 
 Functions in usual activities but not at usual level 
 
 Normal function in usual activities 
 
IMPORTANT: 
Is there enough information available to rate the patient’s level of impairment in HOME & 
HOBBIES? 
If not, please probe further. 
 
Household Tasks: such as cooking, laundry, cleaning, grocery shopping, taking out garbage, 
front and backyard work, simple care maintenance and basic home repair. 
 
Hobbies: Sewing, painting, handicrafts, reading, entertaining, photography gardening, going to 
theatre or concert, woodworking, participating in sports 
Personal Care Questions for Informant: 
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*What is your estimate of his/her mental ability in the following areas: 
 
 Unaided Occasionally 
misplaced buttons 
etc. 
Wrong sequence 
commonly 
forgotten items 
Unable to dress 
A. Dressing (The 
Dementia Scale 
of Blessed) 
0 1 2 3 
     
 Unaided Needs prompting Sometimes needs 
help 
Always or nearly 
always needs 
help 
B. Washing, 
grooming 
0 1 2 3 
     
 Cleanly; proper 
utensils 
Messily; spoon Simple solids Has to be fed 
completely 
C. Eating habits 0 1 2 3 
     
 Normal complete 
control 
Occasionally wets 
bed 
Frequently wets 
bed 
Doubly 
incontinent 
D. Sphincter 
control 
(The Dementia 
Scale of Blessed) 
0 1 2 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
__________________________ 
*A box-score of 1 can be considered if the patient’s person care is impaired from a previous level, 
even if they do not receive prompting. 
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Memory Questions for Patient 
 
1. Do you have problems with memory or thinking?     Yes    No 
 
2. A few moments ago your (spouse etc) told me a few recent experiences you had.  Will 
you tell me something about those? (Prompt for details if needed, such as location of the 
event, time of day, participants, how long the event was, when it ended and how the 
patient or other participants got there.) 
 
    Within 1 week 
1.0 – Largely correct    
0.5    
0.0 – Largely incorrect  
 
    Within 1 month 
1.0 – Largely correct    
0.5    
0.0 – Largely incorrect  
 
3. I will give you a name and address to remember for a few minutes.  Repeat this name and 
address after me: (Repeat until the phrase is correctly repeated or to a maximum of three 
attempts) 
 
Elements    1       2   3         4        5  
John  Brown  42  Market St  Sydney 
John  Brown  42  Market St  Sydney
 John  Brown  42  Market St  Sydney 
 
(Underline elements repeated correctly in each attempt) 
 
4. When were you born?   
 
5. Where were you born?   
 
6.  What was the last school you attended? 
     Name   
     Place  Grade   
 
7. What was your main occupation/job (or spouse’s if not employed)?   
 
8. What was your last major job (or spouse’s if not employed)?   
 
9. When did you (or your spouse) retire and why?   
 
10. Repeat the name and address I asked you to remember: 
 
Elements    1       2   3         4        5  
John  Brown  42  Market St  Sydney 
 
(Underline elements repeated correctly.) 
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Orientation Questions for Patient: 
 
Record the patient’s answer verbatim for each question 
 
1. What is the date today?       Correct    Incorrect 
  
 
2. What day of the week is it?      Correct    Incorrect 
  
 
3. What is the month?       Correct    Incorrect 
  
 
4. What is the year?        Correct    Incorrect 
  
 
5. What is the name of this place?      Correct    Incorrect 
  
 
6. What town or city are we in?      Correct    Incorrect 
  
 
7. What time is it?        Correct    Incorrect 
  
 
8. Does the patient who the informant is (in your judgement)?  Correct    Incorrect 
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9 
Judgement and Problem Solving Questions for the Patient: 
 
Instructions: If initial response by subject does not merit a grade 0, press the matter to 
identify the patient’s best understanding of the problem.  Circle the nearest response. 
 
Similarities: 
 Example: “How are a pencil and pen alike?” (writing instruments) 
   “How are these things alike?”  Patient’s Response 
  
1. turnip..............cauliflower   
  (0 = vegetables) 
  (1 = edible foods, living things, can be cooked, etc) 
  (2 = answers not pertinent; differences; buy them) 
 
2. desk...............bookcase   
  (0 = furniture, office furniture; both hold books) 
  (1 = wooden, legs) 
  (2 = not pertinent, differences) 
 
Differences: 
 Example: “What is the difference between sugar and vinegar?” (sweet vs. sour) 
   “What is the difference between these things?” Patient’s Response 
 
3. lie...................mistake   
  (0 = one deliberate, one unintentional) 
  (1 = one bad, the other good – or explains only one) 
  (2 = anything else, similarities) 
 
4. river................canal   
  (0 = natural – artificial) 
  (2 = anything else) 
 
Calculations: 
 5. How many five cent pieces in a dollar?    Correct    Incorrect 
 
 6. How many 20 cent pieces in $5.40?    Correct    Incorrect 
 
 7. Subtract 3 from 20 and keep subtracting 3 from each   Correct    Incorrect 
    new number all the way down. 
 
Judgement: 
8. Upon arriving in a strange city, how would you locate a friend that you wished to see? 
 
(0 = try the telephone book, city directory, go to the courthouse for a directory; call a 
mutual friend) 
(1 = call the police, call the operator (usually will not give address) 
(2 = no clear response) 
 
9. Patient’s assessment of disability and station in life and understanding of why  
    he/she is present at the examination (may have covered, but rate here): 
 
  Good Insight  Partial Insight     Little Insight 
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NAME  ________________________________ AGE____________   SEX_______ DATE _________________________________________
Cornell Scale for Depression in Dementia
Ratings should be based on symptoms and signs occurring during the week before interview.  No score should be
given if symptoms result from physical disability or illness.
SCORING SYSTEM
a = Unable to evaluate 0 = Absent
1 = Mild to Intermittent 2 = Severe
A.  MOOD-RELATED SIGNS
1. Anxiety;  anxious expression, rumination, worrying
2. Sadness;  sad expression, sad voice, tearfulness
3. Lack of reaction to pleasant events
4. Irritability;  annoyed, short tempered
B.  BEHAVIORAL DISTURBANCE
5. Agitation;  restlessness, hand wringing, hair pulling
6. Retardation;  slow movements, slow speech, slow reactions
7. Multiple physical complaints (score 0 if gastrointestinal symptoms only)
8. Loss of interest;  less involved in usual activities (score 0 only if 
change occurred acutely, i.e., in less than one month)
C.  PHYSICAL SIGNS
9. Appetite loss;  eating less than usual
10. Weight loss (score 2 if greater than 5 pounds in one month)
11. Lack of energy;  fatigues easily, unable to sustain activities
D.  CYCLIC FUNCTIONS
12. Diurnal variation of mood;  symptoms worse in the morning
13. Difficulty falling asleep;  later than usual for this individual
14. Multiple awakenings during sleep
15. Early morning awakening;  earlier than usual for this individual
E.  IDEATIONAL DISTURBANCE
16. Suicidal;  feels life is not worth living
17. Poor self-esteem;  self-blame, self-depreciation, feelings of failure
18. Pessimism;  anticipation of the worst
19. Mood congruent delusions;  delusions of poverty, illness or loss
1. The same CNA (certified nursing assistant) should conduct the interviewed
each time to assure consistency in the response.
2. The assessment should be based on the patient’s normal weekly routine.
3. If uncertain of answers, questioning other caregivers may further define the
answer.
4. Answer all questions by placing a check in the column under the appropriate-
ly numbered answer.  (a=unable to evaluate, 0=absent, 1=mild to intermit-
tent, 2=severe).
5. Add the total score for all numbers checked for each question.
6. Place the total score in the “SCORE” box and record any subjective observa-
tion notes in the “Notes/Current Medications” section.
7 . Scores totaling twelve (12) points or more indicate probable depression.
Score
Score greater than 12 = Probable Depression
a         0         1         2
a         0         1         2
a         0         1         2
a         0         1         2
a         0         1         2
Instruction for use: (Cornell Dementia Depression Assessment Tool)
NOTES/CURRENT MEDICATIONS:
ASSESSOR:
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Geriatric Depression Scale (Short Form) 
Patient’s Name:         Date:     
Instructions: Choose the best answer for how you felt over the past week. Note: when asking the 
patient to complete the form, provide the self-rated form (included on the following page).
No. Question Answer Score
1. Are you basically satisfied with your life? YES / NO
2. Have you dropped many of your activities and interests? YES / NO
3. Do you feel that your life is empty? YES / NO
4. Do you often get bored? YES / NO
5. Are you in good spirits most of the time? YES / NO
6. Are you afraid that something bad is going to happen to you? YES / NO
7. Do you feel happy most of the time? YES / NO
8. Do you often feel helpless? YES / NO
9. Do you prefer to stay at home, rather than going out and doing new things? YES / NO
10. Do you feel you have more problems with memory than most people? YES / NO
11. Do you think it is wonderful to be alive? YES / NO
12. Do you feel pretty worthless the way you are now? YES / NO
13. Do you feel full of energy? YES / NO
14. Do you feel that your situation is hopeless? YES / NO
15. Do you think that most people are better off than you are? YES / NO
TOTAL  
(Sheikh & Yesavage, 1986) 
Scoring:
Answers indicating depression are in bold and italicized; score one point for each one selected. A score of 0 to 5 
is normal. A score greater than 5 suggests depression. 
Sources:
x Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter 
version. Clin Gerontol. 1986 June;5(1/2):165-173. 
x Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709-711. 
x Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: 
a preliminary report. J Psychiatr Res. 1982-83;17(1):37-49.
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Geriatric Depression Scale (Short Form) 
Self-Rated Version 
Patient’s Name:         Date:     
Instructions: Choose the best answer for how you felt over the past week. 
No. Question Answer Score
1. Are you basically satisfied with your life? YES / NO
2. Have you dropped many of your activities and interests? YES / NO
3. Do you feel that your life is empty? YES / NO
4. Do you often get bored? YES / NO
5. Are you in good spirits most of the time? YES / NO
6. Are you afraid that something bad is going to happen to you? YES / NO
7. Do you feel happy most of the time? YES / NO
8. Do you often feel helpless? YES / NO
9. Do you prefer to stay at home, rather than going out and doing new things? YES / NO
10. Do you feel you have more problems with memory than most people? YES / NO
11. Do you think it is wonderful to be alive? YES / NO
12. Do you feel pretty worthless the way you are now? YES / NO
13. Do you feel full of energy? YES / NO
14. Do you feel that your situation is hopeless? YES / NO
15. Do you think that most people are better off than you are? YES / NO
TOTAL  
(Sheikh & Yesavage, 1986) 
272
     273
